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Abstract 
 
The leading cause of mortality in type 2 diabetes mellitus patients is 
cardiovascular disease, with patients exhibiting platelet hyperreactivity and 
prothrombotic propensity. The mechanisms that underpin these effects however 
are unclear. The aim of this study was to determine which of the biochemical 
features associated with type 2 diabetes are responsible for increased platelet 
reactivity.  
 
Whole blood from fasted healthy participants supplemented with increasing 
concentrations of glucose, exhibited a significant elevation in mean platelet 
volume (MPV) and basal IIb3 receptor activation. Platelet aggregation in 
response to ADP and collagen was not increased by acute hyperglycaemia in 
platelet rich plasma or whole blood, and there was no significant increase in –
granule secretion or IIb3 activation following ADP stimulation. Furthermore, in 
type 2 diabetic patients, HbA1c and fasting blood glucose correlated with MPV, 
but not platelet activation or aggregation. This suggests that hyperglycaemia 
elevates MPV and increases IIb3 activation in circulating platelets, but does not 
increase platelet reactivity as previously reported. 
 
The key finding from this study was the strong positive correlation for low-density 
lipoprotein cholesterol (LDL-C) and both ADP and collagen-activated platelet 
aggregation, and this was independent of diabetes. More importantly, patients 
with LDL-C over 2.0 mmol/L had significantly increased platelet aggregation. 
Furthermore, LDL-C was associated with elevated platelet production, and 
iii 
 
participants with LDL-C over 3.0 mmol/L had significantly increased immature 
platelet fraction. 
 
This study demonstrates that LDL-C may act as a biomarker to identify type 2 
diabetes patients who would benefit from antiplatelet prophylaxis. Additionally, 
lipid-lowering medication could indirectly provide antithrombotic benefit by 
reducing LDL-C levels. Moreover, enhanced platelet production mediated by 
elevated LDL-C is likely responsible for both enhanced platelet reactivity and 
reduced antiplatelet efficacy in type 2 diabetic patients. 
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1.1 Type 2 Diabetes: Definition and Global Prevalence 
 
Under normal conditions, insulin induces the uptake of glucose into muscle, liver 
and fat tissue (Nussey and Whitehead, 2001). Diabetes is associated with a 
reduction in insulin secretion and/or insulin resistance, and so the condition is 
defined by the elevation of blood glucose (Nussey and Whitehead, 2001). 
Diabetes UK reports that approximately 3.7 million adults have diabetes in the 
UK and 90% of them have type 2 diabetes mellitus (Diabetes UK, 2017). Further 
analysis by Diabetes UK relating to figures on obesity and waist circumference, 
estimates that 12.3 million people are at risk of type 2 diabetes. According to Hex 
et al. (2012), the National Health Service (NHS) spends approximately £10 billion 
on diabetes per year. Therefore, the disease imposes a large economic burden 
on the NHS and a huge risk to public health.   
 
Type 1 diabetes, is an autoimmune deficiency that leads to -cell death and the 
decline of insulin being released. Type 2 diabetes is a metabolic disease, caused 
by the impairment of insulin-dependent glucose uptake into the cells (insulin 
resistance) and the relative deficiency of insulin secretion by pancreatic β-cells 
(Nussey and Whitehead, 2001). Individuals can exhibit insulin resistance and 
subsequent hyperinsulinemia for more than twenty years before developing the 
disease (Schneider, 2009a).  
 
The risk of developing type 2 diabetes increases more than two-fold with the 
degree and duration of abdominal obesity (Freemantle et al., 2008). Ethnicity also 
plays an important role. The prevalence of type 2 diabetes is up to six times 
greater in African-Caribbean and up to three times greater in the South Asian 
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people compared to the white population (Department of Health, 2001). It is also 
more common in people of Chinese descent. More recently, genome wide 
association studies have detected over eighty loci related to type 2 diabetic 
susceptibility, and these loci were primarily identified in large cohorts from specific 
ethnic groups (Andersen et al., 2016). Other research suggests that the condition 
may begin in the womb. Prenatal exposure to famine might increase the risk of 
developing type 2 diabetes later in life (Lumey et al., 2015), and this may be 
through epigenetic changes (Radford et al., 2014). 
 
The disease is diagnosed by an abnormally high blood glucose level, termed 
hyperglycaemia (Tuch et al., 2000). Fasting blood glucose (FBG) from normal 
individuals tends to be in the range of 3.5-5.5 mmol/L (Tuch et al., 2000). 
However, glucose concentrations vary between different diabetic patients and so 
the definition of diabetes is subjective (Moebus et al., 2011). The cut off points 
were chosen in relation to levels of glycaemia associated with specific diabetic 
complications such as retinopathy. The World Health Organisation (WHO) 
defined diabetes as having fasting plasma levels greater than 7.0 mmol/L (whole 
blood is 6.1 mmol/L) and post-prandial blood glucose greater than 11.1 mmol/L 
(WHO, 2006). The haemoglobin A1c (HbA1c) test gives a better indication of 
glycaemic control over a longer period of time (Tuch et al., 2000). An HbA1c 
measurement of 42-47 mmol/mol indicates prediabetes and a measurement > 48 
mmol/mol indicates diabetes (John, 2012). 
 
Type 2 diabetes is associated with obesity and poor lifestyle, but the cause of 
insulin resistance is not fully understood. It is thought that there are distinct 
3 
 
populations of patients with different characteristics. Greater understanding of 
these subgroups would enable a personalised approach to treatment. In 2018, a  
Scandinavian study of more than 14,000 diabetic patients reported that diabetes 
should be classified into five distinct clusters (Ahlqvist et al., 2018) (see table 1.1).  
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Table 1.1: The five distinct characteristics of diabetes 
 
Cluster Name of disease Characteristics 
1 Severe autoimmune 
diabetes 
Classically known as the Type 1 
diabetes, an autoimmune deficiency 
leads to-cells unable to produce 
insulin. Patients develop the disease 
at a young age and generally have a 
healthy weight. 
 
2 Severe-insulin deficient 
diabetes 
Similar age and weight 
characteristics to cluster 1 and the 
body struggles to produce insulin, but 
the diabetes is not caused by an 
autoimmune disease. Highest risk of 
retinopathy. 
 
3 Severe-insulin resistant 
diabetes 
Generally overweight patients. The 
body cannot respond to the insulin 
being produced. Higher risk of kidney 
disease than clusters 4 and 5. 
 
4 Mild obesity-related diabetes Generally, very overweight patients 
with insulin resistance, who are 
metabolically closer to normal than 
the patients in cluster 3. 
 
5 Mild age-related diabetes They tend to develop insulin 
resistance later in life and their 
symptoms are milder than the 
patients in the other clusters. 
 
 
A Scandinavian study of more than 14,000 diabetic patients reported that diabetes should be 
classified into five distinct clusters (Ahlquist et al., 2018). 
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1.2 Cardiovascular Disease in Type 2 Diabetes Mellitus 
 
Atherothrombosis accounts for the majority of deaths in type 2 diabetic patients 
(Reusch and Drazin, 2007). It has been reported that diabetic patients have a 
two- to four-fold increased risk of coronary artery disease (CAD) and peripheral 
artery disease (Kuusisto and Laakso, 2013). Large-scale studies have shown that 
type 2 diabetic patients are at equal risk of myocardial infarction as non-diabetic 
subjects with a prior myocardial infarction (Haffner et al., 1998; Schramm et al., 
2008). Supporting the concept that diabetes is a cardiovascular disease 
equivalent and that diabetic patients should be given primary prevention prior to 
a myocardial infarction. However, other studies have supported the concept of 
diabetes as a cardiovascular disease equivalent in sub-groups but not the entire 
population (Kuusisto and Laakso, 2013). Sub-groups such as age, gender, 
ethnicity and duration of diabetes can increase the risk of cardiovascular disease. 
The current National Institute for Health and Care Excellence (NICE) guidelines 
is to offer antiplatelet therapy (such as aspirin or clopidogrel) for adults with type 
2 diabetes as a secondary prevention of cardiovascular disease (NICE, 2018). 
 
The disease accelerates the development of atherosclerosis, resulting in plaque 
rupture, platelet activation and thrombosis. Growing evidence demonstrates that 
the mechanisms involved in maintaining the integrity of the vasculature are 
impaired in type 2 diabetic patients. In healthy vasculature, haemostasis is 
regulated by a network of endothelial and smooth muscle cells (SMCs). A 
monolayer of endothelial cells that line the inner arterial wall, release mediators 
that promote vascular haemostasis, such as nitric oxide (NO) and prostacyclin I2 
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(PGI2), and the SMCs regulate the vascular tone of the arteriole walls (Libby et 
al., 2011).  
 
In diabetes, this intricate network is perturbed, resulting in the development of 
atherosclerotic plaques in the inner lining of the arteries, known as atherogenesis 
(Libby et al., 2011). During atherogenesis, endothelial cells express adhesion 
molecules to capture leukocytes on their surfaces when subjected to stimuli such 
as dyslipidaemia, pro-inflammatory molecules and hypertension (Libby et al., 
2011). The monocytes move into the innermost layer of the artery, the tunica 
intima, differentiate into macrophages to engulf biochemically modified low 
density lipoprotein (LDL) particles and become foam cells, forming the 
atherosclerotic plaque (Lusis, 2000). Furthermore, SMCs migrate from the tunica 
media into the tunica intima and produce extracellular matrix proteins, such as 
collagen and elastin, to form a fibrous cap that covers the plaque (Libby et al., 
2011). Rupture of the plaque results in the activation of platelets and coagulation 
factors to form thrombi that disrupts arterial blood flow, ultimately leading to 
myocardial infarction or stroke.  
 
The pathogenesis of atherosclerosis in type 2 diabetes is the same as non-
diabetic subjects but with the added burden of elevated glucose (Hadi et al., 
2005). Driven by hyperglycaemia and oxidative stress, advanced glycation end-
products (AGEs) form to alter vessel wall haemostasis and accelerate the 
progression of atherosclerosis (Hadi and Suwaidi, 2007). Within the vessel wall, 
collagen-linked AGEs may “trap” plasma proteins and interact with membrane 
receptors to alter cellular properties. AGEs initiate oxidative reactions that 
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promote the formation of oxidised-low density lipoprotein (ox-LDL) (Hadi and 
Suwaidi, 2007). Oxidised lipoproteins and reactive oxygen species (ROS) 
penetrate the vascular wall, promoting leukocyte adhesion. The attachment of 
AGEs to endothelium may also quench NO activity to promote platelet activation 
(Hadi and Suwaidi, 2007). 
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1.3 The Role of Platelets in Atherothrombosis  
 
The primary role of platelets is to prevent excess blood loss upon vascular injury 
maintaining haemostasis (Kaplan and Jackson, 2011). This is achieved through 
the generation of platelet rich clots, which plug the damaged area. Through 
similar mechanisms, platelets also play a key role thrombosis, the development 
of pathological clots. In arteries, the most common cause of thrombosis is rupture 
or erosion of atherosclerotic plaques. The loss of the endothelium and exposure 
of extracellular matrix proteins results in platelet adhesion to the vascular wall, 
followed by platelet activation, and aggregation, resulting in atherothrombosis 
(Kaplan and Jackson, 2011).  
 
In addition to their role in later stages of atherothrombosis, the concept of 
platelets as key players in the development of atherosclerosis has become 
increasingly accepted due to accumulating evidence. Under physiological 
conditions, the intact endothelium prevents platelet adhesion. However, under 
inflammatory conditions, circulating platelets adhere to the activated endothelial 
layer via an initial “loose” contact known as platelet rolling (Langer et al., 2017). 
Activated platelets express adhesive ligands, such as P-selectin and IIb3 
receptors, on their membrane surface, and this leads to aggregate formation and 
the recruitment of leukocytes. It has been reported that the role of platelets in 
atherosclerosis might begin in the very early stages of the disease. Using a 
mouse model for atherosclerosis, Massberg et al. (2002) reported that platelet 
adhesion to endothelium occurred before the development of the lesion, 
indicating a proatherogenic platelet phenotype. Using a similar mouse model for 
atherosclerosis, Burger and Wagner (2003) demonstrated that platelet P-selectin 
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contributed to lesion development and that P-selectin expression activates 
monocytes located at the lesion to secrete chemokines that attract or stimulate 
proliferation of SMCs. Thus, the development of biomarkers for circulating 
platelets could be important in the early identification of patients most at risk of 
cardiovascular disease. It also indicates that targeting platelets, in particular the 
P-selectin pathway, may have potential to reduce atherogenesis. 
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1.4 Mechanisms of platelet activation and aggregation 
 
Platelets are small cellular fragments that circulate in the bloodstream for 
approximately ten days before they are cleared by macrophages in the liver and 
spleen (Daly, 2011).  
 
Platelets are formed from the cytoplasm of their parent cells, megakaryocytes, 
which reside in the bone marrow. The normal human platelet count is 
approximately 250-450 x 109/L (Giles, 1981). Abnormalities in platelet production 
can result in two clinically significant disorders. Thrombocytopenia (platelet 
counts below 150 x 109/L) leads to inadequate clot formation and increased 
bleeding, and thrombocythemia (platelet counts above 600 x 109/L) can increase 
the risk of thrombotic events such as stroke and myocardial infarction (Patel et 
al., 2005). 
 
Platelets lack a nucleus and hence cannot adapt to different situations by de novo 
protein synthesis (although they do carry over residual messenger RNA (mRNA) 
from the megakaryocytes) (Clemetson and Clemetson, 2013). Thus, platelets 
have a number of different receptors that are present in the platelet storage 
granules and expressed on the surface after activation. Activation of the platelet 
receptors triggers a series of intracellular events that include the mobilisation of 
intracellular calcium and phosphorylation of proteins to activate a number of 
feedback mechanisms (Colwell and Nesto, 2003). These mechanisms bring 
about morphological and biochemical changes in the activated platelet including 
shape change, thromboxane A2 (TXA2) synthesis and granule secretion. 
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The main function of platelets is haemostasis, and so the function of the major 
receptors is to promote thrombus formation either by platelet adhesion to the 
damaged vessel wall or the activation of other platelets to the site of injury. The 
steps in platelet thrombus formation are sometimes described as initiation, 
extension and stabilisation (Brass et al., 2013). Initiation occurs when the 
platelets tether to exposed von Willebrand factor (vWF)/collagen complexes on a 
monolayer of endothelial cells, enabling platelet adhesion to the damaged vessel 
wall. Extension occurs when additional platelets adhere to the endothelium and 
become activated. Thrombin, adenosine diphosphate (ADP) and thromboxane A2 
(TXA2) released by platelets play an important role in this step. Finally, 
stabilisation refers to the subsequent steps, particularly outside-in signalling, that 
help to stabilise the thrombus so that it cannot disaggregate (Brass et al., 2013). 
These three steps will be discussed in more detail below.  
 
Under high shear stress (typically at sites of atherosclerosis where stenosis of 
the vessel lumen occurs), platelets are tethered to exposed sub-endothelial 
collagen fibres by binding of immobilised von Willebrand factor (vWF) to the 
Glycoprotein (GP) Ib in the platelet membrane GPIb-IX-V complex (Ruggeri and 
Mendolicchio, 2007). Circulating erythrocytes facilitate platelet adhesion to 
collagen by pushing platelets closer to the sub-endothelium allowing GPIb to be 
snared by the vWF A1 domain (Brass et al., 2013). This tethering facilitates 
binding of collagen to the low-affinity GPVI receptor on platelets and the initiation 
of intracellular signalling that leads to inside-out activation of the integrin 
receptors 21 and IIb3 (also known as glycoprotein IIb/IIIa), as well as further 
clustering of GPVI (Nieswandt et al., 2001). These signals mediate stable platelet 
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adhesion and spreading through binding of 21 and IIb3 to collagen and vWF, 
respectively. Platelets have a low-level constitutively active 21 that can bind to 
collagen at lower shear rates. However, GPVI plays the predominant role in 
mediating platelet adhesion at high shear rates (Pollitt et al., 2013).  
 
Once platelets adhere to the sub-endothelial collagen, the primary drivers for 
platelet activation include the signalling events that occur downstream of collagen 
(GPVI), thrombin (protease-activated receptor [PAR] 1 and PAR4), ADP (P2Y1 
and P2Y12) and TXA2 (TP) (Brass et al., 2013). Clustering of GPVI leads to an 
intracellular signalling cascade involving phosphorylation in the Fc receptor  
chain (FcR) cytoplasmic domain, followed by activation of Syk, and 
phosphorylation and activation of phospholipase C2 (PLC2) (Kasirer-Friede et 
al., 2004). This hydrolyses phosphatidylinositol-4,5-bisphosphate (PIP2) to form 
inositol 1,4,5-trisphosphate (IP3) and Diacylglycerol (DAG) (Bye et al., 2016). IP3 
opens up calcium channels in the platelet dense tubular system and DAG 
activates the PKC isoforms expressed in platelets to allow for serine/threonine 
phosphorylation events needed for platelet activation (Brass et al., 2013). One 
consequence of PLC2 activation is the production and release of the secondary 
agonists TXA2 and ADP, which bind to circulating platelets to further increase 
thrombus formation (Brass et al., 2013).  
 
TXA2 stimulates vasoconstriction, granule secretion, and initiates secondary 
aggregation (Gawaz, 2001), however, it does not have a direct effect on the 
formation of the platelet inhibitory molecule, cAMP (Brass et al., 2013). Synthesis 
of TXA2 occurs when calcium is released from the intracellular storage pools and 
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activates phospholipase A2. This enzyme hydrolyses the membrane 
phospholipids to arachidonic acid, which is converted to TXA2 via the aspirin-
sensitive cyclooxygenase (COX)-1 pathway (Angiolillo, 2009). TXA2 can diffuse 
across the membrane and activate other platelets (Brass et al., 2013). 
 
Calcium activation and serine/threonine phosphorylation results in the secretion 
of ADP from the dense granules and binding to the purinergenic receptors, P2Y1 
and P2Y12. In vitro studies have shown that ADP causes TXA2 synthesis, shape 
change, aggregation and secretion (Brass et al., 2013). It also inhibits cyclic 
adenosine monophosphate (cAMP) formation, which, in turn, diminishes the 
platelet inhibitory response. When P2Y1 is blocked or deleted, there is an 
impaired response to ADP (e.g. absent increase in calcium and shape change). 
Nevertheless, ADP is still able to inhibit cAMP formation (Léon et al., 1999). 
However, when P2Y12 is deleted in mice, there is a greatly diminished 
aggregation and the mice also fail to inhibit cAMP formation in response to ADP 
(Foster et al., 2001). Drugs that block P2Y12, such as clopidogrel and ticlopidine, 
have proved to be effective antiplatelet agents (Savi and Herbert, 2005). 
 
Exposure of phosphatidylserine on the surface of activated platelets enables the 
assembly of the prothrombin complex and generation of thrombin (Bye et al., 
2016). Thrombin is a strong agonist and able to activate platelets at 
concentrations as low as 0.1 nM, making it the most potent agonist (Brass et al., 
2013). It appears to cause phosphoinositide hydrolysis and the increase of 
cytosolic calcium more rapidly than other agonists. Human platelets express 
PAR1 and PAR4, and activation of either receptor by thrombin triggers rapid 
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platelet activation and aggregation. Receptor activation occurs when thrombin 
cleaves the extended N-terminus of either PAR1 or PAR4 that serves as a 
tethering ligand, binding intramolecularly to the body of the receptor to effect 
transmembrane signalling (De Candia, 2012). The P2Y12 and PAR-1 pathways 
are known to cross-react in mediating platelet activation (Angiolillo et al., 2010). 
Unlike ADP, which directly activates both Gαi (via P2Y12) and Gαq (via P2Y1) 
signalling, thrombin cannot directly activate both signals and requires the 
secondary Gαi signal from P2Y12 and secreted ADP (thrombin's secondary 
response) to complement the Gαq signals from PAR-1 and PAR-4.  
 
The stabilisation stage is the final step whereby cohesive contacts between 
platelets enable the thrombus to become stable. The receptor-bound ligands 
(fibrinogen, vWF or fibrin) act as a bridge between two IIb3 molecules on 
adjacent platelets to form the stable thrombus (Brass et al., 2013). IIb3 is the 
only receptor uniquely expressed on platelets, with 50,000 to 80,000 copies per 
platelet (Clemetson and Clemetson, 2013). It is activated by inside-out signalling 
via the platelet signalling events initiated by collagen, thrombin, ADP and TXA2 
(Bledzka et al., 2013), which gives rise to conformational changes within IIb3. 
The common event induced by these agonists is activation of a PLC isoform, 
elevation of cytosolic calcium and activation of PKC. Although each of the stimuli 
is capable of initiating inside-out signalling, it is likely that they act co-operatively 
(Bledzka et al., 2013). See figure 1.1 for an overview of the major signalling 
pathways of platelet activation. 
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Although the primary role of platelets is to maintain haemostasis, they also 
contribute to inflammation through platelet-leukocyte interactions. P-selectin is a 
cell adhesion molecule involved in this interaction and it is located in the α-
granules of resting platelets (Blann et al., 2003). It is also located in the Weibel–
Palade bodies of endothelial cells. Upon activation, P-selectin translocates to the 
platelet surface, whereby it mediates the interaction with leukocytes that express 
P-selectin glycoprotein ligand-1 (PSGL-1). Here it facilitates the rolling of platelets 
and neutrophils on activated endothelial cells, and the interaction of platelets with 
monocytes and neutrophils (Blann et al., 2003). There are approximately 10,000 
P-selectin molecules on the surface of an activated platelet (Blann et al., 2003). 
 
Besides leukocyte recruitment and platelet-leukocyte interactions, P-selectin also 
has a role in platelet aggregation. Merten and Thiagarajan (2000) demonstrated 
that P-selectin was maximally expressed ten minutes after maximal IIb3 
activation, and that platelet aggregate size and stability depends on P-selectin. 
Michelson et al. (1996) showed in vivo that P-selectin is rapidly cleaved from 
degranulated platelets and released into the plasma pool as soluble P-selectin 
(sP-selectin), but the degranulated platelets continue to circulate and have the 
ability to form aggregates. 
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Figure 1.1: An overview of the major signalling pathways of platelet 
activation 
Once platelets adhere to damaged endothelium, the primary drivers for platelet activation 
include the signalling events that occur downstream of collagen (GPVI), thrombin (protease-
activated receptor [PAR] 1 and PAR4), ADP (P2Y1 and P2Y12), and TXA2 (TP). In general 
terms, agonists initiate activation of a phospholipase C (PLC) isoform, which hydrolyses 
phosphatidylinositol-4,5-biphosphate (PIP2) to produce the second messenger, inositol-1,4,5-
triphosphate (IP3), needed to raise the calcium (Ca++) levels. This results in a conformational 
change in IIb3 which binds fibrinogen and is the final step in platelet aggregation. P-selectin 
translocates to the membrane to recruit leukocytes. Other abbreviations: AA, arachidonic acid; 
ADP, adenosine diphosphate; cAMP, cyclic adenosine monophosphate; COX-1, 
cyclooxygenase-1; GP, glycoprotein; PGI2, prostacyclin; PKB, protein kinase B; PKC, protein 
kinase C. Diagram adapted from Brass et al. (2013).  
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1.5 Mechanisms of Platelet Inhibition 
 
Within the circulation, each platelet is balanced by approximately fifty endothelial 
cells (Aird, 2005). The endothelium modulates vascular tone and platelet 
inhibition by co-releasing the endothelium-derived vasodilator factors NO and 
PGI2 (Nucci et al.,1988). Endothelial cells constitutively express endothelial nitric 
oxide synthasGPe (eNOS) that, upon calcium binding, generates NO using L-
arginine together with other co-factors (Dhananjayan et al., 2016). NO diffuses 
freely into platelets where it binds to the soluble intracellular receptor, guanylyl 
cyclase, leading to an increase in cyclic guanosine monophosphate (cGMP) 
levels and reduced intracellular calcium (Jensen et al., 2004). The decrease in 
calcium levels inhibits the conformational change of IIb3 into its active form, and 
thus decreases platelet dissociation with fibrinogen (Beaulieu and Freedman, 
2013). NO is important not only for inhibiting aggregation and adhesion, but also 
for modulating platelet function itself. Platelet-derived NO is released from both 
resting and activated platelets to regulate platelet reactivity (Beaulieu and 
Freedman, 2013).  
 
PGI2 is a potent vasodilator and antithrombotic, and it also inhibits the growth of 
SMCs (Beaulieu and Freedman, 2013). PGI2 binds to platelet IP receptors to 
mediate activation of adenylyl cyclase, which leads to an increase in cAMP and 
reduced intracellular calcium (Mitchell et al., 2008). The biosynthesis of PGI2 is 
part of the arachidonic pathway, the same pathway that produces TXA2. It is 
synthesised in endothelial cells and SMCs, but not platelets (Beaulieu and 
Freedman, 2013).  
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In addition to PGI2 and NO, ecto-nucleotidases play an important inhibitory role 
in modulating platelet reactivity. They rapidly hydrolyse activatory ATP and ADP 
to AMP and adenosine, which negatively regulates platelet activity (Lunkes et al., 
2008). These include the nucleoside triphosphate diphosphohydrolase 
(NTPDase), CD39, and the 5’-nucleotidase, CD73, located in the platelet 
membrane.  
 
There is an interplay between the endothelial-derived anti-aggregatory molecules 
and the platelet-derived pro-aggregatory molecules. For example, the activation 
of the P2Y12 receptor by ADP causes inhibition of sAC and this reduces the ability 
for PGI2 (acting through IP receptors) to elevate cAMP, (Cattaneo and Lecchi, 
2007). Therefore, inhibition of the P2Y12 receptor potentiates the inhibitory effects 
of PGI2. In addition to this, Kirby et al. (2013) reported that the ability of NO to 
inhibit platelet aggregation was largely dependent on the inhibition of the P2Y12 
receptor. This is despite the fact that NO acts through a different platelet pathway 
to PGI2, by activating sGC and causing increased cGMP. Another study has 
demonstrated that ADP-induced secondary aggregation is dependent on the 
inhibition of ecto-nucleotidases (Jones et al., 2011). 
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1.6 Platelet Dysfunction in Type 2 Diabetes 
 
The importance of platelets in atherothrombosis has led to the development of 
antiplatelet drugs, such as aspirin and clopidogrel, to reduce the risk of 
cardiovascular events. Although most antiplatelet drugs irreversibly inactivate 
platelet function (Angiolillo, 2009), large-scale studies indicate that type 2 diabetic 
patients are less responsive to the medication than non-diabetic patients (Mehta 
et al., 2000; Ogawa et al., 2009; Belch et al., 2008). Numerous studies have 
reported that type 2 diabetic patients exhibit enhanced platelet activation and 
aggregation (Vinik et al., 2001), and reduced sensitivity to antiplatelet drugs 
(Angiolillo et al., 2005; Schuette et al., 2015). They also exhibit increased 
expression of membrane receptors such as P2Y12 (Hu et al., 2017). There is a 
large body of data suggesting potential mechanisms responsible for the 
enhanced platelet reactivity including elevated release of TXA2 (Halushka et al. 
1981; Davi et al., 1982), reduced sensitivity to the platelet inhibitors NO and PGI2 
(Nolan et al., 1994; Akai et al., 1983), and increased expression of the activation-
dependent adhesion molecules IIb3 and P-selectin (Angiolillo, 2005), however 
the mechanisms are not fully understood. 
 
Type 2 diabetes is multifactorial and associated with biochemical factors such as 
hyperglycaemia, insulin resistance, hyperlipidaemia, chronic inflammation and 
oxidative stress (Kakouros et al., 2011). Although there has been a large amount 
of research focusing on platelet dysfunction in diabetes, a direct connection 
between platelet hyperreactivity and diabetic characteristics has yet to be firmly 
established. Identifying the specific biochemical alterations in diabetic patients 
that correlate with platelet reactivity, could be a useful tool for identifying patients 
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at increased risk of thrombosis and those who would therefore benefit from 
antithrombotic therapy. Understanding the mechanisms responsible for altered 
platelet function and antiplatelet resistance will also facilitate the development of 
novel, more efficacious antiplatelet treatment for these high-risk patients.  
 
The following sub-chapters discuss the literature that has focused on the 
association between platelet hyperreactivity and biochemical risk factors 
(including hyperglycaemia, insulin resistance, hyperlipidaemia and 
inflammation), and highlights the conflicting views that emphasizes the need for 
further research in this field. 
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1.7 Hyperglycaemia and Platelet Dysfunction 
 
Hyperglycaemia is a hallmark of diabetes, and large-scale studies have shown a 
strong relationship between hyperglycaemia and cardiovascular disease in type 
2 diabetic patients. A recent observational study of more than 32,700 type 2 
diabetic patients reported that an HbA1c result over 64 mmol/mol increases the 
risk of macrovascular complications (van Wijingaarden et al., 2017). An 
observational study of more than 3,600 type 2 diabetic patients demonstrated 
that a 1% reduction in HbA1c was associated with a risk reduction of 14% for 
myocardial infarction and 37% for microvascular complications (Stratton et al., 
2000).  A meta-analysis of published data from twenty studies demonstrated that 
a 4.2 to 9 mmol/L rise in FBG increased the relative risk of cardiovascular events 
from 1 to 2.2 (Coutinho et al., 1999). In addition, a meta-analysis of four large 
studies that measured cardiovascular outcomes from intensive glycaemic control 
in type 2 diabetic patients, showed a 15% reduced risk of myocardial infarction 
and 9% reduction in major cardiovascular events (Turnbull et al., 2009).   
 
Although intensive glycaemic control appears to reduce the risk of cardiovascular 
events, the Action to Control Cardiovascular Risk in Diabetes (ACCORD) study 
reported a previously unrecognised harm of intensive glucose lowering in type 
diabetic patients with a target <48 mmol/mol (6.5%) HbA1c (Gerstein et al., 
2008). The ACCORD study was terminated due to increased mortality in the 
intensively treated group, creating an ongoing debate on the potential link 
between hypoglycaemia and increased rate of cardiovascular disease in type 2 
diabetic patients. Consequently, the optimal glucose level remains unknown 
(Ferreiro et al., 2010).   
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The increased risk of cardiovascular risk can exist for many years before the 
onset of hyperglycaemia (Schofield et al., 2016). During this period, patients show 
symptoms of metabolic syndrome, which include obesity, insulin resistance, 
hypertension and dyslipidaemia. The United Kingdom Prospective Diabetes 
Study (UKPDS) observed that one in six newly diagnosed type 2 diabetic patients 
had evidence of previous silent myocardial infarction (Davis et al., 2013). 
Indicating that other risk factors may lead to the early development of CAD.  
 
Chronic hyperglycaemia is associated with the accumulation of endogenous 
AGEs, formed by the non-enzymatic reaction (Maillard reaction) between a 
carbonyl group of reducing sugars and the free amino groups from proteins, 
phospholipids and nucleic acids (Chilelli et al., 2013). Binding of AGEs to the 
receptor for advanced glycation end-products (RAGE) enhances oxidative stress, 
inflammation and apoptosis (Stirban et al., 2014). A key mediator of RAGE 
signalling is nuclear factor kappa-light-chain-enhancer of activated B cells (NF-
), which translocates to the nucleus where it increases transcription of 
proinflammatory and prothrombotic genes (Li and Schmidt, 1997).   
 
Western diet is related to the accumulation of circulating AGEs in type 2 diabetes, 
and this was associated with an increase in markers for inflammation and 
endothelial dysfunction (Negrean et al., 2007). Incubation of platelets with AGEs 
derived from Coca-Cola™ increased the expression of platelet activation markers 
up to 7.1-fold, whilst increasing expression of the receptor for AGEs, RAGE 
(Gawlowski et al., 2009). Though no evidence of an AGE-RAGE interaction was 
confirmed. A later study showed that platelets express RAGE on their surface 
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(Zhu et al., 2012). However, treatment of platelets with a RAGE-blocking antibody 
did not affect specific binding of AGE to the platelet surface. Given that platelets 
do not have nuclei, and that RAGE induces signalling through the transcription 
factor NF-, it is unclear what role RAGE plays in platelets. Of note, Zhu et al. 
(2012) did identify AGEs bound to platelet CD36 a scavenger receptor that 
recognises modified lipoproteins.  
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1.7.1 Platelet Indices and Hyperglycaemia 
  
Platelet indices are a group of platelet parameters measured using an automated 
haematologic analyser and includes platelet count, mean platelet volume (MPV), 
platelet distribution width (PDW) and platelet-larger cell ratio (P-LCR) (Budak et 
al., 2016). MPV quantifies the average size of the platelet population. It is used 
as a biomarker for platelet activation because the larger platelets tend to be 
younger and more reactive (Grove et al., 2011). MPV is associated with cytokines 
(e.g. thrombopoietin, interleukin (IL)-6 and IL-3) that regulate megakaryocyte 
ploidy and platelet number, and result in the production of larger platelets (Budak 
et al., 2016). When platelet production is decreased, younger platelets become 
bigger and more active, and MPV levels increase. PDW is an indicator of volume 
variability in platelet size and reflects the heterogeneity in platelet morphology, 
and P-LCR is an indicator of circulating larger platelets (>12 fL), presented as a 
percentage (Budak et al., 2016).  
 
Several studies have investigated the relationship between MPV and 
hyperglycaemia ex vivo. The majority of them found a positive correlation 
between high MPV and HbA1c in type 2 diabetic patients (Demirtunc et al., 2009; 
Kodiatte et al., 2012; Ozder and Eker, 2014; Ulutas et al., 2014). However, data 
from Hekimsoy et al. (2004) found no relationship between HbA1c and MPV (see 
table 1.2). 
 
Data from studies investigating the relationship between MPV and FBG is more 
inconsistent. Some report a strong relationship between FGB and MPV in type 2 
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diabetic patients (Kodiatte et al., 2012; Ozder and Eker, 2014; Ulutas et al., 2014) 
and other studies found no relationship (Demirtunc et al., 2009; Hekimsoy et al., 
2004) (see table 1.3). In addition, Shimodaira et al. (2013) found a relationship 
between MPV and FBG in prediabetic subjects. The contradictory data from ex 
vivo studies questions the use of MPV as a marker for cardiovascular risk in 
patients with hyperglycaemia. 
 
Although the data is contradictory for correlations between MPV and 
hyperglycaemia, several studies have calculated a significant difference between 
type 2 diabetic patients and non-diabetic subjects (Demirtunc et al., 2009; 
Kodiatte et al., 2012; Ozder and Eker, 2014; Ulutas et al., 2014). These include 
studies that found no relationship between MPV and HbA1c (Hekimsoy et al. 
(2004) and Pananas et al. (2004) (see table 1.4), indicating that additional factors 
are involved.  
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Table 1.2: Relationship between MPV and HbA1c in type 2 diabetic patients  
 
Source of data MPV (fL) 
(mean + SD) 
HbA1c (%) 
(mean + SD) 
R value P value n 
Kodiatte et al (2012) 8.29 + 0.735 9.13 + 2.5 0.29 <0.001 300 
Demirtunc et al. (2009) 8.7 + 0.8 8.4 + 1.2‡ 0.394 0.001 35 
Ozder and Eker (2014) 10.66 + 0.94 8.80 + 1.62 0.357 0.000 201 
Ulutas et al. (2014) 8.3 + 1.3 9.6 + 2.3‡ 0.393 <0.001 32 
Hekimsoy et al. (2004) 10.62 + 1.71 7.49 + 1.5 -0.033 0.74 NS 145 
 
‡Diabetic cohort with an HbA1c >7% was used. NS: data is not significant. 
 
Table 1.3: Relationship between MPV and FBG in type 2 diabetic patients 
 
Source of data MPV (fL) 
(mean + SD) 
FBG (mmol/L) 
(mean + SD) 
R value P value n 
Kodiatte et al (2012) 8.29 + 0.735 8.35 + 3.98 0.269 <0.001 300 
Demirtunc et al. (2009) 8.7 + 0.8 12.21 + 4.2‡ Not 
reported 
NS 35 
Ozder and Eker (2014) 10.66 + 0.94 12.25 + 3.50 0.306 0.000 201 
Ulutas et al. (2014) 8.3 + 1.3 13.68 + 4.57‡ 0.41 <0.001 32 
Hekimsoy et al. (2004) 10.62 + 1.71 9.38 + 2.89 0.099 0.24 NS 145 
 
*Diabetic cohort with an HbA1c >7% was used. NS: data is not significant. 
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Table 1.4: Mean MPV in type 2 diabetic subjects and non-diabetic subjects 
from six separate literature sources 
 
Source of data MPV (fL) in non-
diabetics 
(mean + SD) 
N MPV (fL) in type 2 
diabetic patients 
(mean + SD) 
n 
 
P value 
Kodiatte et al (2012) 7.47 + 0.726 300 8.29 + 0.735 300 <0.001 
Demirtunc et al. (2009) 8.2 + 0.7 40 8.7 + 0.8‡ 35 0.002 
Ozder and Eker (2014) 10.04 + 1.01 201 10.66 + 0.94 201 0.000 
Ulutas et al. (2014) 7.1 + 1.0 40 8.3 + 1.3‡ 32 <0.001 
Hekimsoy et al. (2004) 9.15 + 0.86 100 10.62 + 1.71 145 0.00 
Pananas et al. (2004) 7.1 + 1.2 151 14.2 + 2.2 131 0.01 
 
‡Diabetic cohort with an HbA1c >7% was used. This cohort is considered to have uncontrolled 
diabetes. All studies used the unpaired t-test except those marked with a ‡ that used the one-way 
ANOVA.  
  
 
In contrast to the data shown in table 1.4, Shlomai et al. (2015) calculated an 
MPV of 9.2 + 1.3 fL for both diabetic and non-diabetic patients (n=82 and n=86, 
respectively). This is an important finding because this was a well-designed study 
with stringent exclusion criteria. The two groups were matched for age, body 
mass index (BMI), hypertension, hyperlipidaemia, smoking, medication, co-
morbidities and renal function. All diabetic subjects had well controlled glycaemia 
(the mean HbA1c was 49.7 mmol/mol) and no prior ischemic events. Conversely, 
the limitation of the study was that the diabetic patients had good glycaemic 
control so any possible effects caused by chronic hyperglycaemia may not have 
been observed.  
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It is interesting to note that there was no correlation for MPV vs. duration of 
diabetes (Kodiatte et al., 2012; Demirtunc et al. 2009; Hekimsoy et al., 2004) and 
no significant correlation was shown for MPV vs. vascular complications 
(Demirtunc et al., 2009; Kodiatte et al., 2012). Demirtunc et al. (2009) 
hypothesised that this was caused by the rapid consumption of activated platelets 
in diabetic patients with complications. This is supported by literature that 
investigated MPV in other diseases. For example, Bilen et al (2015) found a 
decrease in MPV in non-diabetic patients with renal failure. In patients with high-
grade inflammatory disorders such as rheumatoid arthritis and systemic lupus 
erythematosus, MPV can be low during the active stage of the disease, 
suggesting that the larger, more active platelets are consumed at the sites of 
inflammation (Gasparyan et al., 2011).  
  
Although the majority of the literature indicates that MPV is increased in type 2 
diabetic patients compared to those without diabetes, it is important to note that 
there was no definitive explanation for this outcome. For example, ex vivo studies 
cannot demonstrate whether the high MPV is simply caused by osmotic swelling 
due to raised levels of glucose metabolites. Alternatively, the increased MPV in 
type 2 diabetes could be an indication of a direct increase in thrombopoiesis or 
enhanced platelet turnover caused by their propensity to atherosclerosis. 
Therefore, if an atherosclerotic plaque ruptures, platelets are required to plug the 
damaged site and so the bone marrow produces more platelets (Kodiatte et al. 
2012).  
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1.7.2 Platelet Production and Hyperglycaemia  
 
Larger platelets are metabolically and enzymatically more active, and have 
greater prothrombotic potential. Furthermore, they are often immature platelets 
that contain residual messenger ribonucleic acid (mRNA) and a greater number 
of dense granules (Mijovic et al., 2015). They are called reticulated platelets due 
to the staining pattern of the cytoplasmic mRNA distribution. A pilot study using 
type 2 diabetic patients (n=30) and non-diabetic controls (n=49), showed that the 
percentage of reticulated platelets in type 2 diabetic patients was significantly 
higher than non-diabetic subjects (Mijovic et al., 2015).  Additionally, Cesari et al. 
(2013) identified a higher percentage of reticulated platelets in those that died 
within a year of being diagnosed with acute coronary syndrome (ACS).  
 
Aspirin is the most widely used drug for the prevention of cardiovascular disease. 
It irreversibly blocks the COX-1 enzyme, inhibiting the platelets for their entire life, 
yet diabetic patients have a lower response to aspirin than non-diabetic patients 
(Angiolillo, 2009). Insufficient platelet inhibition could be explained by increased 
thrombopoiesis, yielding an increased subpopulation of younger, more reactive 
platelets (Grove at al., 2011). Newly produced platelets are more capable of 
producing membrane and secretory proteins because of the considerable amount 
of megakaryocyte-derived mRNA. This could give rise to more reactive platelets 
that are less able to respond to antiplatelet therapy or a subpopulation of newly 
formed platelets that have not been exposed to appropriate doses of aspirin. 
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The rate of thrombopoiesis can be quantified using flow cytometry with 
fluorescent staining of RNA. It can be measured as absolute immature platelet 
count (IPC), or immature platelet fraction (IPF) as a ratio of immature platelets to 
total platelet count and is given as a percentage (Grove at al., 2011). In a study 
looking at both IPC and IPF in a cohort with stable CAD, Grove et al. (2011) 
identified a 17-21% rise in immature platelets in the type 2 diabetic sub-group. 
Interestingly, they noted that IPC significantly correlated with platelet aggregation 
and sP-selectin in the CAD population, whereas IPF did not. Furthermore, IPC 
was not dependent on the total platelet count.  
 
Neergaard-Petersen et al. (2015) also looked at platelet turnover in a CAD 
population but in relation to hyperglycaemia. They separated the groups into non-
diabetic, prediabetic and type 2 diabetes. This was a beneficial study because 
the prediabetic cohort had moderately elevated glucose levels but were not taking 
antidiabetic treatment. All participants were treated with low dose aspirin. A 
number of important findings were reported: 
 
1. CAD patients with diabetes had higher platelet aggregation, sP-selectin 
levels and platelet turnover compared with non-diabetic CAD patients.  
2. Platelet count and MPV did not differ between the non-diabetic and 
diabetic CAD patients. 
3. Prediabetic patients had increased aggregation, platelet count and platelet 
turnover compared with the non-diabetic cohort. However, they did not 
have increased sP-selectin levels. 
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4. HbA1c correlated significantly with platelet aggregation, sP-selectin, IPC 
and platelet count in the whole CAD population; but did not correlate with 
MPV and IPF.  
5. Most importantly, HbA1c did not correlate with platelet aggregation, sP-
selectin, platelet turnover, platelet count and MPV in the diabetic cohort 
alone. However, it did correlate with all parameters in the non-diabetic 
CAD cohort. 
 
Neergaard-Petersen et al. (2015) hypothesised it is the antidiabetic treatment, 
such as Metformin and insulin, that partly explains the lack of correlation between 
HbA1c and platelet reactivity in the diabetic patients with CAD. Literature into the 
effect of Metformin on platelets is limited, although MPV was shown to 
significantly reduce baseline MPV in type 2 diabetic patients after six months of 
treatment (Dolasık et al., 2013). Additionally, studies related to the effect of insulin 
on platelet reactivity is contradictory (Trovati et al., 1988; Yngen et al, 2001; 
Rauchfuss et al., 2008). It is also interesting to note that the platelet count was 
elevated in the prediabetic cohort but not the diabetic cohort.  
 
More recently, Fidler et al. (2017) showed that glucose metabolism is required for 
megakaryocyte-mediated platelet production. Glucose transporter (GLUT) 1 and 
GLUT3 double knock-out mice developed thrombocytopenia through decreased 
platelet production and increased platelet clearance. Although megakaryocyte 
density in the bone marrow was unchanged, the inability of the megakaryocytes 
to take up glucose almost completely abolished their ability to produce platelets.  
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1.7.3 Platelet Activation and Hyperglycaemia 
 
Many studies have investigated hyperglycaemia as a risk factor for increased 
platelet activation and aggregation, though studies have shown conflicting data. 
Singer et al. (2014) measured platelet aggregation and sP-selectin in thirty 
diabetic patients before and after glycaemic control over a four-month period. The 
mean HbA1c at baseline was 9.4% (79.2 mmol/mol) and decreased to 8.1% (65 
mmol/mol). Singer et al. (2014) did not find a significant difference in platelet 
aggregation stimulated with arachidonic acid and ADP using light transmission 
aggregometry (LTA). Neither did they find a significant difference in P-selectin.  
 
Following ADP activation, Shlomai et al. (2015) looked at markers for P-selectin 
expression and IIb3 activation in diabetic and non-diabetic participants, closely 
matched for a number of clinical characteristics. Using flow cytometry, they found 
no significant difference between the percentage of cells positive for P-selectin 
expression and IIb3 activation. However, the diabetic cohort had good 
glycaemic control and this could be the reason for the lack of difference between 
the two groups.   
 
A small study using type 2 diabetic and non-diabetic participants (n=14 and n=7, 
respectively) identified a significant increase in P-selectin expression and IIb3 
activation in response to ADP in both cohorts, after whole blood was incubated 
with 25 mmol/L glucose for one hour (Keating et al., 2003). They concluded that 
acute hyperglycaemia has a direct effect on platelet activity as a result of changes 
in osmolarity. Sudic et al. (2006) showed that 30 mmol/L glucose increased ADP-
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stimulated P-selectin expression but not IIb3 activation in whole blood. 
However, whole blood stimulated with thrombin receptor-activating peptide 
(TRAP) showed an increase in both P-selectin expression and IIb3 activation 
with 30 mmol/L glucose (Sudic et al., 2006).  
 
Tang et al. (2011) demonstrated that 25 mmol/L glucose increased platelet 
aggregation and P-selectin expression in platelet rich plasma (PRP) with collagen 
but not with ADP. De la Cruz et al. (2004) demonstrated a dose-dependent 
increase in platelet aggregation with both collagen and ADP stimulation in whole 
blood, using lesser physiological glucose concentrations (5-16 mmol/L). 
Additionally, acute hyperglycaemia significantly elevated P-selectin expression in 
platelets from type 2 diabetic males compared to healthy controls following an 
oral glucose tolerance test (Yngen et al., 2001).  
 
Clearly there is conflicting data to show whether acute hyperglycaemia has an 
effect on platelet activation and aggregation. Notably with ADP and collagen-
stimulated platelet reactivity using healthy blood. There may be lots of variables 
between the studies (e.g. agonist concentration, glucose concentration, flow 
cytometry thresholds) which are affecting the outcomes of the studies. Further 
research is required to investigate the effect of glucose on platelets.  
 
 
 
 
 
34 
 
1.7.4 Platelet inhibition and hyperglycaemia 
 
Type 2 diabetes is associated with endothelial dysfunction, defined as an 
imbalance in the production of vasodilator factors that results in the predisposition 
towards prothrombotic effects (Dhananjayan et al., 2016). 
 
Endothelial dysfunction is commonly associated with the impairment of reduced 
NO bioavailability, resulting from altered eNOS expression (Schäfer and 
Bauersachs, 2008). Endothelial cells exposed to high glucose generate 
mitochondrial ROS and this leads to oxidisation of the eNOS co-factor, 
tetrahydrobiopterin, in a process known as “eNOS uncoupling” (Edelstein et al., 
2000).  
 
Loss of NO bioavailability has been suggested as a major contributor to platelet 
hyperreactivity in diabetes. Studies using mice with streptozoticin-induced 
diabetes have demonstrated that enhanced platelet reactivity (observed as 
reduced vasodilator-stimulated phosphoprotein (VASP) phosphorylation and 
increased surface expression of P-selectin, CD40L and activated IIb3) is 
abolished when eNOS-tetrahydrobiopterin dissociation is prevented in the 
vascular endothelium (Shäfer et al., 2004). 
 
Some in vitro studies have examined the effect of hyperglycaemia on the 
inhibitory mechanism of NO. Sudic et al. (2006) reported no influence of a NO 
synthase inhibitor on platelet activation under high glucose conditions, indicating 
that endogenous platelet NO is not impaired by high glucose. Aspirin has been 
reported to increase the synthesis of NO in platelets in the absence of endothelial 
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cells (Madajka et al., 2003), specifically through the acetylation of the platelet NO 
synthase type 3 (NOS-3) (O’Kane at al., 2009). Russo et al. (2012) found that 
high glucose had no effect on the NO/cGMP pathway per se, although it did 
impair the ability of aspirin to activate the NO pathway, potentially through the 
interference of NOS-3 acetylation by ROS. 
 
Studies have also found a relationship between hyperglycaemia and ecto-
nucleotidase activity. Lunkes et al. (2003) found that ecto-nucleotidase activity 
was increased in diabetic patients, even though they have a predisposition to 
thrombus formation. To further investigate this paradox, Lunkes et al. (2008) 
evaluated the effect of different glucose levels on the hydrolysis of adenine 
nucleotides, and measured CD39 expression in type 2 diabetic and hypertensive 
patients. They reported a dose-dependent increase in ecto-nucleotidase activity 
with increasing glucose (5-30 mmol/L). They also observed a significant increase 
in CD39 platelet membrane expression of diabetic and hypertensive patients. 
Taking these findings into consideration, it is possible that the rise in ecto-
nucleotidadse activity in high glucose is a compensatory mechanism to 
circumvent platelet hyperreactivity, and that this mechanism of thrombo-
regulation is not working efficiently in diabetic and hypertensive patients.  
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1.8 Insulin Resistance and Platelet Dysfunction 
 
Individuals can exhibit insulin resistance and subsequent hyperinsulinemia for 
more than twenty years before developing type 2 diabetes, and apoptosis of 
pancreatic -cells leads to a relative deficiency of insulin (Schneider, 2009a). A 
human platelet has about 570 insulin receptors (Hajek et al., 1979), therefore, 
insulin should be a prominent target of interest for research into platelet 
hyperreactivity in diabetes. Research into the effect of insulin on platelet function 
is, however, less than consistent. Insulin has been reported to inhibit (Trovati et 
al., 1988) increase (Yngen et al. 2001) and not have any effect on platelet function 
(Rauchfuss et al., 2008).  
 
Early research into the effect of insulin on platelet function was carried out by 
Trovati et al. (1988). They incubated PRP with insulin from fasting healthy 
subjects and observed a significant reduction in platelet activity to a number of 
aggregating agents including ADP and collagen. They also noticed that insulin 
had both dose and time-dependent effects on the platelets. They later 
demonstrated that insulin can inhibit platelet activation by increasing intraplatelet 
concentrations of the inhibitory second messengers, cGMP and cAMP (Trovati et 
al., 1994, Trovati et al., 1997). These second messengers act predominantly to 
reduce cytosolic calcium by different mechanisms within platelets (Trovati and 
Anfossi, 1998).  The team also showed that insulin-induced cGMP and cAMP 
increase is mediated by the platelet inhibitor, NO (Trovati et al., 1997).  
 
Contrary to this, evidence suggests that insulin can enhance platelet activation. 
Yngen et al. (2001) performed whole blood flow cytometry and LTA using blood 
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from healthy subjects. Both the whole blood and PRP was incubated with varying 
concentrations of insulin (1-10,000 U/ml) and induced with 0.3 M ADP. When 
using flow cytometry, a small, but significant, enhancing effect was shown with 
physiological concentrations of insulin (<100 U/ml). The greater enhancing 
effects were shown for IIb3 activation at supraphysiological concentrations of 
insulin (>100 U/ml). P-selectin was less affected by insulin. It is interesting to 
note that with a higher concentration of ADP (1 M), insulin only had a slight 
enhancing effect on IIb3 activation and no effect on P-selectin. They observed 
no change with the addition of glucose or calcium. This both challenges and 
agrees with the data obtained by Anfossi et al. (1996) who showed that ADP-
induced platelet aggregation decreased with physiological and slight 
supraphysiological concentrations of insulin (35-280 U/ml) and increased with 
highly supraphysiological concentrations (>3,500-28,000 U/ml). To support this 
data, they demonstrated that intraplatelet cGMP levels increased with 
physiological insulin concentrations and decreased with highly 
supraphysiological insulin concentrations. A very early publication has provided 
a possible explanation for insulin’s ability to enhance platelet aggregation. Lopez-
Aparicio et al. (1992) revealed that insulin can induce phosphorylation and 
activation of the cGMP-inhibited cAMP phosphodiesterase (PDE) 3 in human 
platelets, leading to a decrease in cAMP and subsequent increase in platelet 
aggregation.  
 
It has been suggested that one of the reasons for the varying platelet responses 
to insulin could be different sources of insulin and solvents. Rauchfuss et al. 
(2008) tested a commercially available insulin with the solvent and the solvent 
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alone. They showed that the pure solvent activated platelets similarly to the 
insulin/solvent mixture. Subsequently, the research team used an insulin 
polypeptide dissolved in pure water for further experimentation. Interestingly, they 
demonstrated that the pure form of insulin failed to alter thrombin-stimulated IIb3 
activation or P-selectin expression using flow cytometry. Furthermore, western 
blot analysis of platelets co-incubated with thrombin and insulin revealed that 
insulin failed to alter phosphorylation of intracellular platelet activation markers: 
protein kinase B (PKB), p38 mitogen-activated protein kinase (MAPK) and 
extracellular signal-regulated kinase (ERK) (Rauchfuss et al., 2008). It also failed 
to alter phosphorylation of the intracellular marker of platelet inhibition, VASP. To 
support this, they showed that insulin did not alter ADP, collagen or thrombin-
induced platelet aggregation, nor did it affect calcium mobilisation, confirming that 
insulin does not have a direct effect on platelet function. Additionally, western blot 
analysis showed that insulin stimulation causes phosphorylation of the insulin 
receptor (IR), endothelial nitric oxide synthase (eNOS), and downstream kinases 
(ERK, p38 MAPK and PKB) in endothelial cells but not platelets (Rauchfuss et 
al., 2008). The data does not directly prove that IR is not expressed in platelets, 
but indicates that either there is no functionally active IR expressed in platelets 
or that the copy number is too low to activate downstream protein kinases. Using 
flow chamber experiments, Rauchfuss et al. (2008) detected an insulin-
dependent increase of endothelial NO production that caused a significant 
reduction in platelet adhesion, indicating that insulin reduces platelet activation 
by direct action on endothelial cells rather than platelets. 
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Haeften et al. (2006) reported that insulin inhibited platelet aggregation in healthy 
subjects but that this inhibition was reduced in type 2 diabetic patients. Patients 
with prediabetes or early stages of type 2 diabetes have increased levels of 
circulating insulin, known as hyperinsulinemia (Kakouros et al., 2011). 
Presumably, this is the body’s compensatory response to insulin resistance. 
Taking this into consideration, it would be expected that hyperinsulinemia would 
suppress platelet activity. However, this is not the case in obesity, a common trait 
in type 2 diabetes.  In a study using insulin infused platelets from non-obese 
healthy participants and obese healthy participants, collagen-stimulated platelet 
aggregation was significantly reduced in the non-obese group but not the obese 
group (Westerbacka et al., 2002), indicating that obesity may abolish the 
inhibitory effect of insulin. 
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1.9 Dyslipidaemia and platelet dysfunction 
 
Type 2 diabetes is associated with atherogenic dyslipidaemia, and it is 
characterised by the following lipid abnormalities: elevated low-density 
lipoprotein-cholesterol (LDL-C), greater number of smaller LDL particles, 
decreased levels of high-density lipoprotein-cholesterol (HDL-C) and increased 
triglycerides (Bell et al., 2011).  
 
A recent study consisting of fifty obese type 2 diabetic and fifty obese non-diabetic 
subjects, showed a significant increase in the levels of serum LDL-C, triglycerides 
and very low-density lipoprotein-cholesterol (VLDL-C) in the diabetic group 
(Songa et al., 2015). They also found a significant decrease in serum HDL in the 
diabetic cohort. There was no significant difference between the levels of total 
cholesterol. Conversely, the Strong Heart Study identified lower levels of LDL-C 
in American Indians when compared against non-diabetics from the same 
population (Howard et al., 2000). Another study examined the lipid profiles of 
African American and white patients with non-insulin dependent diabetes mellitus 
(NIDDM) (Cowie et al., 1994). They found that the mean LDL-C was significantly 
lower in the diabetic African American population when compared to the non-
diabetic African American group, but the LDL-C was slightly higher in diabetic 
subjects in the white population.  
 
For many years, the benefits of intervention on lipoproteins as cardiovascular risk 
factors in diabetes was uncertain and this was because diabetic people were 
excluded from trials of lipid-lowering therapies (Viljoen et al., 2017). However, 
LDL-C is now considered a high-risk factor for cardiovascular disease in diabetic 
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patients. In the Strong Heart Study, Howard et al. (2000) reported that a 10 mg/dL 
increase in LDL-C was associated with a 12% increase in cardiovascular risk. In 
addition to this, a meta-analysis of diabetic patients (n= 18,686) in fourteen 
randomised trials of statins, showed a 21% reduction in major vascular events 
per mmol/L reduction in LDL-C (Cholesterol Treatment Collaborators, 2008). 
However, the same effect was found in non-diabetic people (n=71,370), 
indicating that LDL-C is a major risk factor for cardiovascular disease but it may 
not have a direct effect on cardiovascular risk in diabetes per se.   
 
LDL-C is a measure of the total cholesterol content within LDL particles, with 
regards to both the number of LDL particles and their individual cholesterol 
content (Wadhera et al., 2016). Circulating LDL particles are able to penetrate 
the endothelium, become oxidised and promote inflammation (Hadi and Suwaidi, 
2007). A persistent elevation of LDL-C is linked to early stage fatty streaks that 
narrow the lumen and progress to more unstable plaques that can rupture and 
form a clot. For example, LDL-receptor deficient mice that are unable to clear 
LDL from the circulation, develop severe atherosclerotic lesions (Véniant et al., 
2000).  
 
LDL is a spherical particle which transports esterified cholesterol and triglycerides 
in a hydrophobic core, surrounded by a monolayer of phospholipids and 
unesterified cholesterol (Akkerman, 2008). It is enclosed by the apolipoprotein 
B100 (Apo100) molecule that renders the particle water-soluble. LDL are a 
heterogeneous collection of particles which vary in size, density and lipid 
composition (Berneis and Krauss, 2002). It has been shown that increased levels 
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of small dense, triglyceride-rich, LDL particles have been associated with 
increased cardiovascular risk (Vergés, 2009). In the Strong Heart Study that 
found lower levels of LDL-C in the diabetic American Indian population, they also 
reported significantly elevated small dense LDL (sd-LDL) in the diabetic cohort 
compared with the non-diabetic subjects (Howard et al., 2000).  
 
Having high levels of sd-LDL increases the risk of cardiovascular disease 
because this type of lipoprotein cannot be cleared by hepatocytes and remains 
in the plasma for a longer period. Gaelano et al. (1998) showed evidence that 
this was because sd-LDL has less affinity for LDL receptors and increased 
binding to cell surface proteoglycans of the arterial matrix.  
 
Sd-LDL is more susceptible to chemical modification (e.g. glycation or oxidation) 
and this renders it more atherogenic (Wadhera et al., 2016). Glycation of LDL 
occurs due to the non-enzymatic reaction of glucose and its metabolites with the 
free amino acids in lysine-rich LDL (Younis et al., 2008). Higher concentrations 
of glycated sd-LDL are present in diabetes patients than those without diabetes. 
Oxidation of LDL occurs by a process involving lipid peroxidation (Parthasarathy 
et al., 2010). During this process free radicals take electrons from the lipid 
membranes to form secondary products, resulting in cell damage. The oxidation 
of LDL is a complex process and many different secondary products can be 
formed depending on the type of oxidant, the duration of oxidation and the 
presence or absence of other agents such as redox metals (Parthasarathy et al., 
2010). Ox-LDL accumulates in atherosclerotic plaques and there is ~6 fold more 
ox-LDL in atherosclerotic plaques than in normal intima (Korporaal et al., 2005).  
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Early studies with animals showed that antioxidants could reduce 
atherosclerosis. For example, rabbits fed a 1% cholesterol diet with or without the 
antioxidant butylated hydroxytoluene (BHT) developed typical atherosclerotic 
lesions in the aorta, though the degree of atherosclerosis was considerably lower 
in the rabbits fed BHT (Björkhem et al, 1991). However, meta-analysis data for 
large clinical trials of anti-oxidants such as vitamin E and -carotene 
demonstrated no benefit to cardiovascular outcomes (Kris-Etherton et al., 2004). 
This then prompts the question: is the oxidative modification hypothesis relevant 
to human disease? Those who have done intensive research into ox-LDL would 
argue that the optimum antioxidant dosage has simply not been determined, or 
that the appropriate antioxidant(s) only work in a subset of patients (Steinberg 
and Witztum, 2010). 
 
The evidence that LDL contributes to atherosclerosis is considerable, and as 
platelets play a key role in thrombotic complications, it is possible that LDL directly 
contributes to platelet hyperreactivity in atherothrombosis. Platelets have no 
nucleus and, thus, are unable to synthesise cholesterol (Colwell et al., 1992). 
Therefore, the source of this cholesterol must come from either the parent 
megakaryocyte or the plasma through the interaction with lipoproteins which 
transport cholesterol. Platelets have an n-LDL receptor, Apolipoprotein E 
Receptor 2’ (ApoER2’), a 130-kDa splice variant of apoER2 (Korporaal et al., 
2004). ApoER2’ is activated by contact with the apoB100 of LDL, called the B-
site. Receptor phosphorylation initiates signalling through p38MAPK and 
cytosolic phospholipase A2 leading to formation of TXA2 (Akkerman, 2008). TXA2 
further activates platelets by stimulating the TXA2 receptor, leading to IIb3 
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activation, and ligand-mediated inside-out signalling by IIb3 that induces a 
second wave of activating signals (Akkerman, 2008).  
 
Studies have shown a potential link between the ox-LDL scavenger receptor, 
CD36, and platelet hyperreactivity. Podrez et al. (2007) used apoe-/- / CD36-/- mice 
to demonstrate that diet-induced hyperlipidaemia promotes platelet 
hyperreactivity through the uptake of ox-LDL by CD36 on the platelet surface. 
Magwenzi et al. (2015), however only observed a moderate elevation in platelet 
reactivity by ox-LDL, but demonstrated that ox-LDL can induce the generation of 
platelet ROS through CD36 via a NAD phosphate oxidase (NOX) 2 pathway. 
Furthermore, the NOX2-generated ROS activates platelets indirectly by blocking 
the ability of cGMP to inhibit platelet function, supporting the notion that platelet 
hyperreactivity in diabetes is caused by impaired sensitivity to platelet inhibitors.   
  
Nagy et al. (2011) demonstrated that the P2Y12 receptor pathway significantly 
amplified platelet responses of IIb3 in LDLR-/- mice with elevated cholesterol 
levels. Korporaal et al. (2005) investigated the association of both native-LDL (n-
LDL) and ox-LDL with CD36 in platelets, and its effect on IIb3 activation. They 
reported that n-LDL binds CD36 for <5 mins and ox-LDL is continually associated 
with CD36. Interestingly, they reported an inhibition in IIb3 activation when LDL 
was oxidised >30%. CD36 is known to associate with IIb3 on resting platelets 
(Dorahy et al., 1996) and co-localise with IIb3 and fibrinogen on activated 
platelets (Asch et al., 1985). Korporaal et al. (2005) determined that binding of 
ox-LDL to CD36 blocks binding of CD36 to IIb3, potentially interfering with 
fibrinogen-bound IIb3activation. It is unclear how CD36 is facilitating IIb3 
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activation, however, Kuijpers et al. (2014) reported an anchoring role for CD36 
and its ligand, thrombospondin-1 (a protein released from -granules), 
contributing to the stability of a thrombus.  
 
Hyperlipidaemia often accompanies hyperglycaemia in patients with type 2 
diabetes. To investigate if hyperglycaemia and/or hyperlipidaemia are 
responsible for the prothrombotic state in type 2 diabetes, Zhu et al. (2012) used 
a type 2 diabetic mouse model (DBD) fed a high fat/high fructose diet to induce 
both hyperlipidaemia and hyperglycaemia, and a control group fed a western diet 
to induce hyperlipidaemia but not hyperglycaemia (WD). Interestingly, they found 
that the time to carotid thrombosis was considerably shorter in the DBD mice than 
the WD mice, suggesting that hyperglycaemia is responsible for the 
prothrombotic state in the DBD model, possibly due to lipoprotein modification. 
They also found that a CD36 deletion rescued the carotid thrombi phenotype, 
supporting other studies that demonstrate the involvement of CD36 in thrombus 
formation. 
 
Altered lipid profiles in type 2 diabetic patients has also been demonstrated to 
impair bioavailability of endothelial-derived platelet inhibitors. Studies have 
shown that endothelial NO and PGI2 bioavailability is affected by ox-LDL which 
accumulates in the arterial wall. An early study showed that increased levels of 
ox-LDL interferes with the cAMP and cGMP pathways in isolated arteries (Galle 
et al., 1992). Furthermore, Wang et al. (2011) showed that ox-LDL upregulates 
arginase I which reduces l-arginine availability for eNOS, and this, in turn, 
compromises NO synthesis since arginase and NO share the substrate l-arginine. 
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These findings would suggest that the accumulation of modified lipoproteins in 
the endothelium causes impaired bioavailability of NO and PGI2, which ultimately 
leads to increased platelet activation. 
 
Other literature has shown that cholesterol accumulation disturbs the composition 
of membranes of hematopoietic cells, particularly in lipid rafts, and this enhances 
receptor signalling (Zhu et al., 2010; Yvan-Charvet et al, 2010). This may be 
important in regards to altered platelet signalling in diabetic patients and efficacy 
of antiplatelet medication. For example, P2Y12 has been shown to be located in 
lipid rafts (Quinton et al., 2005) and increased expression of P2Y12 has been 
reported in diabetic patients (Hu et al., 2017). Thus, plasma membrane 
cholesterol accumulation in platelets could potentially alter the membrane 
structure and affect signalling via surface receptors, such as P2Y12. Furthermore, 
this may contribute to antiplatelet resistance in type 2 diabetes. 
 
Although considerable data has concentrated on LDL-C as a potential 
atherogenic marker, Chan et al. (2014) investigated the relationship between 
both LDL-C and HDL-C with platelet reactivity in hyperlipidaemic patients. They 
identified a significant increase in P-selectin expression and IIb3 activation in 
patients with high LDL-C and low HDL-C, but no difference in patients with high 
LDL-C and normal HDL-C. This suggests that the cardio-protective properties of 
HDL-C have an effect on platelet reactivity. 
 
Triglycerides are formed from a single molecule of glycerol combined with three 
fatty acids (Viljoen et al., 2017). The two main sources of triglycerides are 
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exogenous (from dietary fats) carried in chylomicrons produced by the gut and 
endogenous sources carried by VLDL produced by the liver. A meta-analysis of 
262,525 participants found a strong association between serum triglyceride levels 
and cardiovascular risk in Western populations (Sarwar et al., 2007).  
 
Measurement of platelet aggregation with blood from hypertriglyceridemia 
patients cannot be implemented due to the turbid plasma samples, however, 
whole blood flow cytometry can be performed (De Man et al., 2000). Although no 
literature is available to show the relationship between triglycerides and platelet 
reactivity in diabetic patients, a small study (n=16) reported no association 
between high triglycerides and both P-selectin expression and IIb3 activation in 
hypertriglyceridemia patients (De Man et al., 2000).  
 
In conclusion, elevated LDL may contribute to platelet hyperreactivity in 
cardiovascular disease. However, thus far, no research has been obtained to link 
platelet activation with LDL metabolism in the type 2 diabetic population. 
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1.10 Obesity, Inflammation and Platelet dysfunction 
 
According to the World Health Organisation (2017) obesity is defined as BMI > 
30 kg/m2 and, at present, the prevalence of obesity is in the range of 15% to 35% 
in the adult populations of Europe, North America and many Arabic countries. 
Patients become insulin resistant almost always because of obesity and physical 
inactivity (Nussey and Whitehead, 2001). A recent analysis of the European 
Prospective Investigation into Cancer and Nutrition (EPIC)-Potsdam cohort 
revealed that a weight gain of 1 BMI unit between the age of 24 to 40 years 
increased the relative risk of type 2 diabetes by 25%, and, surprisingly, they were 
more at risk than those between the age of 40 and 55 years (Schienkiewitz et al., 
2006). This indicates that weight gain at early adulthood is related to a higher risk 
and earlier onset of type 2 diabetes, than is weight gain between 40 and 55 years 
of age.  
 
A small number of studies have investigated the relationship between obesity and 
platelet reactivity in type 2 diabetic patients. Akinsegun et al. (2014) identified a 
positive relationship between BMI and platelet count in type 2 diabetic patients, 
but no significant association between BMI and MPV. Schneider et al. (2009b) 
reported a correlation with BMI and ADP-induced P-selectin expression in type 2 
diabetic patients with CAD, but no correlation with IIb3 activation. 
 
As previously mentioned, platelet activation is counteracted by the inhibitors NO 
and PGI2, which act by increasing intracellular levels of cGMP and cAMP. Early 
studies reported that insulin had an anti-aggregatory effect on platelets by 
increasing the levels of cGMP and cAMP (Trovati et al., 1997). Interestingly the 
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same team identified that the anti-aggregating effect of insulin, mediated by NO-
induced increase of cGMP, was lost in obese subjects and obese subjects with 
type 2 diabetes but not lean type 2 diabetic (Anfossi et al., 1998). 
 
Obesity is commonly associated with low-level inflammation and insulin 
resistance. In 1993, Hotamisligil and co-workers identified the link between 
obesity and inflammation when it was shown that the inflammatory cytokine, 
tumor necrosis factor (TNF)-, was overexpressed in the adipose tissue of a 
rodent model for obesity. Diabetes often accompanies obesity, and Hotamisligil 
et al (1993) also found that obese mice lacking functional TNF- had a significant 
increase in uptake of glucose by insulin. Once this discovery was made, it 
became clear that many inflammatory mediators respond in a similar manner to 
TNF- in animal models of obesity (Wellen and Hotamisligil, 2005). 
  
A mechanism that may contribute to chronic inflammation in diabetes is oxidative 
stress (Wellen and Hotamisligil, 2005). Due to the increased delivery of glucose 
to the adipose tissue, endothelial cells in the fat pad may take up increasing 
amounts of glucose under hyperglycaemic conditions. These endothelial cells 
produce excess ROS in their mitochondria, which activates metabolic events in 
diabetes such as increased AGEs, PKC and NFactivation (De Bandiera et al., 
2013).  The binding of AGEs to endothelial cells may activate NFto induce 
expression of the leukocyte adhesion molecules vCAM-1, ICAM-1 and E-selectin 
(Basta e al., 2002). Furthermore, the gene regions NFand IL-6 are located at 
the RAGE promoter region, indicating that the expression of the RAGE receptor 
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influences inflammatory responses (De Bandiera et al., 2013, Nonaka et al., 
2018).  
 
The subsequent activation and recruitment of inflammatory cells, including 
monocytes and macrophages, results in enhanced cytokine synthesis and 
release (Lumeng et al., 2007). These cytokines, including TNF-, interleukin (IL)-
1 and IL-6; can downregulate cascades involved in insulin signalling in 
adipocytes, liver and muscle cells, enhancing insulin resistance and impaired 
glucose homeostasis (Badawi et al., 2010). Increased levels of these pro-
inflammatory cytokines lead to hepatic production and secretion of acute-phase 
proteins such as C-reactive protein (CRP) and plasminogen activator inhibitor-1 
(PAI-1) (Badawi et al., 2010). These proteins appear in the early stages of type 2 
diabetes, and their circulating concentrations increase as the disease 
progresses. For example, concentrations of IL-6, PAI-1, CRP, and fibrinogen 
were significantly higher in healthy subjects who became diabetic later in life 
(after 4–10 years) compared to those who did not develop the disease (Pradhan 
et al., 2001). Moreover, levels of pro-inflammatory cytokines (e.g. IL-6, IL-12, 
TNF-), endothelial dysfunction markers (vascular cell adhesion molecule-1 
(vCAM-1), intercellular adhesion molecule-1 (ICAM-1), and nitric oxide), and 
dyslipidaemia were highest in type 2 diabetic patients with cardiovascular 
complications (Mishra et al., 2011). Conversely, Al-Shukaili et al. (2013) reported 
decreased levels of the proinflammatory markers IL-6, IL-1 and TNF-in fifty-
seven type 2 diabetic patients compared to thirty controls, with no difference in 
the levels of lymphocytes. Although there is conflicting data with regards to 
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cytokine levels in type 2 diabetic patients, there does appear to be an alteration 
in the function of the immune system in these patients. 
  
Diabetic patients exhibit increased markers of both platelet activation and 
inflammation (Lim et al., 2004). Furthermore, studies have demonstrated that the 
serum level of chemokines can predict the development of atherosclerosis 
(Ardigo et al., 2007) and also predict acute cardiovascular events (Kraaijeveld et 
al., 2007). Accumulating research has identified platelets as key players in 
(thrombo-) inflammatory processes. In the mid 1990’s it was shown that resting 
and activated platelets could adhere to the vessel wall without vessel injury 
(Frenette et al., 1995). Furthermore, they showed that activated platelets 
preferentially bound leukocytes and this was dependent on the expression of 
endothelial P-selectin. In apoE deficient mice, it was demonstrated that platelets 
could bind to the endothelium before leukocyte invasion and before the 
development of atherosclerotic lesions (Massberg et al., 2002). Moreover, 
antibody blockade of GP1b prohibited leukocyte accumulation and decreased 
atherosclerotic lesion formation.  
 
Using intravital microscopy in mice treated with TNF-, neutrophils were 
visualised migrating to the walls of inflamed blood vessels (Sreeramkumar et al. 
2014). This was shown to be mediated by the platelet P-selectin receptor and 
PSGL-1 on neutrophils. Blocking this interaction reduced the risk of stroke in a 
mouse model for acute lung injury, highlighting the antithrombotic potential of 
PSGL-1.  
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As platelets move through the vasculature of inflamed tissue, they are exposed 
to a number of different inflammatory mediators such as lipid mediators, cytokines 
and chemokines released by activated leukocytes, endothelial cells and 
perivascular cells (Stokes and Granger, 2012). These mediators attach to platelet 
receptors to elicit dense and/or a-granule secretion and activation of platelet 
adhesion molecules. Soluble mediators that can activate platelets are lipid 
mediators (e.g. platelet activating factor (PAF)), cytokines (e.g. interferon-INF-
), interleukin-2 (IL-2) and chemokines (e.g. CXCL12, CCL22) (Gleissner et al., 
2008). 
 
In addition to this, platelets can themselves initiate inflammatory responses 
through their receptors (Vieira-de-Abreu et al., 2012).  For example, thrombin 
stimulates the activation of the mammalian target of rapamycin (mTOR) in 
platelets (Moore at al., 2014). The mTOR cascade mediates major immune 
responses, such as the activation and proliferation of T-cells (Thomson et al., 
2009), suggesting that thrombin may have unrecognised functions in immunity 
(Vieira-de-Abreu et al., 2012). The antagonist of the ADP receptor, clopidogrel, 
was reported to inhibit platelet-leukocyte adhesion (Evangelista et al., 2005), 
indicating that the P2Y12 pathway may be involved in platelet-dependent 
upregulation of inflammatory functions.  Lastly, it has been shown that T-cell 
proliferation is reduced in mice with a deficient TXA2 receptor (Thomas et al., 
2003). 
 
Several hormones and inflammatory mediators influence the release of platelets 
from megakaryocytes in the bone marrow including thrombopoietin (Sato et al., 
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1998) IL-1 and IL-6 (Jiang et al., 1994). Studies have shown that diabetic 
patients with nephropathy have increased platelet count (Sterner et al., 1998) and 
diabetic patients also have increased levels of immature platelets (Mijovic et al., 
2015). Platelet production is regulated to meet the demands for activated 
platelets in certain physiological conditions. In inflammatory disorders, the larger, 
more reactive platelets migrate to inflammatory sites where they are consumed, 
and this enhances thrombopoiesis to increase the quantity of circulating platelets. 
This results in a shift in platelet indices such as MPV and platelet count 
(Gasparyan et al., 2011).  
 
Evidence has accumulated suggesting an important role of MPV as a marker of 
inflammation because the size of circulating platelets is dependent on the 
intensity of the systemic inflammation. For example, it was reported that patients 
with systemic lupus erythematosus and rheumatoid arthritis patients have low 
MPV at the active stage of the disease (Turner-Stokes et al.,1991; Gasparyan et 
al., 2010) and it is thought that this is due to the increased consumption of 
platelets at the sites of inflammation (Gasparyan et a., 2011). 
 
Anti-platelet therapy has been important in preventing cardiovascular events in 
high-risk patients, including those with diabetes. Potentially combining anti-
platelet therapy with anti-inflammatory medication can further improve 
cardiovascular therapies in diabetic patients. 
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1.11 Research Aims and Objectives 
 
Previous research demonstrates that type 2 diabetic patients have hyperreactive 
platelets (Kakouros et al., 2011). However, it is not clear which of the biochemical 
factors related to the disease are responsible, such as hyperglycaemia, insulin 
resistance, chronic inflammation or elevated cholesterol levels. It is also unclear 
whether platelet hyperreactivity in diabetes is intrinsic to the platelet or a 
consequence of endothelial dysfunction or reduced responsiveness to platelet 
inhibitors. 
 
The primary aim of this study was to systematically investigate both the direct 
and indirect mechanisms that contribute to platelet dysfunction in type 2 diabetes 
and identify the key risk factor associated with enhanced platelet reactivity.  
 
The first objective was to examine the acute effects of hyperglycaemia on platelet 
function using in vitro methods. In addition, the indirect effects of hyperglycaemia 
were investigated by looking at the inhibitory effect of NO and PGI2 on platelet 
function in the presence of high glucose.  
 
The second objective was to investigate the relationship between platelet 
reactivity and clinical parameters (e.g. hyperglycaemia, cholesterol levels and 
BMI) in type 2 diabetic patients using ex vivo methods.  
 
The third objective was to investigate the relationship between inflammatory 
markers and platelet reactivity in type 2 diabetic patients, to determine whether 
there is an association between chronic inflammation and platelet hyperreactivity.   
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The final objective was focused on the comparison between different biochemical 
parameters and platelet reactivity in three separate cohorts: control, 
hyperlipidaemic and type 2 diabetic. The control cohort were not taking 
medication related to diabetes and dyslipidaemia. The hyperlipidaemic cohort 
were statin-treated for elevated lipid levels but not diagnosed as diabetic. The 
third cohort were type 2 diabetic patients taking statin medication for 
dyslipidaemia. The purpose of this objective was to determine if the platelet 
hyperreactivity is associated with the diabetic condition per se, or whether platelet 
hyperreactivity is caused by other mechanisms not associated with 
hyperglycaemia. 
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2 Methods 
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2.1 Patient Recruitment 
 
2.1.1 Study population 
 
Healthy participants were used for all in vitro experiments in chapter 3 to evaluate 
the effect of platelet function in high glucose conditions, without the influence of 
a pre-existing medical condition or medication which could trigger or cause 
platelet dysfunction. These include antiplatelet drugs (e.g. ADP antagonists and 
αIIbβ3 receptor blockers), cardiovascular and lipid-lowering drugs, and 
nonsteroidal anti-inflammatory medication (Scharf, 2012). Medical conditions that 
affect platelet function include inherited platelet disorders (e.g. Von Willebrand 
disease and Glanzmann’s thrombasthenia) (Handin, 2005) and acquired platelet 
disorders caused by disease (e.g. cirrhosis, lupus, renal disease, diabetes and 
coronary heart disease) (Casari and Bergmeier, 2016). Other exclusion criteria 
included transmittable bloodborne diseases e.g. HIV/AIDS and hepatitis. A 
medical questionnaire was given to participants before recruitment to ensure no 
pre-existing medical condition or medication (see appendix 9.3.9 for the 
questionnaire). Healthy participants were mainly recruited from Manchester 
Metropolitan University. Ethical approval for this study was given by the Ethics 
Committee at MMU. Inclusion criteria included participants between 18-80 years 
of age. FBG was measured to ensure that they were within the healthy range 3.5-
5.5 mmol/L (Tuch et al., 2000).  
 
For chapters 4 and 5, type 2 diabetic patients were recruited from the Diabetes 
Centre at the Manchester Royal Infirmary (MRI). Platelets from the type 2 diabetic 
cohort were investigated for correlations against risk factors associated with the 
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disease. Patient screening was carried out using DIAMOND, a diabetes 
monitoring database. Inclusion criteria comprised type 2 diabetes, between 18-
80 years old. All patients recruited for the diabetic arm of the study were 
diagnosed and being treated for type 2 diabetes.  Exclusion criteria included 
disorders/medication that could affect platelet function: type 1 diabetes; coronary 
heart disease (such as angina and a previous myocardial infarction); those 
receiving anticoagulant therapy; use of nonsteroidal inflammatory drugs 
(NSAIDs); those taking aspirin or other antiplatelet medication; bleeding 
disorders such as Von Willebrand’s disease. Other exclusion criteria included the 
transmittable bloodborne diseases (HIV/AIDS and hepatitis). Also excluded were 
those with severe hypertriglyceridemia (triglycerides >4.5 mmol/L) because the 
high lipid content in plasma can affect platelet aggregometry tests. Kidney 
disease is common in diabetes and it can affect platelet function (Boccardo et al., 
2004), so creatinine levels were measured to ensure that kidneys were 
functioning properly (normal range 45-90 μmol/L). Medical history and current 
medications were identified using DIAMOND. 
 
For chapter 6, a control group and a hyperlipidaemic group were used to compare 
platelet reactivity with a diabetic group taking lipid-lowering medication. All 
diabetic participants had the same exclusion/inclusion criteria as above, except 
that lipid lowering medication was included in the inclusion criteria. The control 
group were used as a comparison group that was not diabetic and not on lipid-
lowering medication. The hyperlipidaemic group were used as a comparison 
group that was not diabetic and was taking lipid-lowering medication. This was to 
identify whether the lipid lowering medication influenced platelet reactivity, 
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independent of diabetes. Both groups were age-matched to the diabetic group as 
closely as possible as age can affect platelet function (Jones, 2016). HbA1c and 
FBG was measured in both cohorts to ensure that they were not diabetic (HbA1c 
>47.0 mmol/mol or fasting blood glucose >7.0 mmol/L) or prediabetic (HbA1c 
>42.0 mmol/mol or fasting blood glucose >5.6 mmol/L). Creatinine levels were 
also measured to ensure that the kidneys were functioning properly (normal 
range 45-90 μmol/L) as renal disease can affect platelet function (Boccardo et 
al., 2004). Additionally, chronic renal failure is associated with shortened red 
blood cell survival and this could lower HbA1c results (Peacock et al., 2008). 
 
Hyperlipidaemic patients were recruited from the Lipid Clinic held at the 
Outpatients Department in the MRI. Patient screening was carried out using 
Medisec and Chameleon databases. Inclusion criteria comprised patients with a 
diagnosis of hyperlipidaemia, between 18-80 years old, and those taking lipid-
lowering medication.  
 
For the control and hyperlipidaemic participants, exclusion criteria included: 
diabetes; coronary heart disease (such as angina and a previous myocardial 
infarction); those receiving anticoagulant therapy; use of nonsteroidal 
inflammatory drugs (NSAIDs); those taking aspirin or other antiplatelet 
medication; bleeding disorders such as haemophilia and Von Willebrand’s 
disease; HIV/AIDS; severe hypertriglyceridemia (triglycerides >4.5 mmol/L). This 
was identified using the hospital clinic notes for hyperlipidaemic patients, and was 
identified using a questionnaire (see appendix 9.3.9) for the control participants. 
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2.1.2 Ethics 
 
For healthy participants recruited from MMU for the in vitro studies (chapter 3), 
ethical approval was given by the Ethics Committee at MMU.  
 
For type 2 diabetic participants, hyperlipidaemic and healthy controls used for 
chapter 4, 5 and 6, ethical approval for this study was given by the NHS Ethics 
Research Service (REC Reference: 11/NW/0731). Patient Information sheets 
were posted to patients and healthy controls at least 24 hours prior to consent 
(see appendix, section 9.3, for patient information sheets, cover letters and 
consent forms). Informed consent was obtained from all participating subjects. 
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2.2 Sample Preparation 
 
2.2.1 Venepuncture 
 
Blood was collected from healthy participants at Manchester Metropolitan 
University (MMU) according to a protocol approved by the local ethical committee 
of MMU. Healthy subjects were instructed to fast overnight and blood was drawn 
between 8.00am and 10.00am. Blood was obtained from diabetic and 
hyperlipidaemic patients on the day of their appointment at the Diabetes Centre 
or Lipid Clinic. Patients were instructed to fast for 12 hours before the hospital 
appointment.  
 
Blood was drawn from the median cubital vein of rested subjects using a 21-
gauge needle (BD Vacutainer). Blood was collected into BD Vacutainer tubes 
(BD, Manchester, UK) containing citrate (3.2%), dipotassium 
ethylenediaminetetraacetic acid (K2 EDTA) and a serum tube with gel separator. 
Platelets are easily activated, so blood was drawn with minimum trauma. The 
tubes were gently inverted 3-4 times to mix the blood with the anticoagulant. 
Blood specimens were maintained at 20°C. Testing was performed up to 3 hours 
after venepuncture.   
 
2.2.2 Preparation of Serum and Plasma for Immunoassays  
 
Blood collected from healthy and patients (as described in section 2.3) was 
centrifuged at 1500 x g for 10 minutes at 4ºC. Plasma (from citrate and EDTA 
tubes) and serum were stored as 0.5 ml aliquots at -80ºC. 
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2.2.3 Preparation of PRP 
 
PRP was obtained by centrifugation of the blood (from sodium citrate tubes) at 
180 g for 10 min at 20oC. PRP was diluted (1:1) in modified tyrodes-HEPES buffer 
(134 mM NaCl, 2.9 mM KCl, 0.34 mM Na2HPO4, 12mM NaHCO3, 1mM MgCl2, 
20mM HEPES, 5mM glucose). Platelet count and MPV was measured for the 
diluted PRP, as outlined in section 2.3. Platelet poor plasma (PPP) was obtained 
by centrifugation of PRP at 1800 g for 5 minutes at 20oC. 
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2.3 Biochemical Analysis 
 
2.3.1 Full Blood Count  
 
Blood was collected into K2 EDTA tubes and platelet parameters measured 
within 1 hour after venepuncture to avoid bias due to excessive platelet swelling. 
Blood specimens were gently inverted 5 times. A full blood count was measured 
using an automated blood analyser (Sysmex XS 1000iTM, UK). The volume and 
structures of platelets in the blood are heterogenous, so the following 
haematological parameters were studied in all blood samples: platelet count, 
mean platelet volume (MPV), platelet distribution width (PDW) and platelet large 
cell ratio (P-LCR). For MPV, the blood analyser measures the platelet volume 
directly by calculating the log transformation of the platelet volume distribution 
curve to yield a geometric mean (Budak et al., 2016). PDW is an indicator of 
volume variability in platelet size. It calculated using a distribution curve of 
platelets measured at the level of 20% relative height in a platelet-size distribution 
curve, with a total curve height of 100% (Budak et al., 2016). P-LCR is an indicator 
of circulating larger platelets (>12 fL), which is presented as percentage (Budak 
et al., 2016). 
 
2.3.2 Glucose Measurements 
 
For blood glucose readings, 10 µl of K2 EDTA blood was analysed according to 
the manufacturer’s instructions (Accu-Chek Aviva, Roche Diagnostics Ltd, East 
KJKJH, UK). HbA1c was measured in EDTA blood using a haemoglobin testing 
system (BIO-RAD Variant II). 
64 
 
2.3.3 Lipid Profile 
 
Lipids and creatinine were measured in serum using an autoanalyser (Roche 
COBAS 701).  
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2.4 Aggregometry 
 
2.4.1 Light transmission aggregometry 
 
Light transmission aggregometry (LTA), designed by Born in the 1960s (Born, 
1962) is deemed the gold standard in platelet function testing. This test assesses 
the platelet-to-platelet clump formation in a IIb3 manner, known as aggregation 
(Paniccia et al., 2015). The assay is based on the measurement of light 
transmission through the optically dense PRP after the addition of an agonist. As 
the platelets are activated and aggregate, the plasma becomes clearer and the 
light transmission increases. The device records the rate and maximal 
percentage of this increase from 0% (maximal optical density of PRP) to 100% 
(no optical density of autologous platelet-poor plasma) by a photometer. This 
signal is converted automatically in a graphic curve (Paniccia et al., 2015). 
 
LTA was performed for the in vitro experiments in chapter 3 and the ex vivo 
correlation data in chapters 4,5, and 6. For the in vitro experiments, PRP was 
incubated with 0, 5, 15 and 30 mmol/L D-glucose (Sigma, Poole, UK) at room 
temperature and 37oC for one hour prior to platelet aggregation testing. 
 
For dose response curves, PRP was stimulated with 1-10 µmol/L ADP (Sigma, 
Poole, UK), and 1-4 µg/ml collagen (Labmedics, Manchester, UK) at 37oC under 
constant stirring conditions. EC50 values (the concentration necessary to induce 
half-maximal aggregation) were obtained from non-linear regression curves 
(Appendix 9.1). 
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For the in vitro experiments (chapter 3), platelet aggregation was measured in 
response to submaximal concentrations of ADP (2.5 μmol/L) and collagen (1.0 
μg/ml), elucidated from a dose response (appendix 9.1). For the ex vivo 
experiments (chapters 4, 5 and 6), platelet aggregation was measured in 
response to submaximal concentrations of ADP (5.0 μmol/L) and collagen (1.0 
μg/ml), elucidated from a dose response (appendix 9.1).  
 
To measure the maximum aggregation in the presence of platelet inhibitors, a 
dose response was performed in PRP using Sodium Nitroprusside (SNP) (Sigma, 
Poole, UK) and Prostaglandin E1 (PGE1) (Sigma, Poole, UK) to obtain a 
concentration that induces almost complete inhibition (appendix 9.1). For the 
experiment SNP (100 μM) PGE1 (0.25 μΜ) inhibitors were incubated in PRP for 
2.5 minutes at 37ºC before the agonist was added. PRP was stimulated with ADP 
(2.5 µmol/L) and collagen (1 µg/ml).  
 
The aggregation tracing was observed for 5 min using a Chronolog Model 700 
Aggregometer (Haverton, PA, USA). The maximum aggregation (%) was 
displayed using an AGGRO/LINK8 program (Chronolog). 
 
2.4.2 Impedance aggregometry 
 
Impedance whole blood aggregometry allows one to assess platelet function by 
using the anticoagulated whole blood as milieu without any sample processing 
(Paniccia et al., 2015). It is based on the principle that activated platelets stick via 
their surface receptors to artificial surfaces of two electrodes within the whole 
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blood sample positioned at a determined distance between them. Platelet 
aggregation is assessed by detecting the increase in electrical impedance 
generated by the aggregation of other platelets upon those fixed to the 
electrodes. The degree of the increase in impedance is recorded in ohms as a 
graphic curve (Paniccia et al., 2015).  
 
For in vitro experiments (chapter 3), whole blood was incubated with D-glucose 
(0, 5, 15 and 30 mmol/L) at room temperature and 37oC for one hour prior to 
platelet aggregation testing. 
 
Whole blood was diluted (1:1) with pre-warmed tyrodes-HEPES buffer and 
incubated at 37oC for 5 min. For dose response curves, blood was stimulated 
with ADP (1-20 µmol/L) and collagen (0.5-10 µg/ml) at 37oC under stirring 
conditions. EC50 values (the concentration necessary to induce half maximal 
aggregation) were obtained from concentration-effect curves (appendix 9.1). For 
glucose experiments, blood was stimulated with ADP (2.5 µmol/l) and collagen 
(1 µg/ml). The aggregation tracing was observed for 5 min using a Chronolog 
Model 700 Aggregometer (Haverton, PA, USA). The maximum aggregation 
(ohms) was displayed using an AGGRO/LINK8 program (Chronolog, USA). 
 
2.4.3 Lumi-aggregometry 
 
Lumi-aggregometry allows simultaneous measurement of the release of adenine 
nucleotides from platelet granules and platelet aggregation (Paniccia et al., 
2015). The method is based on the measurement of ATP released from activated 
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platelets by different agonists by using a luminescence technique in plasma or 
whole blood. The assay is based on the conversion of ADP, released from the 
platelet dense granules, to ATP that reacts with the luciferin–luciferase reagent. 
The light emitted, proportional to the ATP concentration, is quantified by the lumi-
aggregometer (Chronolog Model 700 Aggregometer) (Paniccia et al., 2015). 
 
Prior to testing, ATP release was calibrated using an ATP Standard (Labmedics, 
Manchester, UK), according to manufacturer’s instructions (Chronolog, USA). 25 
µl CHRONO-LUME™ (Labmedics, Manchester, UK) was added to 475 µl of pre-
warmed PRP. The CHRONO-LUME/PRP was incubated at 37oC for 2 min, before 
the addition of ADP (2.5 µmol/l) and collagen (1 µg/ml). ATP release (nmoles) 
was displayed against platelet aggregation (%) using an AGGRO/LINK8 program 
(Chronolog, USA). 
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2.5 Flow Cytometry 
 
2.5.1 Measurement of Platelet Adhesion Molecules 
 
Flow-cytometric measurement of platelet surface glycoproteins in fixed whole 
blood is a sensitive and quantitative analysis of platelet activation (Goodhall and 
Appleby, 2004). It involves the rapid analysis of thousands of individual cells per 
second as they pass through a laser light source. Reflected light is translated into 
an electronic signal, which represents a measure of the cells’ size and granularity 
based on forward scatter and side scatter, respectively. This can identify the 
different cell types using their distinct morphological characteristics within whole 
blood. Thus, platelets can be identified without the need for separation from the 
other blood cells (Goodhall and Appleby, 2004). Additionally, whole blood can be 
preincubated with fluorescently-labelled antibodies that recognise antigens on 
the platelet surface. The flow cytometer can measure the number of fluorescent 
antibodies on each cell, which is directly proportional to the number of antigens 
on the platelet surface. Fluorescence measurement can be expressed as either 
the % of positive cells above a threshold set with an appropriate negative control, 
or as the mean or median fluorescent intensity (MFI) of a population of cells 
(Goodhall and Appleby, 2004). 
 
In this study, a dual-fluorescent assay was used. In which, platelets were co-
labelled with an antibody that recognises the fibrinogen-binding site on the 
activated IIb3 receptor (PAC-1 antibody) and an antibody for -granule 
secretion (CD62P antibody).  
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Aliquots (5μl) of whole blood were added to 45 μl of tyrodes buffer containing 5μl 
fluorescent monoclonal antibodies, PE Mouse Anti-Human CD62P (BD 
Biosciences) and PAC-1 FITC (BD Biosciences). An aliquot (5μl) of APC Mouse 
Anti-Human CD42b (BD Biosciences) was added to all samples for platelet 
identification in the whole blood. The CD42b antibody recognises the GPIb in 
platelets. The samples were incubated in the dark at room temperature for 20 
minutes with vehicle or agonist (5.0 μmol/L ADP). For the in vitro experiments 
(chapter 3) samples were also incubated with 0, 5, 15 or 30 mmol/L glucose. To 
measure the quantity of platelet adhesion molecules in the presence of platelet 
inhibitors, SNP (100 μM) and PGE1 (0.25 μΜ) was added to the samples. After 
incubation, the samples were diluted and mildly fixed with 0.4% (v/v) 
paraformaldehyde and phosphate buffer solution (PBS) before analysis using a 
BD FacsVerse™ flow cytometer (BD Biosciences). Platelets were identified on 
their logarithmic side scatter and CD42b positivity expression. Analysis was 
performed with computer software (BD FACSuite™ Software). 
 
The PE (CD62P antibody) and FITC (PAC-1 antibody) fluorochromes are excited 
at neighbouring channels which can lead to ‘bleed-through’. This occurs when 
the signals of the two fluorescence antibodies are detected in the same channel.  
To avoid this from occurring, the flow cytometer was set up so that the PE and 
FITC signals were not overlapping. Quadrant gates were set up to divide the 
populations into CD62P-/PAC-1-, CD62P+/PAC-1-, CD62P-/PAC-1+ and 
CD62P+/PAC-1+ (see figure 9.10 in appendix). Any bleed-through was removed 
by adjusting the photomultiplier tube voltage. 
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For the SNP and PGE1 in vitro flow cytometry experiments (chapter 3) the % 
inhibition (of basal) was determined as follows:  
Four samples were set up for each experiment: non-stimulated whole blood, non-
stimulated whole blood + Inhibitor, ADP-stimulated whole blood, ADP-stimulated 
whole blood + Inhibitor. The % inhibition was calculated as follows: 
= Stimulated (MFI) – Non-stimulated (MFI) = x 
= Stimulated with inhibitor (MFI) – Non-stimulated with inhibitor (MFI) = y 
= (y/x) *100 
= % Inhibition (of basal conditions) 
 
2.5.2 Immature Platelet Fraction 
 
Newly formed platelets, although anucleated, contain mRNA and are able to 
synthesize small amounts of protein (Robinson et al., 1998). They are called 
reticulated platelets due to the staining pattern of the cytoplasmic mRNA 
distribution (Mijovic et al., 2015). The measurement of reticulated platelets has 
considerable clinical utility for monitoring thrombopoiesis and platelet turnover 
(Robinson et al., 1998). Thiazole orange (TO) is a fluorescent nucleic acid dye 
used for flow cytometric detection of reticulated platelets (Robinson et al., 1998).  
 
Venous blood samples anticoagulated with K2 EDTA, were kept at room 
temperature until analysis was performed, less than 4 hours after blood collection. 
5 l of whole blood was added to 1 ml of TO (BD Retic-Count™, BD Biosciences, 
US). A negative control was used for each sample, and prepared using 5 l whole 
blood and 1 ml of PBS with 0.1% sodium azide. All samples were labelled with 5 
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l APC Mouse Anti-Human CD42b (BD Biosciences, US) for the identification of 
platelets among the other blood cells. Samples were incubated for 30 min at room 
temperature in the dark. They were read in the cytometer (BD FACSVerse™, BD 
Biosciences, US). Platelets were identified on their logarithmic side scatter and 
CD42b positivity expression. Analysis was performed with computer software 
(BD FACSuite™ Software). A dot plot (CD42b-APC vs. TO fluorescence) was 
generated, and the reticulated platelet rate was expressed as a percentage of 
both TO and CD42b-APC positive population among 10,000 identified platelets. 
The threshold of TO fluorescence was chosen so that >99% of the CD42b-APC 
positive population was negative for TO. The number of positive events in the 
negative control was subtracted from the number of positive events in the sample. 
Reticulated platelets were expressed as mean % of TO-positive platelets. 
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2.6 Immunoassays 
 
2.6.1 ELISA 
 
A commercially available sandwich ox-LDL enzyme-linked immunosorbent assay 
(ELISA) kit (LifeSpan BioSciences, Inc., Seattle, USA) was used for the 
quantitative detection of human ox-LDL in EDTA plasma samples from type 2 
diabetic patients, previously stored at -80ºC and thawed on ice. The protocol was 
carried out according to the manufacturer’s instructions (LifeSpan BioSciences, 
Human ox-LDL / Oxidised LDL ELISA kit, catalogue no. LS-F23411). An initial 
experiment was undertaken to determine the optimum sample dilution factor. This 
was to ensure that the protein concentration for each sample fell within the range 
of Optical Density (OD) values distinguished by a standard curve (detection range 
for the ELISA kit was 31.25-2000 pg/ml). The optimisation experiment determined 
that the plasma samples should be undiluted for the ELISA assay. Absorbance 
was measured at 450nm using a microplate reader. To quantify the protein 
concentration, a standard curve was constructed by plotting the mean 
absorbance for each standard on the x-axis against the concentration on the y-
axis and a line of best fit curve was drawn (see appendix 9.2 for the standard 
curve). To measure the extent of oxidation, the ox-LDL and LDL-C values were 
both converted to mg/dL, and the ox-LDL was divided by the LDL-C to get the ox-
LDL/LDL-C ratio. 
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2.6.2 Luminex Assay 
 
Multiplex Bead Array Assays technology, enable simultaneous detection and 
quantitation of multiple secreted proteins (cytokines, chemokines, growth factors, 
etc.) (Elshal and McCoy, 2006). This high-throughput technology produces 
results comparable to ELISA but with potential cost and time-saving. Thus, a 
multiplex assay, using Luminex xMAP (multi-analyte profiling) technology, was 
used for the analysis of inflammatory markers and platelet reactivity due to the 
high number of cytokines/chemokines involved in inflammation. The Luminex 
xMAP technology uses digital signal processing capable of identifying 
polystyrene beads (microspheres) dyed with designated proportions of red and 
near-infrared fluorophores (Elshal and McCoy, 2006). These microspheres are 
coated with specific antibodies, which can be read by flow cytometry because the 
microspheres have distinguishable fluorescent signatures. Up to one hundred 
different detection reactions can be carried out simultaneously on the various 
bead populations in very small sample volumes. 
 
Plasma (3.2% citrate) was thawed on ice and centrifuged at 10,000 x g for 10 
minutes to remove particulates. The multiplex assay used for this study was the 
Inflammation 20-Plex Human ProcartaPlex™ Panel (ThermoFisher Scientific, 
US). The manufacturer recommended that plasma samples not be diluted prior 
to assay performance due to the low-level cytokine concentrations in human 
plasma. Protocol was performed as described according to the ProcartaPlex™ 
Multiplex Immunoassay (ThermoFisher Scientific, US) user guide. The magnetic 
bead panel was able to simultaneously quantify E-selectin, granulocyte-
macrophage colony-stimulating factor (GM-CSF), interferon(IFN)-, IFN-, 
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interleukin (IL)-1, IL-1, IL-10, IL12p70, IL-13, IL-17A, IL-4, IL-6, IL-8, interferon 
gamma-induced protein (IP)-10, monocyte chemoattractant protein (MCP)-1, 
macrophage inflammatory protein (MIP)-1, MIP-1, P-selectin, soluble 
intercellular adhesion molecule (sICAM)-1, tumour necrosis factor (TNF)- in a 
96-well plate. Standards were prepared as outlined in the ProcartaPlex™ 
Multiplex Immunoassay (ThermoFisher Scientific, US) user guide. The standards 
contained a mix of multiple proteins, detailed in the Certificate of Analysis 
document that came with the kit. The protocol included an overnight incubation 
at 4ºC to improve assay sensitivity.  
 
The plate was analysed on the Luminex 200™ Multiplex instrument. Prior to 
running the assay, calibration of the Luminex 200™ instrument was undertaken 
using a Luminex 200™ Calibration kit (ThermoFisher, US) in full accordance with 
the manufacturer’s instructions. Additionally, the probe height was calibrated with 
a 96-well flat bottom plate supplied with the kit. Information provided in the 
Certification of Analysis was used set up the Luminex Acquisition Software™ 
prior to running the assay. These included details of bead region and standard 
concentrations (pg/ml) for each analyte. Protocol was performed as described 
according to the Luminex® 200™ System User Manual. The concentration of the 
analytes was calculated from the standard curve using the Luminex™ 
xPONENT® software (Luminex™ version 3.1.871).  
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2.7 Statistical Analysis 
 
Data is presented as mean + standard deviation (SD) or standard error (SE). The 
Shapiro-Wilk test was used to estimate parametric and non-parametric data. A 
Spearman or Pearson correlation was used to calculate the correlation between 
two independent variables. A paired or unpaired samples t-test was used to 
calculate the difference between two related groups and two independent groups, 
respectively. One-way analysis of variance (ANOVA) was used to calculate the 
significant difference between three or more independent groups. Repeated 
measures ANOVA was used to calculate the significant difference between three 
or more related groups. A Dunnett’s multiple comparison test was used to 
compare the differences of the groups against the control. A Tukey’s multiple 
comparisons test was used to compare all groups to each other for parametric 
data. A Dunn’s multiple comparisons test was used to compare all groups to each 
other for non-parametric data. All p-values <0.05 were considered to be 
statistically significant. Statistical analysis was carried out using IBM SPSS 
Statistics 24 or GraphPad Prism 7.04. 
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3 The Effects of Acute Hyperglycaemia on Platelet 
Function In Vitro  
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3.1 Introduction 
 
The clinical diagnosis of diabetes is based on HbA1c over 48 mmol/mol, and 
large-scale studies have linked high blood glucose with cardiovascular disease 
in type 2 diabetic patients (Stratton et al., 2000; Coutinho et al., 1999 and Turnbull 
et al., 2009). To prevent cardiovascular events from occurring, diabetic patients 
are prescribed antiplatelet medication such as aspirin. Despite this, clinical 
studies have shown that the response to antiplatelet drugs is weaker in diabetic 
patients compared to non-diabetic people with vascular complications (Angiolillo, 
2009).  
 
A number of ex vivo and in vitro studies have investigated the effect of 
hyperglycaemia on platelet reactivity, however, the data is contradictory (see 
section 1.7). Consequently, the literature does not confirm that hyperglycaemia 
is causing platelet hyperreactivity in diabetes. To further investigate the effect of 
high glucose on platelet reactivity, this study used in vitro techniques to measure 
platelet activation and aggregation in the presence of increasing glucose 
concentrations. The study also investigated the effect of high glucose on NO and 
PGI2-mediated platelet inhibition. 
 
The aims of this chapter were to determine whether acute elevations in glucose 
levels have a direct effect on platelet function. Alterations in platelet size and 
activation state were analysed in resting platelets from healthy donors following 
incubation with increasing concentration of glucose or mannitol. Platelet reactivity 
to standard physiological platelet agonists were also assessed, to determine 
whether acute hyperglycaemia has the potential to directly promote a 
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prothrombotic platelet phenotype in the circulation. The effects of hyperglycaemia 
on the platelet inhibitory pathways mediated by NO and PGI2 were also 
investigated.  
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3.2 Results 
 
3.2.1 The Effect of Acute Glucose on Platelet Size  
 
Much of the work so far, investigating hyperglycaemia and platelet function 
reported in the literature, has looked at the relationship between MPV and high 
glucose ex vivo.  To establish whether acute glycaemia in the circulation can 
directly influence platelet size, an in vitro method was employed. 
 
For the in vitro method, the platelet count, MPV, PDW and P-LCR were measured 
in whole blood from fasted healthy participants, incubated with increasing glucose 
concentrations at 37°C for 1 hour. Mannitol was used as a metabolically-inactive 
control, to investigate the effects of platelet swelling. 
 
The mean + SD of fasting glucose for the healthy subjects before testing was 
4.62 + 0.56 mmol/L (n=10). This mean is within the 3.5-5.5 mmol/L range, 
representative of normal fasting glucose for healthy people (Tuch et al., 2000). 
The platelet parameters platelet count, MPV, P-LCR and P-LCR for the ten 
healthy subjects were initially assessed to ensure that they were in the normal 
range (Table 3.1.). 
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Table 3.1: Baseline mean values for platelet parameters in healthy subjects 
Platelet parameter  Mean + SD (n=10) Normal Range 
Platelet Count (x109/L) 243.7 + 74.64 150 – 450≠   
Mean platelet volume (fL) 10.54 + 1.05   7.0 – 10.5≠  
Platelet distribution width (fL) 12.73 + 2.38 10.0 - 17.9$ 
Platelet-large cell ratio (%) 29.64 + 8.69 15.0 – 35.0≈ 
Normal ranges taken from the following sources: ≠Giles, 1981; $ Farias et al., 2010; ≈Budak et al., 
2016. 
 
The unit of measurement for MPV (femtolitres (fL)) is considerably small so any 
significant differences may not be shown, therefore the data was normalised to 
represent the fold change against the control. A repeated measures one-way 
ANOVA showed no significant difference between the mean platelet count for the 
four glucose concentrations (Table 3.2). There was a statistically significant 
difference between the mean MPV values for all four glucose concentrations 
(p=<0.0001) (Table 3.2 and Figure 3.1), together with PDW (p=0.004) and P-LCR 
(p=<0.0001) (Table 3.2). A Dunnett’s multiple comparison test showed that the 5, 
15 and 30 mmol/L added glucose significantly increased the MPV when 
compared to the control (p=0.025, p=<0.0001, p=0.0001 respectively) (Figure 
2.1).  In contrast, the osmotic control, mannitol, had no significant effect on the 
MPV (p=0.491) (Table 3.3 and Figure 3.2). The 30 mmol/L added glucose also 
had a significant effect on PDW when compared to no added glucose (p=0.008). 
For P-LCR, 5, 15 and 30 mmol/L were significantly increased compared to the 
control (p=0.0125, p=0.0001 and p=0.0003, respectively). Mannitol had no 
significant effect on PDW (p=0.118), however there was a small but significant 
reduction in P-LCR for 15 mmol/L compared to the control (p=0.021).  
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Table 3.2: Fold change for platelet parameters in blood with increasing 
glucose concentrations 
Added 
glucose 
(mmol/L) 
 
0.0 
 
5.0 
 
15.0 
 
30.0 
 
p-value 
Platelet 
count 
(x109/L) 
1.0 + 0.0 0.99 + 0.02 1.01 + 0.03 0.98 + 0.02 0.467 
MPV (fL) 1.0 + 0.0 1.02 + 0.005 1.03 + 0.004 1.06 + 0.008 <0.0001 
PDW (fL) 1.0 + 0.0 1.05 + 0.03 1.07 + 0.03 1.10 + 0.03 0.004 
P-LCR (%) 1.0 + 0.0 1.05 + 0.01 1.11 + 0.02 1.20 + 0.03 <0.0001 
Fold change for platelet parameters in healthy blood with added glucose (5-30 mmol/L) when 
compared to the non-treated blood (0 mmol/L added glucose). A repeated measures one-way 
ANOVA was used to calculate the p value. Values presented as mean + SEM (n=10). 
 
 
Table 3.3: Fold change for platelet parameters in blood with increasing 
mannitol concentrations 
Added 
mannitol 
(mmol/L) 
0.0 5.0 15.0 30.0 p-value 
Platelet 
count 
(x109/L) 
1.0 + 0.0 1.05 + 0.02 0.99 + 0.02 1.02 + 0.02 0.061 
MPV (fL) 1.0 + 0.0 1.00 + 0.007 0.99 + 0.004 1.00 + 0.006 0.491 
PDW (fL) 1.0 + 0.0 0.98 + 0.02 0.98+ 0.006 0.98 + 0.009 0.118 
P-LCR (%) 1.0 + 0.0 1.00 + 0.02 0.97 + 0.01 0.97 + 0.01 0.028 
Fold change for platelet parameters in healthy blood with mannitol (5-30 mmol/L) when compared 
to the non-treated blood (0 mmol/L added glucose). A repeated measures one-way ANOVA was 
used to calculate the p value. Values given as mean + SEM (n=10). 
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Figure 3.1: The effect of added glucose on MPV in healthy blood 
Whole blood from healthy fasted donors was supplemented with increasing concentrations of 
glucose (0-30 mmol/L) for 1h and the MPV measured. Values given as mean + SEM (n=10). Data 
analysed using a Dunnett’s multiple comparison test (*p=<0.0001 and *p=0.0001). 
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Figure 3.2: The effect of mannitol on MPV in healthy blood 
Whole blood from healthy fasted donors was supplemented with increasing concentrations of 
glucose (0-30 mmol/L) for 1h and the MPV measured. Values given as mean + SEM (n=10). Data 
analysed using a repeated measures one-way ANOVA (F (1.9, 17.1) = 0.728, p=0.491). 
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3.2.2 The Effect of Acute Glucose on Platelet Activation  
 
In the in vitro study investigating the effect of high glucose on platelet size (section 
3.2.1), it was identified that MPV is increased in the presence of glucose but not 
mannitol, demonstrating a direct effect on peripheral platelets. To investigate 
whether the increased size is also accompanied by an increase in surface 
activation markers, the effects of hyperglycaemia on platelet P-selectin (CD62P) 
surface expression and IIb3 activation (PAC-1 binding) was assessed on resting 
platelets in whole blood using flow cytometry. P-selectin is an adhesion molecule 
stored in platelet -granules and translocated to the platelet surface upon α-
granule secretion. PAC-1 is an antibody, which specifically binds to activated 
IIb3 on the platelet surface, and is an indication of platelet aggregation.  
  
To prevent results being affected by patient variability, the data was normalised 
by calculating the fold change of the control. The mean + SD baseline glucose 
concentration for the participants was 4.72 + 0.42 (n=10). A repeated measures 
one-way ANOVA showed a trend towards an increase in P-selectin surface 
expression with increased glucose concentrations (p=0.067) (Figure 3.3).  A 
significant increase in PAC-1 binding was shown with increased glucose 
(p=0.024) (Figure 3.4). A Dunnett’s multiple comparison test showed that 15 
mmol/L added glucose was significantly higher compared to the 0 mmol/L 
glucose control (p=0.032). 5 mmol/L glucose was not significantly different to the 
control (p=0.172), but 30 mmol/L glucose was very close to significance 
(p=0.051).  
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To investigate the effect of hyperglycaemia on activated platelets, CD62P surface 
expression and PAC-1 binding was assessed in platelets stimulated with ADP in 
whole blood flow cytometry.  A repeated measures one-way ANOVA showed no 
significant effect in P-selectin surface expression increasing glucose 
concentrations (p=0.389) (Figure 3.5). However, a repeated measures one-way 
ANOVA showed a significant decrease in PAC-1 binding (p=0.010) (Figure 3.6). 
A Dunnett’s multiple comparison test showed that 30 mmol/L added glucose was 
significantly decreased compared to the 0 mmol/L glucose control (p=0.025). 5 
mmol/L and 15 mmol/L added glucose were not significantly different to the 
control (p=0.312 and p=0.389, respectively). 
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Figure 3.3: The effect of glucose on -granule secretion in rested platelets 
Whole blood from healthy fasted donors was supplemented with increasing concentrations of 
glucose (0-30mmol/L) for 1h and surface expression of P-selectin measured using flow cytometry. 
Values given as mean + SEM (n=10). Data analysed using a repeated measures one-way 
ANOVA (F (2.488, 22.39) = 2.874, p=0.0674).  
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Figure 3.4: The effect of glucose on PAC-1 binding in resting platelets 
Whole blood from healthy fasted donors was supplemented with increasing concentrations of 
glucose (0-30mmol/L) for 1h and PAC-1 binding measured using flow cytometry. Values given as 
mean + SEM (n=10). Data analysed using a Dunnett’s multiple comparison test (*p=0.032). 
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Figure 3.5: The effect of glucose on -granule secretion in ADP-activated 
platelets 
Whole blood from healthy fasted donors was supplemented with increasing concentrations of 
glucose (0-30 mmol/L) for 1h and surface expression of P-selectin measured using flow 
cytometry. Values given as mean + SEM (n=10). Data analysed using a repeated measures one-
way ANOVA (F (1.278, 11.5) = 4.604, p=0.389).  
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Figure 3.6: The effect of glucose on PAC-1 binding in ADP-activated 
platelets 
Whole blood from healthy fasted donors was supplemented with increasing concentrations of 
glucose (0-30 mmol/L) for 1h and PAC-1 binding measured using flow cytometry. Values given 
as mean + SEM (n=10). Data analysed using a Dunnett’s multiple comparison test (*p=0.025). 
 
 
 
 
To identify whether platelets are indirectly affected by high glucose, through 
reduced sensitivity to platelet inhibitors, the efficacy of the nitric oxide donor SNP 
and PGE1 was assessed in hyperglycaemic conditions and platelet activation 
measured by flow cytometry. 
  
The mean baseline glucose for the participants was 4.76 + 0.58 mmol/L (n=5). 
Data was represented as the % inhibition of basal conditions and this was 
calculated as described in section 2.5.1. Interestingly, the inhibition of α-granule 
secretion evoked by SNP (100 μmol/L) was significantly enhanced in the 
presence of 30 mmol/L glucose (p=0.036). No difference was observed for PAC-
1 binding (p=0.202) (see figure 3.7). Glucose had no effect on CD62P surface 
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expression or PAC-1 binding in the presence of PGE1 (0.25 μmol/L) (p=0.536 and 
p=0.353, respectively) (see figure 3.8). 
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Figure 3.7: The effect of glucose and SNP-mediated inhibition on platelet 
activation 
Figure A: Whole blood from healthy fasted donors was supplemented with increasing 
concentrations of glucose (0-30 mmol/L) and CD62P surface expression was measured in 
platelets stimulated with ADP (2.5 µmol/L) with and without SNP (100 μmol/L). Values given as 
mean + SEM (n=5). Data is represented as the % inhibition (of basal). Data calculated using a 
repeated measures one-way ANOVA (F (1.844, 7.376) = 5.49, p = 0.036). Figure B: Whole blood 
from healthy fasted donors was supplemented with increasing concentrations of glucose (0-30 
mmol/L) and PAC-1 binding was measured in platelets stimulated with ADP (2.5 µmol/L) with and 
without SNP (100 μmol/L). Values given as mean + SEM (n=5). Data was analysed as % of basal 
inhibition, using a repeated measures one-way ANOVA (F (1.237, 4.949) = 2.206, p = 0.202). 
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Figure 3.8: The effects of glucose and PGE1-mediated inhibition on platelet 
activation  
Figure A: Whole blood from healthy fasted donors was supplemented with increasing 
concentrations of glucose (0-30 mmol/L) and CD62P surface expression was measured in 
platelets stimulated with ADP (2.5 µmol/L) with and without PGE1 (0.25 μmol/L). Values given as 
mean + SEM (n=5). Data was analysed as % of basal inhibition, using a repeated measures one-
way ANOVA (F (1.473, 5.893) = 0.589, p = 0.536). Figure B: Whole blood from healthy fasted 
donors was supplemented with increasing concentrations of glucose (0-30 mmol/L) and PAC-1 
binding was measured in platelets stimulated with ADP (2.5 µmol/L) with and without PGE1 (100 
μmol/L. Values given as mean + SEM (n=5). Data was analysed as % of basal inhibition, using a 
repeated measures one-way ANOVA (F (1.883, 7.531) = 1.187, p = 0.353).  
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3.2.3 The Effect of Glucose on Platelet Aggregation 
  
To investigate whether acute hyperglycaemia directly modulates platelet 
reactivity, PRP from healthy subjects was incubated with increasing 
concentrations of glucose and stimulated with submaximal concentrations of 
physiological platelet agonists collagen or ADP. 
  
The mean + SD of fasting glucose for the healthy subjects before testing was 
4.48 mmol/L + 0.36 mmol/L (n=5). This mean is within the 3.5-5.5 mmol/L range, 
representative of normal fasting glucose for healthy people (Tuch et al., 2000). 
  
PRP was incubated with glucose for 1 hour at room temperature. Platelet 
aggregation was measured in response to submaximal concentrations of ADP 
(2.5 μmol/L) and collagen (1.0 μg/ml), elucidated from a dose response 
(Appendix 9.1). LTA demonstrated that glucose did not significantly alter ADP- or 
collagen-stimulated platelet aggregation (p=0.395 and p=0.431, respectively) 
(Figure 3.9 and Figure 3.10). 
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Figure 3.9: The effect of glucose on ADP-activated platelet aggregation in 
PRP 
PRP from healthy fasted donors was supplemented with increasing concentrations of glucose (0-
30 mmol/L) for 1h and platelet aggregation was stimulated with ADP (2.5 µmol/L). Values given 
as mean + SEM (n=5). Data analysed using a repeated measures one-way ANOVA (F (1.455, 
5.778) = 0.995, p=0.395).  
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Figure 3.10: The effect of glucose on collagen-induced platelet aggregation 
in PRP 
PRP from healthy fasted donors was supplemented with increasing concentrations of glucose (0-
30 mmol/L) for 1h and platelet aggregation was stimulated with collagen (1.0 µg/ml). Values given 
as mean + SEM (n=5). Data analysed using a repeated measures one-way ANOVA (F (1.051, 
4.203) = 0.781, p=0.431).  
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The literature has shown that research teams used different conditions to 
measure platelet aggregation in the presence of glucose (section 1.7.3). Thus, 
PRP was incubated with glucose at 37oC for 1 hour to investigate whether a 
physiologically relevant temperature would give a significant effect on platelet 
aggregation.  
 
The mean + SD of the fasting glucose concentration for the healthy subjects 
before experimentation was 4.52 mmol/L + 0.16 mmol/L (n=10), within the range 
for normal fasting glucose levels. 
 
Contrary to the results obtained at room temperature, there was a surprising dose 
dependent reduction in platelet aggregation shown with ADP (2.5 μmol/L) 
activation for 15 and 30 mmol/L glucose (see Figure 3.11 and Figure 3.12) 
(Dunnett’s, p=0.036 and p=0.007, respectively). Conversely, glucose 
concentration did not have a significant effect on aggregation stimulated with 
collagen (1.0 μg/ml) (p=0.435) (Figure 3.13).  
 
To further investigate the effect of glucose on platelet function, luminescence 
aggregometry was undertaken in six healthy participants, to measure the release 
of ATP in PRP stimulated with ADP (2.5 μmol/L) and collagen (1.0 μg/ml). 
Although there was a dose-dependent reduction in ATP release for ADP-
activated PRP, a repeated measures one-way ANOVA demonstrated that there 
was no significant difference (p=0.152) (Figure 3.14). No significant difference 
was shown with collagen (p=0.461) (Figure 3.15).  
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Figure 3.11: Platelet aggregation and ATP release induced with ADP 
 
An example of platelet aggregation (%) and ATP release (nm) from one fasted healthy participant. 
The image shows that both the ATP release and platelet aggregation was reduced as the glucose 
concentration was increased. In the legend the colours represent the glucose concentration 
(mmol/L) for platelet aggregation (%) and ATP release (nm).  
 
 
Figure 3.12: The effect of glucose on ADP-induced platelet aggregation in 
PRP 
 
PRP from healthy fasted donors was supplemented with increasing concentrations of glucose (0-
30 mmol/L) for 1h at 37ºC and platelet aggregation was stimulated with ADP (2.5 µmol/L). Values 
given as mean + SEM (n=10). Data analysed using a Dunnett’s multiple comparison test 
(*p=0.036 and *p=0.007). 
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Figure 3.13: The effect of glucose on collagen-induced platelet 
aggregation in PRP 
PRP from healthy fasted donors was supplemented with increasing concentrations of glucose (0-
30 mmol/L) for 1h at 37ºC and platelet aggregation was stimulated with collagen (1.0 µg/ml). 
Values given as mean + SEM (n=10). Data analysed using a repeated measures one-way 
ANOVA (F (2.632, 23.69) = 0.922, p = 0.435).  
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Figure 3.14: Effect of glucose on ATP secretion in PRP activated with ADP 
 
PRP from healthy fasted donors was supplemented with increasing concentrations of glucose (0-
30 mmol/L) for 1h at 37ºC and ATP secretion was measured in platelets stimulated with ADP (2.5 
µmol/L). Values given as mean + SEM (n=6). Data analysed using a repeated measures one-way 
ANOVA F (1.459, 7.297) = 2.529, p=0.152).  
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Figure 3.15: Effect of glucose on ATP secretion in PRP induced with 
collagen 
 
PRP from healthy fasted donors was supplemented with increasing concentrations of glucose (0-
30 mmol/L) for 1h at 37ºC and ATP secretion was measured in platelets stimulated with collagen 
(1.0 µg/ml). Values given as mean + SEM (n=6). Data analysed using a repeated measures one-
way ANOVA (F (1.786, 8.932) = 0.812, p=0.461).  
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To investigate the effect of glucose in the presence of other blood components, 
platelet aggregation was measured in whole blood. The blood was stimulated 
with ADP (2.5 µmol/L) and collagen (1.0 µg/ml) to induce platelet aggregation.  
 
The mean fasting glucose concentration of the healthy subjects before 
experimentation was 5.29 + 0.22 (n=10). The results show no significant 
difference between the glucose concentrations for whole blood stimulated with 
ADP or collagen (p=0.248 and p=0.199, respectively) (Figure 3.16 and Figure 
3.17). 
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Figure 3.16: The effect of glucose on ADP-induced platelet aggregation in 
whole blood 
 
Whole blood from healthy fasted donors was supplemented with increasing concentrations of 
glucose (0-30 mmol/L) for 1h at 37ºC and maximal aggregation was measured in platelets 
stimulated with ADP (2.5 µmol/L). Values given as mean + SEM (n=10). Data analysed using a 
repeated measures one-way ANOVA (F (2.261, 20.35) = 1.494, p=0.248).  
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Figure 3.17: The effect of glucose on collagen-induced platelet aggregation 
in whole blood 
 
Whole blood from healthy fasted donors was supplemented with increasing concentrations of 
glucose (0-30 mmol/L) for 1h at 37ºC and maximal aggregation was measured in platelets 
stimulated with collagen (1.0 µg/ml). Values given as mean + SEM (n=10). Data analysed using 
a repeated measures one-way ANOVA (F (1.58, 14.22) = 1.829, p=0.199).  
 
 
 
Previous results from this study showed that high glucose did not directly affect 
platelet hyperreactivity. To further investigate whether platelets are indirectly 
affected by high glucose, through reduced sensitivity to platelet inhibitors, platelet 
aggregation was measured in the presence of SNP or PGE1 under 
hyperglycaemic conditions.  
 
To determine a suitable concentration of SNP and PGE1, a dose response was 
performed, and the concentration that almost abolished ADP-induced platelet 
aggregation was selected for SNP (100 μmol/L) and PGE1 (0.25 μmol/L) 
(Appendix 9.1).  
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Acute elevation in glucose levels had no significant effect on the inhibition of ADP-
mediated aggregation, evoked by SNP (100 μmol/L) (p=0.645) (Figure 3.18). 
Similarly, the inhibition of platelet aggregation achieved with PGE1 (0.25 μmol/L) 
(p=0.212) (Figure 3.19), was not significantly altered by elevated glucose levels.  
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Figure 3.18: The effect of glucose and SNP-mediated inhibition on platelet 
aggregation 
 
PRP from healthy fasted donors was supplemented with increasing concentrations of glucose (0-
30 mmol/L) for 1h at 37ºC and maximal aggregation was measured in platelets stimulated with 
ADP (2.5 µmol/L) with and without SNP. Values given as mean + SEM (n=5). Data analysed using 
a repeated measures one-way ANOVA without SNP (F (1.87, 7.481) = 1.552, p=0.272) and with 
SNP (100 μM) (F (1.797, 7.188 = 0.432, p=0.645).  
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Figure 3.19: The effect of glucose and PGE1-mediated inhibition on platelet 
aggregation 
 
PRP from healthy fasted donors was supplemented with increasing concentrations of glucose (0-
30 mmol/L) for 1h at 37ºC and maximal aggregation was measured in platelets stimulated with 
ADP (2.5 µmol/L) with and without PGE1. Values given as mean + SEM (n=5). Data analysed 
using a repeated measures one-way ANOVA without PGE1 (F (1.392, 5.567) = 0.508, p = 0.564) 
and with PGE1 (0.25 μmol/L) (F (1.988, 7.95) = 1.899, p=0.212). 
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3.2 Discussion 
 
Hyperglycaemia is recognised as the main cause of vascular complications in 
diabetes. Despite this, both ex vivo and in vitro studies investigating the effect of 
high glucose on platelet hyperreactivity report contradictory conclusions.  
 
Larger platelets with MPV tend to be more reactive and release more 
prothrombotic factors such as TXA2 (Shimodaira et al., 2014). Therefore, MPV is 
considered to be an independent risk factor for myocardial infarction and stroke, 
and it is emerging as a clinical biomarker for cardiovascular disease. The majority 
of ex vivo studies investigating the relationship between MPV and HbA1c in type 
2 diabetes identified a positive correlation (Demirtunc et al., 2009; Kodiatte et al., 
2012; Ozder et al, 2014; Ulutas et al., 2014). However, similar studies disagreed 
with this data (Hekimsoy et al., 2004 and Pananas et al., 2004). Additionally, data 
from ex vivo studies investigating the relationship between MPV and FBG in type 
2 diabetic patients report both a strong relationship (Kodiatte et al., 2012; Ozder 
et al., 2014; Ulutas et al., 2014) and no relationship (Demirtunc et al., 2009; 
Hekimsoy et al., 2004). Furthermore, no study has investigated the relationship 
between MPV and high glucose using in vitro techniques. Therefore, it is unclear 
whether any alterations in platelet size were through increased thrombopoeisis 
and release of larger immature platelets, or whether glucose has a direct effect 
on platelets in the circulation. 
 
Using in vitro techniques, this study showed that a significant increase in MPV 
with increasing glucose concentrations (p=<0.0001). This is possibly due to the 
uptake of glucose by the GLUT transporters which may lead to an increase in 
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water diffusion into the cell causing cell swelling, as shown by Lösche et al. (1989) 
in erythrocytes. This suggests that hyperglycaemia enhances platelet size 
directly in the circulation. It doesn’t, however, rule out that glucose may influence 
megakaryocytes and thrombopoiesis as well.  
 
It has been suggested that circulating platelets can be primed so that they have 
an increased response to stimuli. For example, Massberg et al. (2002) reported 
that mice with atherosclerosis had circulating platelets that expressed surface P-
selectin, which potentiated the inflammatory response and contributed to 
atherogenesis. To assess whether the increase in platelet size, stimulated by 
acute hyperglycaemia, was accompanied by an elevation in activation markers, 
surface levels of P-selectin and activated IIb3 were measured. In resting 
platelets, there was no significant difference in -granule secretion. There was a 
small but significant increase in PAC-1 binding observed, and this may represent 
an increase in activation of the IIb3 receptors present, but not an upregulation 
in IIb3 which occurs following α-granule secretion. A recent study investigating 
the effect of compression force on circulating platelets from a streptozotocin 
murine model of diabetes, also reported elevated activation of IIb3 (Ju et al., 
2018). Additionally, the team identified that >95% of the platelets did not have P-
selectin expression, supporting the notion that hyperglycaemia does not increase 
surface P-selectin expression.  Also consistent with our study, they showed no 
difference in agonist-induced platelet activation between control and diabetic 
platelets, indicating that hyperglycaemia does not directly enhance platelet 
reactivity. Ju et al., (2018) did however demonstrate a distinct pressure 
dependent mechanism, induced by hyperglycaemia, which enhanced the affinity 
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of IIb3 for fibrinogen, through a PI3K–dependent mechanism. It is possible that 
this could be a consequence of the cell swelling effects observed in our study, 
since cell swelling has been shown to activate the PI3K/AKT signalling axis in 
other cell types (Webster et al., 2000).   
 
No significant increase in platelet aggregation was observed in either PRP or 
whole blood experiments. However, there was a significant reduction in ADP-
activated platelet aggregation in the presence of 15 mmol/L and 30 mmol/L 
glucose at 37oC. Furthermore, PAC-1 binding was significantly reduced in ADP-
activated platelets incubated with 30 mmol/L glucose. The high glucose could be 
triggering platelet apoptosis, yet the results in section 3.2.1 demonstrate that the 
platelet count remains the same in high glucose compared to low glucose 
concentrations. A possible explanation is that the high glucose increases ecto-
nucleotidases, which, in turn, increases the hydrolysis of ATP/ADP to AMP and 
adenosine (Lunkes et al., 2008). This would reduce the level of ADP that would 
otherwise trigger the activation of circulating platelets.  
 
Acute glucose does not reduce the inhibitory effect of SNP and PGE1. This 
supports other in vitro studies that have reported no influence of inhibitory activity 
on platelet activation under high glucose conditions (Sudic et al., 2006; Russo et 
al. 2012). Although it has been demonstrated that glucose impairs the ability for 
aspirin to activate the NO/cGMP pathway (Russo et al. 2012), suggesting that 
glucose alters the efficacy of antiplatelet therapy rather than altering NO activity 
per se. The inhibitory effect was significantly increased for CD62P surface 
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expression in SNP-treated platelets. This, again, supports the idea that high 
glucose increases ecto-nucleotidases, further increasing platelet inhibition.  
 
In conclusion, whilst the data demonstrates that acute hyperglycaemia directly 
enhances platelet size and may lead to low-level IIb3 activation, there is no 
evidence to suggest that it has any effect on platelet reactivity and 
responsiveness to agonist stimulation. Furthermore, the lack of platelet 
hyperreactivity in hyperglycaemic conditions observed in this study is in contrast 
with several published studies (Keating et al., 2003; De la Cruz et al., 2004; Tang 
et al., 2011) and the experimental conditions may contribute to the outcomes. 
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4 Identification of Biochemical Parameters Associated 
with Platelet Reactivity in Type 2 Diabetic Patients 
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4.1 Introduction 
 
In the previous chapter, in vitro studies indicated that acute hyperglycaemia does 
not enhance platelet reactivity directly through potentiating agonist responses or 
indirectly through reducing platelet sensitivity to inhibitor signalling pathways.  
 
Since the viability of platelets in vitro is limited to a few hours, the chronic effects 
of glucose on platelet function cannot be investigated by glucose 
supplementation. In vitro studies also do not allow for altered platelet function 
through effects on the parent megakaryocyte to be interrogated. In order to 
examine the effects of hyperglycaemia on platelets over a longer period, ex vivo 
experiments were undertaken using blood from type 2 diabetic patients.  
 
As well as hyperglycaemia, type 2 diabetes is associated with alterations in the 
blood milieu caused by dyslipidaemia and oxidative stress (Kakouros et al., 
2011). Thus, correlations between platelet reactivity and lipoprotein levels (LDL-
C, HDL-C, triglycerides and ox-LDL) was also investigated. Clinical 
characteristics were also incorporated into the correlations to determine whether 
platelet reactivity is associated with age, BMI or duration of diabetes. 
Measurements of platelet reactivity include platelet indices (e.g. platelet count, 
MPV), IPF (as a measurement of platelet production), platelet activation and 
aggregation.  
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4.2 Results 
 
4.2.1 Baseline Characteristics for the Type 2 Diabetic Cohort  
A total of forty subjects diagnosed with type 2 diabetes were recruited for this 
study. A summary of the baseline characteristics for the type 2 diabetic patients 
are given in Table 4.1. There were twenty female diabetics and twenty male 
diabetics in the study. The mean age of the diabetic population was 58.6 + 9.1 
years. The mean duration of diabetes was 11.9 + 5.8 years. The mean BMI was 
32.3 + 5.8 kg/m2, with twenty-four (60.0%) of the forty patients with a BMI over 
30 kg/m2 and categorised as obese (World Health Organisation, 2017). Only four 
(10.0%) of the forty diabetic subjects was a current smoker and thirteen (32.5%) 
were previous smokers. 
 
Out of the forty diabetic subjects, twenty-three (57.5%) were injecting insulin, and 
thirty-two (80.0%) were taking other anti-hyperglycaemic medication such as 
Metformin, sulfonylureas, SGL-2 inhibitors and DPP-4 inhibitors. Twenty-six 
(65.0%) were taking antihypertensive medication and thirty-five (87.5%) were 
taking lipid lowering medication, with thirty-two (80.0%) taking statins.  
 
The mean FBG was 9.2 + 3.6 mmol/L. The mean HbA1c level was 66.6 + 19.1 
mmol/mol. The mean total cholesterol was 4.7 + 1.3. The mean HDL-C was 1.3 
+ 0.5 mmol/L. The mean LDL-C was 2.4 + 1.0 mmol/L. The mean triglyceride 
level was 2.1 + 1.1 mmol/L. The serum creatinine gives an indication of kidney 
function and the range (min-max) for females was 51-123 μmol/L and for males 
63-190 μmol/L. Normal reference ranges are between 45-84 μmol/L for females 
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and 59-104 μmol/L for males (Central Manchester University Hospitals NHS 
Foundation Trust, 2018). The mean values for platelet count and MPV, PDW and 
P-LCR are given in table 4.2.  
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Table 4.1: Baseline characteristics for the type 2 diabetic cohort 
 
 n=40 
M/F (n) 20/20 
Age (yr), mean + SD 58.6 + 9.1 
Duration of diabetes (yr), mean + SD 11.9 + 5.8$ 
BMI (kg/m2), mean + SD 32.3 + 5.8 
Current smoker (%) 10.0 
Previous smoker (%) 32.5 
Medication Profile (%)  
Insulin 57.5 
Other anti-hyperglycaemic medication  80.0 
Antihypertensive agents 65.0 
Lipid lowering drugs (incl. statins) 87.5 
History of (%)  
Peripheral neuropathy 17.5 
Retinopathy 17.5 
Acute kidney injury 7.5 
Hypertension 70.0 
Laboratory variables  
Fasting blood glucose (mmol/L), mean + SD 9.2 + 3.6 
HbA1c (mmol/mol), mean + SD 66.6 + 19.1 
Total Cholesterol (mmol/L), mean + SD 4.7 + 1.3 
LDL-C (mmol/L), mean + SD 2.4 + 1.0 
HDL-C (mmol/L), mean + SD 1.3 + 0.5 
Triglycerides (mmol/L), mean + SD 2.1 + 1.1 
Serum creatinine (μmol/L), range (min-max)  Female: 51-123, Male: 
63-190 
$ denotes missing data for 1 patient (n=39) 
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4.2.2 Platelet Indices  
 
Elevated MPV has been reported to be associated with the risk of myocardial 
infarction (Martin et al., 1991) and hyperglycaemia (Demirtunc et al., 2009; 
Kodiatte et al., 2012; Ozder et al, 2014; Ulutas et al., 2014). The measurement 
of MPV is a cheap, effective test that may be used to predict cardiovascular risk 
in type 2 diabetic patients. The aim of this study was to investigate the relationship 
between platelet count and platelet size in type 2 diabetic patients. 
 
Table 4.2: Platelet parameters for the type 2 diabetic cohort 
 
Platelet parameter  Mean + SD (n=40) 
Platelet count (x109/L) 250.73 + 54.93 
MPV (fL) 10.75 + 1.08   
PDW (fL) 13.73 + 2.57 
P-LCR (%) 33.23 + 8.95 
 
Platelet count for all patients fell within the normal range and there was no 
correlation with platelet count and FBG or HbA1c.  There was also no relationship 
between platelet count and LDL-C, HDL-C or duration of diabetes. There was 
however a significant positive correlation between platelet count and BMI 
(p=0.019; Table 4.3). There was also a trend towards a positive correlation with 
triglycerides, though not significant (p=0.096). To assess whether 
hyperglycaemia was associated with platelet size in the diabetic cohort, FBG and 
HbA1c were correlated with MPV, PDW and P-LCR.  There was a significant 
positive correlation between HbA1c and all measures of platelet size tested (MPV 
p=0.040; PDW p=0.033; and P-LCR p=0.039). In contrast, FBG did not correlate 
with any of the measures of platelet size (Table 4.3). 
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Correlations with other biochemical and demographic characteristics associated 
with diabetes revealed no relationship between platelet size and LDL-C, HDL-C, 
triglycerides or BMI. However, there was a strong negative relationship for the 
duration of diabetes and MPV (p=0.002, PDW p=0.004 and P-LCR, p=0.003, 
Table 4.3). 
   
Table 4.3: Correlations for platelet indices and biochemical parameters in 
type 2 diabetic patients 
 
 Platelet 
count 
 MPV  PDW  P-LCR  
Variable R  P value R  P value R  P value R  P value 
Age -0.096 0.559 -0.148 0.363 -0.157 0.332 -0.152 0.350 
HbA1c -0.111 0.495 0.106 0.040* 0.338 0.033* 0.328 0.039* 
FBG -0.252 0.117 0.166 0.298 0.178 0.272 0.177 0.276 
LDL-C 0.169 0.298 -0.033 0.835 -0.077 0.638 -0.039 0.809 
HDL-C -0.118 0.468 0.126 0.434 0.019 0.909 0.101 0.536 
Triglycerides 0.267 0.096 -0.083 0.604 -0.171 0.291 -0.048 0.770 
BMI 0.370 0.019* -0.184 0.257 -0.301 0.059 -0.167 0.302 
Duration of 
diabetes 
0.135 0.412 -0.412 0.009** -0.454 0.004** -0.418 0.008** 
Pearson correlation coefficient used to calculate the correlations for HbA1c, LDL-C, triglycerides 
and BMI. All other correlations calculated using the Spearman test. * represents p=<0.05. ** 
represents p=<0.005. *** represents p=<0.0005. All tests n=40, except duration of diabetes 
(n=39). 
 
 
It has been shown that type 2 diabetic patients with an HbA1c above 64 mmol/mol 
are more at risk of macrovascular complications (van Wijingaarden et al., 2017). 
Consequently, an independent t-test was performed to determine if patients with 
HbA1c >64 mmol/mol had an elevated MPV. The mean + SD MPV was 10.47 + 
0.23 fL for <63 mmol/mol and was significantly higher at 11.32 + 0.20 fL for >64 
mmol/mol (p=0.009; Figure 4.1A).   
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To determine whether there was a significant difference in MPV between higher 
and lower FBG levels, the patient samples were grouped into those <8.9 mmol/L 
and those >9.0 mmol/L. These values were based on evidence from a large meta-
analysis, which identified 9.0 mmol/L FBG as a level that increased the relative 
risk of cardiovascular events from 1 to 2.2 (Coutinho et al., 1999). Results showed 
no significant difference in MPV between the lower and higher FBG groups (10.83 
+ 0.22 fL and 10.98 + 0.26 fL, respectively, p=0.811; Mann-Whitney, Figure 4.1B).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
112 
 
  A                                                              B            
<
6
3
 
>
6
4
8
1 0
1 2
1 4
1 6
H b A 1 c  ( m m o l / m o l )
M
P
V
 
(
f
L
)
0
  p = 0 . 0 0 9
<
8
. 9
 
>
9
. 0
8
1 0
1 2
1 4
1 6
F B G  ( m m o l / L )
M
P
V
 
(
f
L
)
0
 
Figure 4.1: Comparison of MPV in type 2 diabetic patients with high and low 
glucose levels 
Figure A: An independent t-test identified a significant increase in MPV in patients with HbA1c 
>64 mmol/mol (p=0.009, n=20, 20). Figure B: A Mann-Whitney test showed no significant 
difference in MPV in patients with FBG >9.0 mol/L (p=0.811) (n=24, 16). Bars represented as 
mean + SEM.  
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4.2.3 Thrombopoiesis 
 
Larger, younger platelets are metabolically and enzymatically more active, and 
have greater prothrombotic potential (Chu et al., 2009). Furthermore, they are 
often immature platelets that contain residual mRNA and a greater number of 
dense granules (Mijovic et al., 2015). A larger number of immature platelets in 
the platelet population reflects increased thrombopoiesis (Hannawi et al., 2018). 
To assess whether increased thrombopoiesis and a larger number of immature 
platelets contributes to the increased platelet size observed with hyperglycaemia 
(Table 4.3), the percentage of reticulated platelets (known as ‘IPF’) was 
correlated with HbA1c and FBG in a subset of twenty of the type 2 diabetic 
patients recruited to the study (see Table 4.1 for baseline characteristics of the 
cohort).  
 
The mean IPF for the diabetic cohort was 12.14 + 8.56 % (n=20) and the mean 
platelet count was 245.0 + 51.7 x109/L. There was no correlation between the 
platelet count and reticulated platelets (r=0.057, n=20, p=0.811). 
 
Correlations with other diabetic-related parameters however showed that 
reticulated platelets positively correlated with LDL-C in type 2 diabetic patients 
(p=0.044) (Table 4.4). No correlation was observed with any other clinical 
parameter. 
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Table 4.4: Correlations for reticulated platelets and 
clinical parameters in type 2 diabetic patients 
 
 Reticulated 
platelets 
 
Variable R  P value 
Age 0.345 0.136 
HbA1c -0.144 0.545 
FBG -0.762 0.762 
LDL-C 0.454 0.044* 
HDL-C 0.324 0.164 
Triglycerides 0.124 0.603 
BMI -0.095 0.691 
Duration of diabetes 0.207 0.381 
All correlations calculated using the Spearman test. * represents 
p=<0.05, n=20. 
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4.2.4 Platelet Activation Markers 
 
Data related to platelet activation markers in diabetic patients without prior CV 
events is limited and conflicting (Shlomai et al., 2015). To investigate the 
activation state of circulating platelets in type 2 diabetic patients, -granule 
secretion (CD62P) and IIb3 activation (PAC1 binding) was measured in resting 
and activated platelets. Due to technical failures with the flow cytometer, 
measurements were performed on thirty of the forty diabetic patients recruited 
(see Table 4.1 for baseline characteristics for the forty patients). In resting 
platelets, the mean fluorescent intensity (MFI) representing CD62P membrane 
expression was 25.03 + 19.69 in resting platelets, with a significant increase to 
1422.53 + 497.86 following ADP stimulation (5.0 μmol/L) (Mann Whitney test, 
p=<0.0001) (Figure 4.2A). PAC-1 levels significantly increased from a resting 
level of 11.66 + 5.00 to 321.0 + 98.30 following ADP stimulation (5.0 μmol/L) 
(Mann Whitney test, p=<0.0001) (Figure 4.2B).    
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Figure 4.2: Activation markers in resting and ADP-activated platelets in 
type 2 diabetic patients 
Figure A: Mean CD62P surface expression (MFI) in resting and ADP-activated platelets (ADP 
5.0 μmol/L) type 2 diabetic patients. Figure B: Mean PAC-1 binding (MFI) in resting and ADP-
activated platelets (ADP 5.0 μmol/L) type 2 diabetic patients. Values represented as mean + SEM. 
**** represents p=<0.0001 (n=30). 
 
 
CD62P expression in resting platelets ranged from 6 to 99 MFI and in activated 
platelets ranged from 289 to 2536. Correlations with the clinical parameters of the 
patients showed no correlation with any of the parameters and the extent of 
CD62P exposure in resting or ADP-activated platelets (Table 4.5). Although there 
was a close to significant relationship between the duration of diabetes and 
CD62P expression in activated platelets (p=0.052). PAC-1 binding in resting and 
ADP-activated platelets ranged from 1 to 22; and 289 to 580, respectively, within 
the diabetic cohort. Similar to CD62P, there was no correlation with any of the 
clinical parameters assessed and extent of IIb3 activation (Table 4.5). 
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Table 4.5: Correlations for platelet activation markers and clinical 
parameters in type 2 diabetic patients 
 
 CD62P:  
Resting 
platelets 
 PAC-1 
Resting 
platelets 
 CD62P: 
Activated 
platelets 
 PAC-1: 
Activated 
platelets 
 
Variable R  P 
value 
R  P 
value 
R  P 
value 
R  P 
value 
Age 0.072 0.706 -0.089 0.640 0.326 0.079 0.145 0.446 
HbA1c 0.193 0.306 -0.130 0.493 0.059 0.758 -0.024 0.898 
FBG 0.289 0.122 -0.088 0.644 -0.083 0.661 -0.077 0.688 
LDL-C 0.065 0.735 -0.287 0.125 -0.019 0.919 -0.177 0.349 
HDL-C -0.068 0.720 -0.333 0.072 0.102 0.591 -0.003 0.987 
Triglycerides -0.010 0.959 -0.081 0.671 -0.188 0.320 -0.221 0.241 
BMI 0.092 0.628 -0.143 0.452 0.154 0.415 -0.243 0.196 
 
Duration of 
diabetes 
0.260 0.165 -0.194 0.305 0.359 0.052 0.011 0.955 
All correlations calculated using Pearson, except those with the variables HbA1c, LDL-C and 
HDL-C, and correlations for CD62P expression in resting platelets, which used the Spearman test 
(n=30). 
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4.2.5 Soluble P-selectin 
 
Circulating sP-selectin (originating from endothelial cells and platelets) has been 
implicated in the development of atherosclerotic lesions (Burger and Wagner, 
2003), and elevated levels of sP-selectin have been found in diabetic patients 
(Kopp et al., 1998). sP-selectin levels have also been shown to be a good marker 
of in vivo platelet activation status (Ferroni et al., 2009). To determine whether 
there was a relationship between in vivo platelet activation state and any of the 
clinical characteristics associated with the diabetic patients, sP-selectin was 
measured and correlated with the clinical parameters of the group.  
 
The mean sP-selectin for the 40 patients was 5275.99 + 2184.91 pg/ml, with a 
range of 2481.88 to 14514.01 pg/ml. Table 4.6 shows the correlations for sP-
selectin and clinical parameters. There was a significant positive correlation for 
sP-selectin and duration of diabetes (p=0.034). All other variables did not 
significantly correlate with sP-selectin. 
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Table 4.6: Correlations for sP-selectin and 
clinical parameters in type 2 diabetic patients 
 
 Soluble P-
selectin 
 
Variable R  P value 
Age 0.176 0.277 
HbA1c -0.101 0.536 
FBG -0.031 0.850 
LDL-C -0.105 0.519 
HDL-C -0.087 0.593 
Triglycerides 0.141 0.385 
BMI 0.228 0.157 
Duration of diabetes$ 0.340 0.034* 
All correlations calculated using the Pearson test, except 
HDL-C (Spearman). * represents p=<0.05, n=40 (except 
variable denoted $ with n=39). 
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4.2.6 Platelet Aggregation 
 
Light transmission aggregometry (LTA) is the gold standard method for assessing 
platelet function. To investigate whether platelet aggregation is associated with 
clinical characteristics associated with diabetes (e.g. hyperglycaemia, 
dyslipidaemia and BMI), PRP from diabetic subjects was stimulated with 
submaximal concentrations of physiological platelet agonists collagen or ADP. 
  
Plasma was available for thirty-five of the forty diabetic patients recruited to 
perform LTA. A summary of the baseline characteristics for the type 2 diabetic 
patients are given in Table 4.1.  
 
Platelet aggregation was measured in response to submaximal concentrations of 
ADP (5.0 μmol/L) and collagen (1.0 μg/ml), elucidated from a dose response 
(Appendix 9.1). Maximal aggregation for ADP was 76.23 + 14.07 % following 5 
minutes stimulation and 81.80 + 6.69 % for collagen. To investigate whether the 
level of agonist induced platelet reactivity in the diabetic cohort was related 
specifically to anyone of the clinical parameters measure a series of correlations 
were performed (Table 4.7). 
 
Data showed no correlation between the extent of ADP or collagen-induced 
aggregation and HbA1c or FBG further supporting the notion, that 
hyperglycaemia does not enhance platelet reactivity. The data did however show 
a strong positive correlation with LDL-C levels and the maximal aggregation 
achieved with ADP (Spearman, r=0.501, p=0.002) and collagen (Spearman, 
r=0.535; p=0.001) (Figure 4.3A and B). In addition, there was a significant 
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negative correlation for BMI and ADP-stimulated aggregation. (Spearman, r=-
0.426, n=35, p=0.011). 
 
 
Table 4.7: Correlations between platelet aggregation and 
clinical parameters in type 2 diabetic patients 
 
 ADP- 
activated 
aggregation 
(maximum %) 
 Collagen- 
activated 
aggregation  
(maximum %) 
 
Variable R  P value R  P value 
Age -0.027 0.876 0.012 0.946 
HbA1c -0.162 0.354 -0.078 0.055 
FBG -0.063 0.718 0.122 0.485 
LDL-C 0.501 0.002** 0.535 0.001** 
HDL-C 0.266 0.122 0.220 0.205 
Triglycerides -0.117 0.504 0.114 0.514 
BMI -0.470 0.004** -0.273 0.113 
Duration of 
diabetes 
-0.264 0.125 -0.294 0.087 
Pearson correlation coefficient used to calculate the correlations for age, 
triglycerides, BMI and duration of diabetes. All other correlations, including those 
correlated against collagen, were calculated using the Spearman test. ** 
represents p=<0.005 (n=35). 
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Figure 4.3: The relationship between LDL-C and maximal platelet 
aggregation in type 2 diabetic patients 
Figure A: represents the correlation between LDL-C and ADP-stimulated aggregation in type 2 
diabetic patients (Spearman, p=0.002, n=35). Figure B: represents the correlation between LDL-
C and collagen-stimulated aggregation (Spearman, p=0.001, n=35). 
 
 
 
 
Although NICE guidelines recommend using non-HDL-C to assess 
cardiovascular risk (NICE, 2018), guidance from the Joint British Societies 
(2005), recommended that people at high risk of cardiovascular disease, 
including diabetic patients, should aim for a target LDL-C of < 2.0 mmol/L and the 
NHS states that diabetic patients should have LDL-C <2.0 mmol/L (NHS, 2018). 
To assess whether platelet reactivity is significantly altered between LDL-C levels 
below and above 2.0 mmol/L, aggregation responses to ADP and collagen were 
grouped based of LDL-C plasma concentration and a Mann-Whitney U test 
performed to statistically compare responses (Figure 4.4A and Figure 4.4B). 
Patients with LDL-C above 2.0 mmol/L demonstrated significantly increased 
platelet aggregation in response to both ADP- and collagen (p=0.005 and 
p=0.016, respectively). 
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Figure 4.4: Maximal platelet aggregation in type 2 diabetic patients with 
LDL-C levels above and below 2.0 mmol/L 
Figure A: represents ADP-stimulated platelet aggregation in type 2 diabetic patients with LDL-C 
<2.0 mmol/L and >2.0 mmol/L. The mean + SEM for platelet aggregation were 69.38% + 3.51% 
and 82.0% + 2.65%. Figure B: represents collagen-stimulated platelet aggregation in type 2 
diabetic patients with LDL-C <2.0 mmol/L and >2.0 mmol/L. The mean + SEM for platelet 
aggregation were 80.44% + 0.84% and 82.95% + 1.95%. P values calculated using the Mann-
Whitney U test for non-parametric data. Bars represented as mean + SEM (n=16, n=19). 
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4.2.7 Oxidised LDL 
 
The correlation data from section 4.2.6 identifies LDL-C as the most important 
biochemical risk factor for platelet hyperreactivity in type 2 diabetic patients. 
Literature suggests that circulating ox-LDL is increased in type 2 diabetic patients 
(Nakhjavani et al., 2010) and that platelet hyperreactivity is associated with ox-
LDL (Podrez et al., 2007). However, research also indicates that platelet 
hyperreactivity is induced by ox-LDL via an indirect effect caused by modulation 
of cGMP signalling (Magwenzi et al., 2015). In this study, we investigated whether 
there is a relationship between ox-LDL levels and the clinical parameters 
associated with the diabetic cohort and also whether ox-LDLC levels are related 
to platelet responsiveness to agonists. 
 
An ox-LDL ELISA was performed on the plasma samples for the forty diabetic 
patients recruited in this study. The ox-LDL levels were detected within the 
standard curve for thirty-one of the forty plasma samples. The mean + SD ox-
LDL for these samples was 1161.27 pg/ml + 188.95 pg/ml.  
 
Correlations were carried out with ox-LDL (pg/ml) concentrations against clinical 
characteristics and platelet reactivity. Research suggests that the ox-LDL/LDL-C 
and ox-LDL/HDL-C ratios can be used as predictors of CAD (Huang et al., 2008), 
therefore correlations were also performed with the ox-LDL/LDL-C and ox-
LDL/HDL-C ratios.  
 
A positive correlation with BMI and both ox-LDL/LDL-C ratio (p=0.006) and ox-
LDL/HDL-C ratio (p=0.020) (Table 4.8 and Figure 4.5A). 
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The ox-LDL levels did not significantly correlate with ADP-stimulated aggregation 
(p=0.279) or collagen-stimulated aggregation (p=0.567) (Table 4.9).  
Paradoxically, there was a strong inverse correlation between ox-LDL/LDL-C and 
ADP and collagen-stimulated aggregation (p=<0.00003 and p=0.0003, 
respectively) (Table 4.9 and Figure 4.5C and Figure 4.5D). There was also a 
negative association between ADP-stimulated platelet aggregation and ox-LDL-
C/HDL-C ratio (p=0.010). 
 
Additionally, there was a strong negative association with CD62P surface 
expression and ox-LDL in resting platelets (p=0.004) (Table 4.9 and Figure 4.5B). 
 
Table 4.8: Correlations between clinical parameters and ox-LDL, ox-
LDL/LDL-C and ox-LDL/HDL-C in type 2 diabetic patients  
  
 Ox-LDL  Ox-
LDL/LDL-
C 
 Ox-
LDL/HDL-
C 
 N 
Variable R P value R P value R  P value  
Age -0.130 0.486 -0.148 0.426 -0.230 0.214 31 
HbA1c 0.012 0.949 0.058 0.755 0.137 0.462 31 
FBG -0.189 0.307 -0.147 0.431 -0.006 0.974 31 
BMI -0.065 0.728 0.479 0.006** 0.417 0.020* 31 
Duration of 
diabetes 
-0.186 0.318 0.209 0.200 0.299 0.215 31 
All correlations calculated using the Pearson coefficient, except correlations with FBG which was 
calculated using the Spearman test. * represents p < 0.05, ** represents p < 0.01. 
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Table 4.9: Correlations between platelet reactivity and ox-LDL in type 2 
diabetic patients 
 
 Ox-LDL  Ox-
LDL/LDL-
C 
 Ox-
LDL/HDL-
C 
 N 
Platelet 
count 
-0.110 0.557 -0.188 0.311 0.210 0.257 31 
MPV -0.255 0.167 -0.043 0.820 -0.196 0.291 31 
CD62P in 
resting 
platelets 
-0.632 0.004** -0.303 0.208 -0.129 0.600 19$ 
PAC-1 in 
resting 
platelets 
0.028 0.909 0.218 0.370 0.151 0.538 19$ 
CD62P in 
activated 
platelets 
-0.008 0.974 0.013 0.957 0.207 0.395 19$ 
PAC-1 in 
resting 
platelets 
0.210 0.389 -0.168 0.492 0.183 0.452 19$ 
ADP- 
stimulated 
aggregation 
-0.201 0.279 -0.679 0.00003**** -0.455 0.010* 31 
Collagen-
stimulated 
aggregation 
-0.107 0.567 -0.607 0.0003**** -0.147 0.430 31 
All correlations calculated using the Pearson coefficient, except correlations with FBG, CD62P 
expression in resting platelets and collagen-stimulated aggregation which were calculated using 
the Spearman test. * represents p < 0.05, ** represents p < 0.01 and **** represents p < 0.0001. 
$ 19 samples were correlated with CD62P and PAC-1 binding due to technical problems with the 
flow cytometry. 
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Figure 4.5: Correlations for ox-LDL in type 2 diabetic patients 
Figure A: represents a Pearson correlation for ox-LDL/LDL-C and BMI (r=0.479, n=31, p=0.006). 
Figure B: represents a Spearman correlation for ox-LDL and CD62P membrane expression in 
resting platelets (r=-0.632, n=19, p=0.004). Figure C: represents a Pearson correlation for ox-
LDL/LDL-C and ADP-stimulated platelet aggregation (r=-0.0679, n=31, p=0.00003). Figure D: 
represents a Spearman correlation for ox-LDL/LDL-C and collagen-stimulated platelet 
aggregation (r=-0.0607, n=31, p=0.0003).   
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4.3 Discussion 
 
This study has shown that elevated platelet count is associated with BMI in 
diabetic patients (p=0.019), with a trend towards an elevated platelet count with 
increased triglycerides (p=0.096). This supports research by Akinsegun et al. 
(2014) who also identified a positive relationship between BMI and platelet count 
in a type 2 diabetic cohort. Samocha-Bonet et al. (2008) identified elevated 
platelet counts in obese subjects, particularly in subjects with elevated C-reactive 
protein levels (a marker of inflammation). They suggested that elevated platelet 
count is associated with chronic inflammation due to higher body fat mass. A 
large amount of the literature suggests that inflammatory mediators are 
associated with obesity (Wellen and Hotamisligil, 2005), and platelets are now 
being considered as key players in inflammation (Stokes and Granger, 2012). 
 
MPV is positively correlated with HbA1c levels in type 2 diabetic patients, 
indicating that hyperglycaemia is associated with increased platelet size. This 
supports the in vitro data in section 3.1 and the literature which shows an 
association between HbA1c and MPV ex vivo (Demirtunc et al., 2009; Kodiatte 
et al., 2012; Ozder et al, 2014; Ulutas et al., 2014). Furthermore, patients with 
HbA1c >64 mmol/L have significantly elevated MPV. Conversely, FBG does not 
correlate with type 2 diabetes, and this supports the work by Demirtunc et al. 
(2009) and Hekimsoy et al. (2004) who reported a correlation between MPV and 
HbA1c, and no correlation between MPV and FBG. The increased platelet size 
does not appear to be related to increased platelet reactivity. Given that a) we 
observed an effect in vitro, independent of any contribution from thrombopoiesis 
and b) there was no relationship between hyperglycaemia and IPF in diabetic 
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samples, the increase in platelet volume evoked by hyperglycaemia is likely 
through osmotic/diffusion effects. This phenomenon has also been observed in 
erythrocytes by uptake of glucose via the GLUT transporters (Lösche et al., 
1989).  
 
Unexpectedly, we have demonstrated that MPV is inversely related to the 
duration of diabetes. The majority of patients in this study are taking statins and 
anti-diabetic medication such as metformin, and research suggests that statins 
decrease MPV (Sivri et al., 2013; Xian-Yu et al., 2015; Akyüz et al., 2016) as well 
as metformin (DolasıK et al., 2013). It could be postulated that the longer the 
patients have diabetes, the longer they take this medication and the more the 
MPV will decrease. Another reason for the inverse correlation could be due to 
platelet consumption at the sites of high-level inflammation that correspond to 
diabetic complications, such as renal failure (Bilen et al., 2015). Another 
explanation is that patients with late stage diabetes have more vascular disease 
and there is an increase in vivo platelet activation demonstrated by elevated sP-
selectin levels (Kopp et al., 1998). Larger more active platelets are therefore 
immobilised in vessels leaving the smaller, less active platelets in the circulation. 
This explanation is supported by the sP-selectin correlation data (Section 4.2.5) 
that showed a significant relationship between sP-selectin and duration of 
diabetes. This corroborates findings from Aref et al. (2005) that showed 
insignificantly elevated sP-selectin in early-stage diabetic patients (without CAD) 
compared to controls, and significantly elevated sP-selectin in late stage diabetes 
with CAD. 
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A positive correlation was identified with LDL-C and reticulated platelets. This 
indicates that high levels of LDL-C increase the thrombopoiesis, particularly since 
there was no overall increase in platelet number. Research has shown that 
younger platelets are metabolically and enzymatically more active, and have 
greater prothrombotic potential (Mijovic et al., 2015). Furthermore, diabetic 
patients do not respond well to antiplatelet therapy such as aspirin, and it is 
thought that this is due to the high levels of immature platelets because the newly 
released platelets have not been inhibited by the aspirin (Guthikonda et al., 2007). 
Consequently, the results from this study suggest that elevated LDL-C levels can 
increase the levels of immature platelets, and this in turn reduces the patient’s 
response to the aspirin. 
 
The key finding from this study is that there is a strong positive correlation 
between LDL-C and both ADP and collagen-stimulated platelet aggregation. This 
supports the results for the correlations with thrombopoiesis and LDL-C. 
Potentially, the high level of younger, more metabolically active platelets is 
increasing their ability to aggregate, and this is dependent on the levels of LDL-
C in the circulation.  
 
There were no significant correlations for the platelet activation markers, CD62P 
and PAC-1. Considering PAC-1 binding measures IIb3 activation, the final step 
towards platelet aggregation, one would assume that PAC-1 binding would 
correlate with LDL-C.   
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When we investigated the relationship between ox-LDL and platelet reactivity, we 
identified a negative relationship between ox-LDL/LDL-C and platelet 
aggregation. This would indicate that it is native LDL that is potentiating the 
platelet aggregation in type 2 diabetic patients, not ox-LDL. Additionally, BMI 
negatively correlates with platelet aggregation but positively correlates with ox-
LDL/LDL-C, demonstrating that elevated BMI decreases platelet aggregation 
because the n-LDL is converted to ox-LDL.  
 
Most of the literature has pointed to ox-LDL as a reason for platelet 
hyperreactivity, however, we have shown a negative correlation with ox-
LDL/LDL-C and a positive correlation with LDL-C. It is possible that the native 
LDL is potentiating platelet aggregation, however, further research is required to 
investigate this. Other literature has shown that cholesterol accumulation disturbs 
the composition of the membrane in various hematopoietic cells and enhances 
receptor signalling (Zhu et al., 2010; Yvan-Charvet et al, 2010). Increased 
expression of P2Y12 has been reported in diabetic patients (Hu et al., 2017). Thus, 
plasma membrane cholesterol accumulation in platelets could potentially alter the 
membrane structure and affect signalling via surface receptors, such as P2Y12. 
This, in turn, would reduce the ability for antiplatelet therapies (such as 
clopidogrel) to work effectively. 
 
To the best of our knowledge, this is the first study to identify LDL-C as a risk 
factor for platelet hyperreactivity in type 2 diabetic patients, and that LDL-C may 
act as a biomarker to identify type 2 diabetic patients who would benefit from 
antiplatelet prophylaxis. Additionally, enhanced platelet turnover mediated by 
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elevated LDL-C may be responsible for reduced antiplatelet efficacy in type 2 
diabetic patients. 
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5 Identification of Inflammatory Mediators Associated 
with Platelet Reactivity in Type 2 Diabetic Patients  
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5.1 Introduction 
 
The majority of type 2 diabetic patients become insulin resistant because of 
obesity and physical inactivity, and this is associated with chronic inflammation 
(Wellen and Hotamisligil, 2005). The proposed mechanism that causes low-level 
inflammatory is increased adipose tissue and hyperglycaemia, which leads to 
oxidative stress and the accumulation of macrophages in the endothelium 
(Wellen and Hotamisligil, 2005). Macrophages release proinflammatory cytokines 
that alter insulin signalling pathways, enhancing insulin resistance and impaired 
glucose homeostasis (Badawi et al., 2010). Consequently, type 2 diabetic 
patients have differing cytokine profiles to healthy people (Al-Shukaili et al., 
2013). 
 
Accumulating studies are showing that platelets have (thrombo)-inflammatory 
responses (Stokes and Granger, 2012). As platelets move through the 
vasculature of inflamed tissue, inflammatory mediators can activate platelets 
such as cytokines and chemokines (Gleissner et al., 2008). Also, platelets can 
themselves initiate inflammatory responses through their receptors (Vieira-de-
Abreu et al., 2012).  
  
To investigate the relationship between platelet reactivity and inflammation in 
type 2 diabetes, we used a multiplex immunoassay to simultaneously measure 
inflammatory mediators including cytokines, chemokines and growth factors. The 
inflammatory profile of the plasma was measured using a panel of twenty 
inflammatory molecules, of these ten had plasma concentration in the detectable 
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range in fifteen samples or more (Table 5.1). Inflammatory markers detected in 
less than fifteen samples were not included in the correlations. 
 
Table 5.1: Inflammatory markers used in the immunoassay 
 
 
Target 
protein 
Anti- or pro-
atherogenic 
Roles in atherosclerosis and 
diabetes  
Roles in platelet 
function and 
production 
 
E-selectin Pro Expressed on endothelial cells. 
AGEs bind to RAGE on 
endothelial cells and induce 
expression of E-selectin (Basta et 
al., 2002). 
Knockout of P-selectin 
and E-selectin decreases 
atherosclerosis in murine 
models (Collins et al., 
2000). 
IL-1 Pro Activation of macrophages and 
endothelial cells (Fatkhullina et al., 
2016). Increased expression 
associated with hyperglycaemia 
(Butkowski and Jelinek, 2016). 
Synthesised in platelets 
(Vieira de Abreu et al., 
2012). Stimulates 
thrombopoiesis (Jiang et 
al., 1994). 
IL-12p70 Anti Active heterodimer of the 
inflammatory cytokine, IL-12 (Gee 
et al., 2009). Involved in anti-
angiogenesis. 
IL-12 caused platelets to 
be hyperreactive and 
spread (Page et al., 
2018). 
IL-13 Anti Inhibits foam cell formation by 
Inhibiting MCP-1transcriptionin 
macrophages (Berkman et al., 
1996).  
 
 
Expressed by a human 
megakaryocyte-like cell 
line (Soslau et al., 1997). 
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Table cont.    
IL-6 Pro Foam cell formation (Fatkhullina et 
al., 2016). Increased expression 
associated with hyperglycaemia 
(Butkowski and Jelinek, 2017). 
 
 
Stimulates 
thrombopoiesis (Jiang et 
al., 1994). 
IP-10 ?? 
 
Inhibition of angiogenesis by IL-12 
is mediated by IP-10 (Sgadari et 
al., 1996). Chemoattractant for 
monocytes and lymphocytes 
(Taub et al., 1993). 
Mediates IL-12 activation 
(10 (Sgadari et al., 1996). 
IL-12 caused platelets to 
be hyperreactive and 
spread (Page et al., 
2018). 
MCP-1 
(CCL2) 
Pro Chemoattractant for monocytes 
(Deshmane et al., 2009). 
Contributes to macrophage 
recruitment and insulin resistance 
(Kamei el., 2006). 
Secreted by endothelial 
cells in the presence of 
activated platelets (Cha 
et al., 2000). 
MIP1
(CCL3) 
Pro Foam cell formation (Berkman et 
al., 1996).   
Stored in platelets 
(Klinger et al., 1995). 
Secreted by endothelial 
cells in the presence of 
activated platelets (Cha 
et al., 2000). 
sICAM-1 Pro Promotes adhesion of leukocytes 
to the endothelium. AGEs bind to 
RAGE on endothelial cells and 
induce expression of ICAM-1 
(Basta et al., 2002). 
 
Activated platelets bind to 
endothelium via ICAM-1 
(Bombelli et al., 1998) 
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Table cont.    
TNF- Pro Deficiency in TNF- reduces foam 
cell formation and the expression 
of several proinflammatory 
markers. 
TNF- triggers TXA2 
activation (Pignatelli et 
al., 2005). 
 
IL: Interleukin; IP: Interferon gamma-induced protein, MCP: Monocyte chemoattractant protein, 
sICAM: soluble intercellular adhesion molecule, TNF: Tumor necrosis factor. 
 
 
 
 
 
 
 
In this chapter, the aim was to determine whether the inflammatory status of the 
diabetic cohort was related to any of the other clinical characteristic associated 
with type 2 diabetes (e.g. glycaemic control, lipoprotein levels or BMI) or whether 
it was independent of these parameters. More importantly, correlations were 
performed to evaluate whether inflammatory status was related to platelet 
reactivity or the activation state of platelets ex vivo, and more specifically which 
cytokines or inflammatory markers.  
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5.2. Results 
 
5.2.1 Inflammatory Mediators and Clinical Parameters  
 
Diabetes and obesity are associated with chronic inflammation induced by 
oxidative stress (De Bandiera et al., 2013). This may be caused by AGE-RAGE 
signalling pathways activating NF which, in turn, triggers cytokine transcription 
and leukocyte recruitment to the vascular wall (De Bandiera et al., 2013, Nonaka 
et al., 2018).  Moreover, Butkowski and Jelinek (2017) identified several 
inflammatory markers associated with hyperglycaemia including IL-1, IL-6, IL-
10 and MCP-1. Conversely, a study reported that elevated fatty acids induce an 
increase in inflammatory adhesion molecules (e.g. ICAM-1), not hyperglycaemia, 
in an endothelial cell line mimicking diabetic retinopathy (Chen et al., 2003).  
  
To investigate the inflammatory status of the diabetic cohort and determine 
whether it was related to any of the other diabetes-related characteristics of the 
cohort, an inflammatory cytokine multiplex assay was performed on the patient 
plasma samples and correlated with the clinical parameters. The mean plasma 
concentrations of each of the ten markers measured are shown in Table 5.2. 
Correlation data demonstrated that HbA1c negatively correlated with IL-1 and 
positively correlated with IP-10 (p=0.013 and p=0.045, respectively) (Table 5.3). 
Age negatively correlated with E selectin and positively correlated with IL-1 
(p=0.030 and p=0.013, respectively). HDL-C negatively correlated with E-selectin 
and siCAM1 (p=0.021 and p=0.013, respectively). There was a negative 
association with IL-13 and triglycerides (p=0.045).   
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Table 5.2: Mean values for inflammatory mediators in type 2 diabetic 
patients 
 
Inflammatory marker  Mean + SD (pg/ml)  N 
E-selectin 46115.45 + 6695.58 40 
IL-1 160.77 + 147.25 26‡ 
IL-12p70 809.87 + 574.35 36‡ 
IL-13 177.62 + 271.05 32‡ 
IL-6 2933.13 + 2590.38 23‡ 
IP-10 288.85 + 294.66 40 
MCP-1 414.85 + 200.74 40 
MCP-1 302.27 + 312.34 26‡ 
sICAM-1 30701.51 + 15124.68 40 
TNF 1515.16 + 858.00 40 
‡ denotes correlations with missing data due to the protein concentration being below the lower 
limit of detection. 
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$ denotes 1 missing value, no record of duration of diabetes on patient record. E.sel.: E-selectin, IL: Interleukin; IP: Interferon 
gamma-induced protein, MCP: Monocyte chemoattractant protein, sICAM: soluble intercellular adhesion molecule, TNF: Tumor 
necrosis factor. N=40 (some cytokine data was outside the limit of detection). 
 
 
Table 5.3: Clinical characteristics correlated with inflammatory mediators 
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5.2.2 Inflammatory Mediators and Platelet Indices 
 
Diabetic patients have elevated platelet count (Sterner et al., 1998) and increased 
immature platelets (Mijovic et al., 2015). It has been reported that the larger, more 
reactive platelets migrate to inflammatory sites where they are consumed, and 
this enhances thrombopoiesis to increase the quantity of circulating platelets, 
resulting in a shift in platelet size (such as MPV) and platelet count (Turner-
Stokes et al.,1991; Gasparyan et al., 2010). Moreover, inflammatory mediators 
influence the release of platelets from megakaryocytes including IL- and IL-6 
(Jiang et al., 1994). 
 
To assess whether inflammatory status in diabetic patients was associated with 
platelet count or size, the panel of inflammatory markers was correlated with the 
platelet parameters obtained from a full blood count (n=31).  
 
It was determined that platelet size (MPV and P-LCR) correlated with TNF- 
(p=0.041 and p=0.045, respectively) and MCP-1 correlated with platelet 
count(p=0.003) (Table 5.4).  
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Table 5.4: Correlations for platelet indices and inflammatory markers 
 
 Platelet 
count  
 MPV  PDW  P-LCR  N 
 R P  R P R P R P  
E-
selectin 
0.125 0.503 -0.037 0.844 -0.137 0.462 -0.126 0.499 31 
IL-1 0.413 0.088 0.274 0.271 0.173 0.493 0.128 0.614 18‡ 
IL-12p70 -0.277 0.162 0.346 0.775 0.323 0.100 0.345 0.078 27‡ 
IL-13 -0.060 0.785 0.132 0.548 0.209 0.338 0.238 0.273 23‡ 
IL-6 -0185 0.509 -0.427 0.112 -0.342 0.213 -0.299 0.280 15‡ 
IP-10 -0.237 0.200 0.194 0.295 0.176 0.344 0.160 0.391 31 
MCP-1 0.182 0.328 -0.183 0.325 -0.209 0.194 -0.122 0.514 31 
MCP-1 0.652 0.003** -0.257 0.303 -0.227 0.364 -0.184 0.464 18‡ 
sICAM-1 -0.165 0.374 0.044 0.812 0.025 0.895 0.040 0.830 31 
TNF -0.025 0.894 0.370 0.041* 0.219 0.237 0.363 0.045* 31 
All p values calculated using the Pearson correlation coefficient except the correlations with IL-
1, IP-10, IL-13 and E selectin. ‡ denotes correlations with missing data due to the protein 
concentration being below the lower limit of detection. * denotes p < 0.05 and ** denotes p < 0.01. 
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5.2.3 Inflammatory Mediators and Platelet Activation 
 
Under inflammatory conditions, circulating platelets adhere to activated 
endothelial cells and recruit leukocytes (Langer et al., 2017). Intravital microscopy 
in inflamed murine vessels demonstrated that the migration of neutrophils is 
mediated by the platelet P-selectin receptor and PSGL-1 (Sreeramkumar et al. 
2014). In addition, Burger and Wagner (2003) reported that platelet P-selectin 
influences the secretion of chemokines from monocytes, to stimulate the 
proliferation of SMCs and promote atherogenesis. Moreover, Massberg et al. 
(2002) reported that IIb3 activation was required for firm adhesion of platelets 
to endothelium.  
 
The levels of CD62P (P-selectin) and PAC-1 binding (IIb3 activation) in resting 
platelets were correlated with the inflammatory molecules measured in the 
plasma (Table 5.5). Significant correlations were observed between CD62P 
membrane expression and IL-12p70 (p=0.043), MCP-1 (p=0.033), sICAM-1 
(p=0.022) and TNF (p=0.042), demonstrating a positive relationship between 
these inflammatory pathways and platelet α-granules secretion. No significant 
correlations were identified between PAC-1 binding and the inflammatory status 
of the patients. 
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Table 5.5: Correlations for activation markers in resting platelets and 
inflammatory markers 
 
 CD62P 
expression  
 PAC-1 
binding 
 N 
 R P  R P  
E-selectin 0.166 0.419 -0.014 0.946 26 
IL-1 0.271 0.222 -0.128 0.570 22‡ 
IL-12p70 0.399 0.043* -0.022 0.913 26 
IL-13 0.222 0.298 -0.199 0.351 24‡ 
IL-6 0.414 0.070 0.082 0.730 20‡ 
IP-10 -0.180 0.317 -0.048 0.816 26 
MCP-1 0.204 0.255 -0.210 0.240 26 
MCP-1 0.490 0.033* -0.267 0.268 18‡ 
sICAM-1 0.448 0.022* 0.098 0.586 26 
TNF 0.402 0.042* -0.163 0.427 26 
All p values calculated using the Spearman test for CD62P expression in resting platelets. All p 
values for PAC-1 binding correlations were calculated using the Spearman test except E-selectin 
and siCAM-1 which used the Pearson test for parametric data. ‡ denotes correlations with missing 
data due to the protein concentration being below the lower limit of detection. * denotes p < 0.05. 
 
 
 
The levels of sP-selectin in the patient plasma was also correlated with the panel 
of inflammatory markers, to further investigate the relationship with circulating 
activation status and inflammation. The mean + SD for sP-selectin was 5800.62 
+ 2595.40 pg/ml, demonstrating a large variation across the cohort. Significant 
positive correlations were identified with sP-selectin and IL-1 (p=0.005), IL-
12p70 (p=0.033), IP-10 (p=0.003), MCP-1 (p=0.006) (Table 5.6). 
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Table 5.6: Correlations for sP-selectin and inflammatory 
markers 
 
 sP-selectin    
 R P  N 
E-selectin 0.196 0.224 40 
IL-1 0.535 0.005** 26‡ 
IL-12p70 0.301 0.074 36‡ 
IL-13 0.303 0.092 32‡ 
IL-6 0.185 0.398 23‡ 
IP-10 0.423 0.007** 40 
MCP-1 0.396 0.012** 40 
MCP-1 -0.087 0.672 26‡ 
sICAM-1 0.260 0.105 40 
TNF 0.420 0.007** 40 
All p values calculated using the Spearman test for non-parametric data. ‡ 
denotes correlations with missing data due to the protein concentration being 
below the lower limit of detection. * denotes p < 0.05 and ** denotes p < 0.01. 
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Correlations for both ADP (5.0 μmol/L)-induced CD62P expression and PAC-1 
binding and plasma inflammatory molecules demonstrated no relationship 
between inflammatory status and platelet reactivity in the cohort (Table 5.7).  
 
 
Table 5.7: Correlations for activation markers in ADP-activated platelets 
and inflammatory markers 
 
 CD62P 
expression  
 PAC-1 
binding 
 N 
 R P  R P  
E-selectin 0.046 0.822 -0.068 0.740 26 
IL-1 -0.094 0.677 -0.103 0.648 22‡ 
IL-12p70 0.181 0.377 -0.132 0.520 26 
IL-13 -0.270 0.202 -0.130 0.545 24‡ 
IL-6 -0.068 0.776 -0.095 0.690 20‡ 
IP-10 0.025 0.904 0.025 0.904 26 
MCP-1 -0.058 0.777 0.089 0.666 26 
MCP-1 -0.041 0.871 0.251 0.315 18‡ 
sICAM-1 0.139 0.822 0.032 0.876 26 
TNF -0.160 0.434 -0.144 0.484 26 
All p values were calculated using the Spearman test except correlations with E-selectin and 
siCAM-1 which used the Pearson test for parametric data. ‡ denotes correlations with missing 
data due to the protein concentration being below the lower limit of detection. 
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5.2.4 Inflammatory Mediators and Platelet Aggregation 
 
The levels of platelet aggregation were correlated with the inflammatory 
molecules measured in the plasma. The mean + SD for ADP-activated 
aggregation was 74.68 + 13.39 % and for collagen was 80.25 + 9.14 %. No 
significant correlations with inflammatory markers were identified (Table 5.8).  
 
Table 5.8: Correlations for platelet aggregation and inflammatory markers 
 
 ADP-
activated 
aggregation  
 Collagen-
activated 
aggregation 
 N 
 R P  R P  
E-selectin -0.016 0.935 0.042 0.832 28 
IL-1 -0.220 0.430 0.227 0.417 15‡ 
IL-12p70 -0.024 0.913 0.302 0.152 24‡ 
IL-13 0.277 0.237 0.017 0.944 20‡ 
IL-6 0.053 0.869 -0.095 0.770 12‡ 
IP-10 -0.185 0.345 -0.114 0.565 28 
MCP-1 -0.118 0.548 -0.117 0.552 28 
MCP-1 0.245 0.360 -0.168 0.535 16‡ 
sICAM-1 -0.269 0.166 -0.037 0.853 28 
TNF -0.016 0.935 0.113 0.566 28 
All p values were calculated using the Spearman test. ‡ denotes correlations with missing data 
due to the protein concentration being below the lower limit of detection. 
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1.1 Discussion 
 
Components of the immune system are altered in type 2 diabetes, with elevated 
levels of circulating inflammatory mediators such as IL-6 and IL-1 (Donath and 
Shoelson, 2011). Recent research shows that platelets play an important role in 
(thrombo)-inflammatory processes (Stokes and Granger, 2012). This chapter 
examined the relationship between platelet reactivity and inflammatory mediators 
in type 2 diabetic patients.  
 
The data demonstrated that both E-selectin and siCAM-1 were negatively 
associated with HDL-C. A study showed that subjects with low HDL had 
significantly higher concentrations of inflammatory markers (including siCAM-1 
and E-selectin) (Ahmad et al., 2015). They also found higher levels of biomarkers 
associated with oxidative stress in the low-HDL group. HDL has been shown to 
protect against the development of atherosclerosis and have antioxidant 
properties (Barter, 2005). It is also involved in reverse cholesterol transport which 
is the process of removing excessive free cholesterol from the vessel wall 
(Ahmad et al., 2015). Thus, HDL-C could be used as an independent predictor of 
endothelial activation, however, given that this study found no correlation 
between HDL-C and platelet reactivity (Chapter 4.2), this mechanism may not 
involve platelet activation. 
 
IL-13 has anti-angiogenetic effects by inhibiting expression of the pro-atherogenic 
marker, MCP-1 in macrophages, to reduce foam cell formation (Berkman et al., 
1996)This study found that IL-3 negatively correlated with triglycerides. A 
characteristic finding in atherosclerosis is the accumulation of triglycerides in 
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macrophages, leading to foam cell formation (Feingold et al., 2012). This might 
suggest that the anti-angiogenic effects of IL-13 are reduced in the presence of 
high levels of triglycerides in type 2 diabetic patients, elevating macrophage 
activation and foam cell formation. 
 
The data demonstrated that both platelet count and CD62P expression in resting 
platelets positively correlated with the chemokine, MIP-1This inflammatory 
mediator is secreted by endothelial cells in the presence of activated platelets 
(Vieira de Abreu et al., 2012). It is stored in -granules and released upon platelet 
activation (Vieira de Abreu et al., 2012). Cha et al. (2000) demonstrated that ADP-
activated platelets induced the secretion of MCP-1 from endothelial cells. TNF-
correlated with both CD62P expression in resting platelets and platelet size, 
and siCAM-1 correlated with CD62P in resting platelets. TNF- is an 
inflammatory cytokine that has been linked with obesity and diabetes 
(Hotamisligil et al (1993). TNF- has been shown to stimulate the arachidonic 
acid pathway in heart failure patients (Pignatelli et al., 2005). Furthermore, TNF-
 induces the expression of the adhesion molecule, iCAM-1 on endothelium and 
activated platelets can bind to the endothelial cells via iCAM-1 (Bombelli et al., 
1998). Additionally, two studies reported elevated iCAM-1 expression in 
endothelial cells in the presence of activated platelets (Gawaz et al., 1998; Cha 
et al., 2000).  
 
This study also showed that IL-12p70 was associated with CD62P expression in 
resting platelets. IL-12p70 is the active heterodimer of the inflammatory cytokine, 
IL-12 (Gee et al., 2009). IL-12 has an anti-angiogenic effect in that it blocks the 
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formation of new blood vessels. It does this indirectly by increasing the levels of 
IP-10 via interferon gamma (Sgadari et al., 1996). The literature to explain the 
link between platelets and IL-12/IL-12p70 is limited. However, a recent 
publication reported that the presence of low-level IL-12 (representative of 
chronic inflammation) caused platelets to be hyperreactive and spread (Page et 
al., 2018).  
 
sP-selectin is a marker of platelet activation and section 4.2.5 showed that sP-
selectin correlates with duration of diabetes. Work from this chapter has identified 
significant positive correlations with sP-selectin and the inflammatory markers IL-
1, MCP-1 and IP-10. IL-1 is a proinflammatory cytokine synthesised from 
mRNA within activated platelets (Vieira de Abreu et al., 2013), and both IL-1 and 
MCP-1 are secreted by endothelial cells in the presence of activated platelets 
(Gawaz et al., 1998; Cha et al., 2000). IP-10 correlated with -granule secretion 
in activated platelets. Given that IP-10 is a downstream molecule to IL-12 in 
angiogenesis inhibition (Sgadari et al., 1996), one could propose that an anti-
angiogenic effect is initiated by platelet hyperactivation in a positive feedback 
mechanism. It is interesting to note that HbA1c was positively associated with IP-
10. This, again, could be a feedback mechanism to reduce angiogenesis in the 
presence of high glucose. 
  
It has been known since the 1990’s that both resting and activated platelets could 
adhere to the vessel wall without vessel injury and recruit inflammatory cells 
(Frenette et al., 1995). Results from this study further our understanding of 
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platelets and inflammation by showing that both stimulated and non-stimulated 
platelets in type 2 diabetic patients are proinflammatory. 
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6 Comparison of Platelet activity in healthy, 
Hyperlipidaemic and Diabetic Participants 
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6.1 Introduction 
 
Evidence suggests that type 2 diabetic patients have increased platelet reactivity 
compared to healthy subjects, such as elevated expression of surface activation 
markers (Keating et al., 2003; (Yngen et al., 2001). Conversely, Shlomai et al. 
(2015) reported no difference in P-selectin expression and IIb3 activation 
between diabetic patients and a closely matched control group (Singer et al., 
2014).  
 
As hyperglycaemia is the cornerstone of diabetes, many studies have focused on 
the relationship between hyperglycaemia and platelet hyperreactivity, with 
differing results. For example, induction of hyperglycaemia in healthy groups has 
been shown to increase platelet activation and aggregation (De la Cruz et al., 
2004; Sudic et al., 2006; Tang et al., 2011). Yet these results can vary depending 
on the conditions of the experiment e.g. incubation times, agonist used and the 
agonist concentration. Although hyperglycaemia is the sine qua non of diabetes, 
patients also exhibit altered lipid levels, and hyperlipidaemia has been reported 
to increase platelet reactivity (Chan et al., 2014). Thus, hyperglycaemia and/or 
hyperlipidaemia could increase platelet reactivity in subjects with type 2 diabetes. 
 
The correlation data from section 4.2.6 identified that the most significant risk 
factor for platelet hyperreactivity in type 2 diabetic patients is LDL-C. This 
indicated that dyslipidaemia, not hyperglycaemia, is associated with platelet 
hyperreactivity in diabetes. To investigate this further, a pilot study was designed 
to measure biochemical parameters and platelet reactivity in three cohorts: 
control, hyperlipidaemic and type 2 diabetic patients. The control group consisted 
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of participants who were not treated for any health complications. The 
hyperlipidaemic group was chosen because the participants had similar baseline 
characteristics to the diabetic cohort (such as BMI and lipid profile) but did not 
have hyperglycaemia. It was hypothesised that the control group would exhibit 
reduced platelet reactivity compared to the other groups, and the hyperlipidaemic 
and diabetic groups would exhibit similar platelet activation due to having similar 
lipid levels.  
 
To compare platelet reactivity between the three groups, measurements of 
platelet indices, IPF, platelet activation and aggregation was undertaken. 
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6.2 Results 
 
6.2.1 Baseline Characteristics for the Participants  
 
Forty-five participants were recruited for this small pilot study to investigate 
platelet reactivity in patients with similar LDL-C levels, with and without diabetes. 
Fifteen hyperlipidaemic patients, were recruited from the Lipids Clinic at the 
Manchester Royal Infirmary (MRI), fifteen diabetic patients were recruited from 
the Diabetic Clinic (MRI) and a control group of fifteen participants who did not 
have diabetes or hyperlipidaemia were recruited. The three groups were matched 
as closely as possible for age, male/female ratio and BMI (Table 6.1). The BMI 
for the diabetic cohort, however, was significantly higher than the control group 
(Tukey, p=0.01), and age was significantly lower in the control group. No 
participant from the control group had a BMI over 30 kg/m2, and, thus, not 
categorised as obese (World Health Organisation, 2017). In contrast, three 
(21.0%) of hyperlipidaemic patients and eight (53.3%) diabetic patients were 
obese. 
  
All hyperlipidaemia and diabetic patients recruited to the study were taking lipid 
lowering medication (statins). Two (13.3%) hyperlipidaemic and ten (66.6%) 
diabetic patients were also on anti-hypertensive drugs. The control group were 
not on any medication for hypertension, hyperlipidaemia or diabetes. There were 
no current smokers in the control group, four (26.6%) in the hyperlipidaemic group 
and two (13.3%) in the diabetic group.  
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As expected, the mean FBG and HbA1c was similar for the healthy and 
hyperlipidaemic, and significantly increased in the diabetic group (Table 6.1). 
There was no significant difference between all three groups for the total 
cholesterol, HDL-C and triglycerides. Contrary to what was expected, the control 
group had significantly higher LDL-C levels than the hyperlipidaemic and diabetic 
groups (p=0.04 and p=0.02, respectively). It is likely that the lipid lowering 
medication was causing this significant reduction in LDL-C levels in the 
hyperlipidaemic and diabetic groups. The serum creatinine was considerably out 
of range for the males in the diabetic group (n=3) over the recommended level of 
104 μmol/L), and moderately out of range for one of the hyperlipidaemic males, 
suggesting that kidney injury was present within these two cohorts. However, the 
means are within the recommended creatinine levels for all three cohorts.  
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Table 6.1: Baseline characteristics for the control, hyperlipidaemic and 
diabetic participants 
 
 Control 
n=15 
Hyperlip-
idaemic 
n=15 
Diabetic  
n=15 
P value 
control 
vs. lipid 
P value 
control 
vs. 
diabetic 
 
P value 
lipid vs. 
diabetic 
M/F (n) 7/8 7/8 6/9 ---- ---- ---- 
Age (yr), mean 
+ SD 
45.9 + 
10.2 
55.1 + 
10.7 
62.9 + 6.8 0.010** <0.0001 
**** 
0.064 
Age (yr), range 32-65 27-75 52-71 ---- ---- ---- 
Duration of 
diabetes (yr), 
mean + SD 
0.0 0.0 12.6 + 4.9 ---- ---- ---- 
BMI (kg/m2), 
mean + SD 
25.8 + 3.7 27.0 + 3.5 30.8 + 5.9 0.764 0.012** 0.082 
Obesity (BMI 
>30) (%) 
0.0 21.0 53.3 ---- ---- ---- 
Current smoker 
(%) 
0.0 26.6 13.3 ---- ---- ---- 
Previous 
smoker (%) 
13.3 0.0 6.6 ---- ---- ---- 
Medication 
Profile (%) 
      
Insulin 0.0 0.0 46.6 ---- ---- ---- 
Other anti-
hyperglycaemic 
medication  
0.0 0.0 60.0 ---- ---- ---- 
Antihypertensive 
agents 
0.0 13.3 66.6 ---- ---- ---- 
Lipid lowering 
drugs (incl. 
statins) 
 
0.0s 100.0 100.0 ---- ---- ---- 
History of (%)       
Peripheral 
neuropathy 
 
 
0.0 0.0 20.0 ---- ---- ---- 
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Table 6.1 cont       
 Control 
n=15 
Hyperlip-
idaemic 
n=15 
Diabetic  
n=15 
P value 
control 
vs. lipid 
P value 
control 
vs. 
diabetic 
 
P value 
lipid vs. 
diabetic 
History of (%)       
Retinopathy 0.0 0.0 26.6 ---- ---- ---- 
Acute kidney 
injury 
0.0 0.0 0.0 ---- ---- ---- 
Hypertension 0.0 27.3 50.0 ---- ---- ---- 
Laboratory 
variables 
      
FBG (mmol/L), 
mean + SD 
4.9 + 0.5 4.9 + 0.7 9.6 + 4.1 >0.999 0.008** 0.009** 
HbA1c 
(mmol/mol), 
mean + SD 
33.4 + 3.3 36.9 + 3.0 66.8 + 
20.7 
0.67 <0.0001 
**** 
<0.0001 
**** 
Total 
Cholesterol 
(mmol/L), mean 
+ SD 
5.2 + 0.9 4.7 + 1.1 4.8 + 1.2 0.50 0.68 0.95 
LDL-C (mmol/L), 
mean + SD 
3.2 + 0.8 2.4 + 1.1 2.3 + 0.8 0.04* 0.02* >0.99 
HDL-C 
(mmol/L), mean 
+ SD 
1.3 + 0.3 1.6 + 0.4 1.5 + 0.5 0.35 0.57 0.92 
Triglycerides 
(mmol/L), mean 
+ SD 
 
1.5 + 0.6 1.6 + 1.0 2.0 + 0.9 >0.99 0.39 0.39 
Serum 
creatinine 
(μmol/L), range 
(min-max)  
 
 
 
 
Female: 
59-74, 
Male: 61-
109 
Female: 
58-81, 
Male: 67-
142 
Female: 
51-82, 
Male: 63-
190 
 
 
---- ---- ---- 
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Table 6.1 cont.       
 
 
 
 
 
 
Control 
n=15 
Hyperlip-
idaemic 
n=15 
Diabetic  
n=15 
P value 
control 
vs. lipid 
P value 
control 
vs. 
diabetic 
P value 
lipid vs. 
diabetic 
       
Serum 
creatinine, mean 
+ SD 
78.8 + 
15.3 
78.6 + 
20.6 
84.5 + 
38.4 
>0.99 >0.99 >0.99 
All p-values calculated using the Tukey’s multiple comparisons test for parametric data, except 
data for the variables FBG, LDL-C, VLDL-C, triglycerides and serum creatinine, which were 
calculated using the Dunn’s test for non-parametric data. P values < 0.05 represented as *. P 
values < 0.01 represented as **. P values < 0.001 represented as ***. P < 0.0001 represented as 
****. 
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6.2.2 Platelet Indices  
 
Elevated MPV has been reported to be associated hyperglycaemia (Demirtunc 
et al., 2009; Kodiatte et al., 2012; Ozder et al, 2014; Ulutas et al., 2014) and data 
from this study has shown that platelet count is linked with obesity (Table 4.3). 
Comparisons were made for platelet indices in the three cohorts (Table 6.2). 
 
The hyperlipidaemic and diabetic groups had lower platelet counts compared to 
the control group, a one-way ANOVA showed no significant difference between 
all three groups (p=0.430) and they were all within the normal reference range. 
In addition, there was no significant difference in the MPV, PDW or P-LCR for all 
three groups (one-way ANOVA, p=0.595, p=0.397 and p=0.509, respectively), 
nonetheless the diabetic group did have the highest MPV, PDW and P-LCR. The 
modest sample size in the present study (n=15) may have contributed to the 
limiting significance of the two platelet parameters.  
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Table 6.2: Mean platelet count and MPV for control, hyperlipidaemic and 
diabetic participants 
 
 Control 
n=15 
Lipid 
n=15 
Diabetic  
n=15 
P value 
control vs. 
lipid 
P value 
control vs. 
diabetic 
P value 
lipid vs. 
diabetic 
Platelet 
count 
(x109), 
mean + SD 
286.5 + 
80.8 
257.0 + 
71.9 
257.3 + 
57.0 
0.632 0.468 >0.999 
MPV (fL), 
mean + SD 
10.8 + 1.2 10.8 + 0.7 11.1 + 0.9 0.995 0.683 0.624 
PDW (fL), 
mean + SD 
13.08 + 
2.42 
12.95 + 
1.60 
13.92 + 
2.18 
0.982 0.526 0.419 
P-LCR (%), 
mean + SD 
32.21 + 
9.58 
31.73 + 
6.17 
34.89 + 
7.77 
0.985 0.630 0.528 
P-values for the MPV calculated using the Tukey’s multiple comparisons test for parametric data. 
P values for the platelet count calculated using the Dunn’s test for non-parametric data. 
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6.2.3 Thrombopoiesis  
 
High levels of reticulated platelets are associated with elevated thrombopoiesis 
and Mijovic et al. (2015) reported that reticulated platelets were increased in 
diabetic patients compared to control subjects. Moreover, hyperlipidaemic mice 
had increased platelet turnover and clearance from the circulation, suggesting 
that cholesterol metabolism effects turnover (Dole et al., 2008).  
 
To investigate whether thrombopoiesis was altered between the three groups, 
the percentage of reticulated platelets was measured as an indication of IPF. A 
Kruskal-Wallis test showed a significant increase in the % of reticulated platelets 
in the control group compared to the hyperlipidaemic group (p=0.032) (Table 6.3 
and Figure 6.1). Given that the control group had the highest LDL-C levels (Table 
6.1) this data was consistent with data from the diabetic cohort (Chapter 4), which 
showed a positive correlation between percentage of reticulated platelets and 
LDL-C (Figure 4.4). To determine whether the relationship between LDL-C and 
reticulated platelets was present across the three groups and independent of 
diabetes, a Spearman correlation was performed using the combined data for the 
3 groups (n=45). There was a significant correlation with LDL-C levels when the 
3 cohorts were combined (r=0.373, p=0.016, n=45) (Figure 6.2A).  
 
The forty-five participants were separated into three groups according to LDL-C 
level (<2.0, 2.1-2.9 and >3.0 mmol/L). A Kruskal-Wallis test showed a significant 
difference between the groups (p=0.009) (Table 6.4). A Dunn’s multiple 
comparisons test showed a significant increase in the % of reticulated platelets 
for participants with LDL-C >3.0 mmol/L compared to participants with LDL-C 
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<2.0 mmol/L (p=0.008) (Figure 6.2B). No significant difference was observed with 
<2.0 vs. 2.1-2.9 mmol/L (p=>0.999) and with >3.0 mmol/L vs. 2.1-2.9 mmol/L 
(p=0.123). 
 
Table 6.3: Mean % of reticulated platelets for control, hyperlipidaemic and 
diabetic participants 
 
 Control 
n=15 
Lipid 
n=15 
Diabetic  
n=15 
P value 
control vs. 
lipid 
P value 
control vs. 
diabetic 
P value 
lipid vs. 
diabetic 
Reticulated 
platelets 
(%), mean 
+ SD 
11.57 + 
5.82 
8.46 + 
7.23 
10.31 + 
5.02 
0.032* >0.999 0.481 
P values calculated using the Dunn’s test for non-parametric data. * represents p <0.05. 
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Figure 6.1: Mean values of reticulated platelets in control, hyperlipidaemic 
and diabetic patients 
A Kruskal-Wallis test showed a significant increase in the % of reticulated platelets for the control 
group compared to the hyperlipidaemic group (p=0.032, n=15 per group). Bars represented as 
mean + SEM. 
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Table 6.4: The comparison between LDL-C levels and reticulated platelets 
 
 LDL-C 
<2.0 
mmol/L 
n=17 
LDL-C 
2.1-2.9 
mmol/L 
    n=14 
LDL-C 
>3.0 
mmol/L  
n=14 
P value 
<2.0 vs. 
2.1-2.9 
mmol/L 
P value 
<2.0 vs. 
>3.0 
mmol/L 
P value 
2.1-2.9 
vs. >3.0 
mmol/L 
Reticulated 
platelets 
(%), mean 
+ SD 
7.99 + 
4.32 
8.57 + 
4.35 
14.24 + 
7.55 
>0.999 0.008** 0.123 
P values calculated using the Dunn’s multiple comparisons test for non-parametric data. ** 
represents p <0.01. 
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Figure 6.2: Correlation between reticulated platelets and LDL-C 
Figure A: Spearman test for non-parametric data shows a significant positive correlation for 
reticulated platelets and LDL-C (r=0.373, P=0.016) (n=45). Figure B: The reticulated platelets 
(%) in three groups separated by LDL-C levels: below 2.0, 2.0 – 3.0 and above 3.0 (n=17,14 and 
14, respectively). A Kruskal-Wallis test showed a significant difference in the % of reticulated 
platelets for the three groups (p=0.004). A Dunn’s multiple comparisons test showed a significant 
increase with >3.0 mmol/L compared to <2.0 mmol/L. Bars represented as mean + SEM. 
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6.2.4 Platelet Activation Markers 
 
Elevated expression of surface activation markers is associated with diabetes 
(Keating et al., 2003; Yngen et al., 2001) and hyperlipidaemia (Pawelczyk et al., 
2009). In this study, the levels of platelet activation markers CD62P and activated 
IIb3 on non-stimulated platelets were measured in the three cohorts to assess 
the activation status of circulating platelets. The -granule secretion, indicated by 
CD62P surface expression was increased in the hyperlipidaemic and diabetic 
participants, however this was not statistically significant (Table 6.5). The PAC-1 
binding was very similar in all three groups (p=>0.9 for each Tukey multiple 
comparison test. 
  
Agonist induced -granule secretion was significantly increased in platelets from 
diabetic patients compared to control subjects (p=0.002) (Table 6.6 and Figure 
6.3B). No significant difference was observed for PAC-1 binding in activated 
platelets for the three groups.  
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Table 6.5: Mean MFI for activation markers in resting platelets from control, 
hyperlipidaemic and diabetic participants 
 
 Control 
n=15 
Lipid 
n=15 
Diabetic  
n=15 
P value 
control 
vs. lipid 
P value 
control 
vs. 
diabetic 
P value 
lipid vs. 
diabetic 
CD62P 
expression 
(MFI), mean + 
SD 
15.5 + 9.4 26.3 + 25.8 21.3 + 
14.2 
0.861 0.654 >0.999 
PAC-1 binding 
(MFI), mean + 
SD 
10.9 + 8.7 10.3 + 6.2 10.7 + 4.0 0.966 0.998 0.979 
CD62P 
expression 
(MFI), mean + 
SD 
952.1 + 
396.1 
1268.5 + 
381.7 
1515.1 + 
510.8 
0.125 0.002** 0.275 
PAC-1 binding 
(MFI), mean + 
SD 
286.5 + 
103.5 
271.7 + 
71.6 
302 + 
77.7 
0.885 0.873 0.599 
All p-values calculated using the Tukey’s multiple comparisons test for parametric data except 
CD62P expression in resting platelets. 
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Figure 6.3: -granule secretion in ADP-activated platelets from control, 
hyperlipidaemic and diabetic participants 
Figure A: A histogram to show -granule secretion in one control (black), hyperlipidaemic (red) 
and diabetic (green) participant. The CD62P MFI for each participant is 814, 1389 and 1965, 
respectively. Figure B: A one-way ANOVA showed a significant difference in -granule secretion 
(CD62P membrane expression) in ADP-activated platelets between the three groups (p=0.004). 
A Tukey’s multiple comparison test showed a significant increase in -granule secretion in type 
2 diabetic patients compared to the control group (p = 0.002) and no difference between control 
vs. hyperlipidaemic and diabetic vs. hyperlipidaemic (p=0.125 and p=0.275 respectively). Bars 
represented as mean + SEM (n=15 per group). 
 
 
The significant increase in α-granule secretion observed in the diabetic group 
compared to the control group indicates that hyperglycaemia may be responsible 
for the increased platelet reactivity to ADP, since the diabetic group had a 
significantly higher FBG and HbA1c (Table 6.2). This is inconsistent however with 
data in Chapter 4, where there was no relationship between hyperglycaemia and 
platelets reactivity. Other characteristics that were significantly different between 
the diabetic and control group were age and BMI. Correlations were therefore 
performed across all three groups to investigate whether the enhanced α-granule 
secretion observed in the diabetic group was related to the increased age or BMI 
of the group. It was determined that age significantly correlated with CD62P 
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activation (p=0.002), indicating that this was the reason for the enhanced α-
granule secretion in the diabetic cohort.  
 
Table 6.6: Correlation between ADP-induced CD62P 
vs. BMI and age 
 
 CD62P in resting 
platelets 
n=45 
 
 R P 
Age 0.456 0.002** 
BMI <0.001 0.998 
P values calculated using a Pearson test. ** represents p <0.01. 
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6.2.5 Platelet Aggregation 
 
Increased platelet aggregation is associated with hyperglycaemia (De la Cruz et 
al., 2004; Sudic et al., 2006; Tang et al., 2011) and hyperlipidaemia (Chain et al., 
2014). To investigate whether platelet aggregation was altered between the three 
groups, PRP was stimulated with collagen (1 μg/ml) or ADP (5 μmol/L) and 
maximal aggregation measured after 5 minutes. The lag time was also assessed 
to determine whether the initial rate of aggregation was altered. The diabetic and 
healthy cohorts had similar maximal ADP-activated aggregation (79.2 ± 9.6% and 
76 ± 19.0% respectively, p=<0.999; Figure 6.4A) with similar lag times (15.3 ± 6.4 
sec and 12 ± 3.1 sec, respectively, p=0.169; Figure 6.4B). The hyperlipidaemic 
patients had reduced ADP-activated aggregation, although this was not 
significant. The lag time (19.7 ± 8.8 sec) however was significantly longer than 
the control group (13 ± 3.1 sec; p=0.002).  
 
Collagen-activated aggregation was increased in control participants (87.5 ± 
4.4%) compared to hyperlipidaemic participants (79.8 ± 9%; p=0.025), but no 
significant difference was shown with the diabetic cohort (Figure 6.4C). The lag 
time for collagen induced-aggregation was also significantly lower in the control 
group (45.5 ± 17.4s) compared to the hyperlipidaemic (70.4 ± 16.2s; p=0.0004) 
and the diabetic group (67.53 ± 15.5, p=0.002) (Figure 6.4D).  
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Figure 6.4: Platelet aggregation and lag time in control, hyperlipidaemic and 
diabetic participants 
Figure A: There was no statistical difference in ADP-activated maximal aggregation between the 
three groups. Figure B: There was significantly longer lag time for hyperlipidaemic participants 
compared to control participants (p=0.002, Dunn’s test). Figure C: There was a significant 
increase in collagen-activated platelet aggregation compared to control participants (p=0.026, 
Kruskal Wallis test). Figure D: There was a strong significant increase in lag-time for 
hyperlipidaemic participants compared to the control group (p=0.0004, Tukey test) and control 
compared to the diabetic group (p=0.002, Tukey). Bars represented as mean + SEM (n=15 per 
group). 
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6.2.6 LDL-C and Platelet Aggregation 
 
Platelet aggregation assays indicate that the control group, which has 
significantly higher LDL-C levels than both the hyperlipidaemic and diabetic 
groups (Table 6.2), also presents with more responsive platelets. To determine 
whether there was a relationship between LDL-C and platelet aggregation, 
comparisons were carried out for collagen and ADP-induced aggregation/lag time 
responses against LDL-C levels (<2.0, 2.1-2.9 and >3.0 mmol/L).  
 
The data demonstrated that there were no significant differences between the 
LDL-C levels for ADP and collagen maximal % aggregation (Table 6.7 and Figure 
6.5A and C). There was no significant difference between <2.0 and >3.0 mmol/L 
for ADP-stimulated lag, and a significant increase in lag-time for <2.0 for collagen-
stimulated lag-time compared to >3.0 mmol/L (p=0.024) (Table 6.7 and Figure 
6.5B and D). 
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Table 6.7: Mean platelet aggregation (%) for different LDL-C levels 
 
 <2.0 
mmol/L 
LDL-C  
 
2.1-2.9 
mmol/L 
LDL-C 
>3.0 
mmol/L 
LDL-C 
P value 
<2.0 vs. 
2.1-2.9 
P value 
<2.0 vs. 
>3.0 
P value 
2.1-2.9 
vs. >3.0 
ADP-
stimulated 
aggregation 
(%)  
70.12 + 
18.5 
79.63 + 
7.23 
11.76 + 
18.6 
0.444 >0.999 >0.999 
ADP-
stimulated 
lag time 
(sec) 
17.12 + 
7.03 
14.08 + 
4.25 
15.41 + 
8.75 
0.797 0.142 >0.999 
Collagen-
stimulated 
aggregation 
(%)  
81.12 + 
7.12 
82.6 + 
10.46 
85.23 + 
7.43 
0.331 0.342 >0.999 
Collagen-
stimulated 
lag time 
(sec) 
72.33 + 
16.36 
57.17 + 
22.29 
54.47 + 
17.15 
0.097 0.024* 0.921 
All p values calculated using the Kruskal Wallis test for non-parametric data except the 
comparisons with collagen-stimulated lag time. Data represented as mean + SD. 
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Figure 6.5: Comparisons between LDL-C levels and platelet aggregation 
Figure A: LDL-C levels do not have significantly different ADP-stimulated platelet aggregation. 
Figure B: LDL-C levels do not have significantly different ADP-stimulated lag-time. Figure C: 
LDL-C levels do not have significantly different collagen-stimulated platelet aggregation. Figure 
D: Participants with LDL-C levels <2.0 mmol/L have significantly increased lag-time compared to 
those with >3.0 mmol/L (Tukey, p=0.024) (n=16, 12, 17, respectively). Bars represented as mean 
+ SEM. 
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6.3 Discussion 
 
Many studies have focused on hyperglycaemia as a proposed risk factor for 
platelet hyperreactivity in type 2 diabetes. Yet diabetes patients also exhibit 
characteristics of dyslipidaemia such as elevated LDL-C, decreased HDL-C and 
increased triglycerides (Bell et al., 2011), and hyperlipidaemia is associated with 
elevated platelet activation (Chan et al., 2014).  
 
The study aimed to further our understanding of the risk factors associated with 
diabetes, by investigating whether hyperglycaemia and/or hyperlipidaemia is 
involved in altered platelet function. This was attained by comparing the lipid 
profile and platelet reactivity in control, hyperlipidaemic and type 2 diabetic 
patients. Participants were matched as closely as possible for age, sex and BMI 
since these have all been demonstrated to affect platelet function responses 
(Gleerup and Winther, 1995; Cowman et al., 2015; Schneider et al., 2009b).  
 
The data from earlier chapters has shown that hyperglycaemia is not associated 
with platelet reactivity, and that LDL-C correlates significantly with platelet 
aggregation. Consequently, we hypothesised that the hyperlipidaemic and 
diabetic groups would both have elevated platelet reactivity due to altered lipid 
levels in the blood milieu.  
 
Unexpectedly, measurement of the baseline cholesterol levels identified that the 
control group had increased LDL-C levels compared to the hyperlipidaemic and 
diabetic cohorts. This observation ascertained that the statin treatment was 
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having a significant effect on LDL-C levels in the hyperlipidaemic and diabetic 
groups.  
 
Findings from sections 3.2.1 and 4.2.2 showed that high glucose was associated 
with increased MPV, and that this may be through osmotic stress associated with 
uptake of glucose via GLUT transporters (Lösche et al., 1989). In this study there 
was a trend towards a large MPV in the diabetic cohort, however the smaller 
sample size did not allow it to reach significance. Previous studies that have 
found a significant difference used a large sample size (Demirtunc et al., 2009; 
Kodiatte et al., 2012; Ozder et al, 2014; Ulutas et al., 2014). 
 
The control group had an elevated % of reticulated platelets compared to the 
hyperlipidaemic group. Additionally, the IPF correlated with LDL-C across the 
three groups, and subjects with LDL-C over 3.0 mmol/L had significantly elevated 
IPF compared to LDL-C under 2.0 mmol/L. Previous studies have linked plasma 
lipid levels with platelet biogenesis and /or turnover. For example, Fessler et al. 
(2013) reported a correlation between platelet count and non-HDL in 10,000 
participants. Unesterified cholesterol accumulation in the platelet membranes of 
hyperlipidaemic mice led to increased platelet turnover and clearance from the 
circulation to induce thrombocytopenia (Dole et al., 2008). Our study, however, 
did not show any difference in platelet count, indicting no effect on platelet 
destruction. To the best of our knowledge, this is the first study to associate 
elevated levels of LDL-C with IPF, and further work is required to investigate the 
mechanisms that contribute to increased platelet production in the presence of 
high LDL-C. 
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Studies have reported an association between platelet activation markers with 
diabetes (Keating et al., 2003; Yngen et al., 2001) and hyperlipidaemia 
(Pawelczyk et al., 2009). Although the CD62P expression and PAC-1 binding was 
increased in resting platelets for the hyperlipidaemic and diabetic groups, this 
increase was not significant. Also, no significance was shown for PAC-1 binding 
in both resting and ADP-activated platelets for the three cohorts. A significant 
increase in CD62P expression in ADP-activated platelets was found to be 
associated with age. Shlomai et al. (2015) reported no difference in platelet 
expression markers between diabetic and non-diabetic groups without prior 
ischemic events. However, the diabetic subjects used for the study had well-
controlled glycaemia. The diabetic subjects in our study had significantly elevated 
HbA1c, representing a group with poorly controlled glycaemia.  
 
The platelet aggregation was increased in the control group compared to the 
hyperlipidaemic group and diabetic group. Findings from section 6.2.3 showed 
an association between LDL-C and the % of reticulated platelets, independent of 
diabetes. Previous in vitro work has shown increased aggregating potential in 
reticulated platelets, that formed the core of aggregates to recruit older platelets 
(Armstrong et al., 2017). 
  
The data showed that there was a significant increase in lag-time for collagen-
stimulated aggregation in participants with LDL-C <2.0 mmol/L compared to 
those with >3.0 mmol/L. This demonstrates that the effect of LDL-C on platelet 
aggregation is independent of diabetes. This potentiation could be caused by 
cholesterol accumulation in the platelet membranes which disturbs the 
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membrane structure, and enhances platelet receptor signalling, as shown in 
various hematopoietic cells (Zhu et al., 2010; Yvan-Charvet et al, 2010).  
 
It is important to note that the hyperlipidaemic group had significantly decreased 
platelet aggregation compared to the control group, but the diabetic group did 
not. It has been reported that statin treatment can reduce platelet aggregation in 
hyperlipidaemic patients (Sikora et al., 2013).  Potentially, diabetic patients have 
additional complications (possibly associated with hyperglycaemia) that alters the 
beneficial effects statin treatment has on reducing platelet function, although 
these mechanisms remain unclear. Further studies to compare the effect of 
statins on platelet function in diabetic and non-diabetic subjects would be 
beneficial to further our understanding of platelet hyperreactivity in statin-treated 
diabetic patients. 
 
In conclusion, this study has identified a link between the % of immature platelets 
and LDL-C, that is independent of diabetes. Understanding the mechanistic 
processes that contribute to the regulation of platelet production and activation 
by cholesterol could identify new therapeutics for atherothrombosis. Additionally, 
statin therapy can reduce platelet reactivity, however, they are not as effective at 
reducing platelet aggregation in type 2 diabetic patients. 
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7 Key findings and Clinical Outcomes 
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7.1 Overall Discussion 
 
Atherothrombosis is the leading cause of death in type 2 diabetic patients 
(Reusch and Drazin, 2007) and they are at equal risk of myocardial infarction as 
non-diabetic subjects with a prior myocardial infarction (Haffner et al., 1998; 
Schramm et al., 2008). Despite this, the current NICE guidelines are to offer 
antiplatelet therapy (such as aspirin or clopidogrel) for adults with type 2 diabetes 
as a secondary prevention of cardiovascular disease (NICE, 2018). Platelet 
hyperreactivity and reduced sensitivity to standard antiplatelet agents has been 
repeatedly reported in the literature (Mehta et al., 2000; Ogawa et al., 2009; Belch 
et al., 2008).  
 
Enhanced platelet reactivity may contribute to the development of atherosclerosis 
and plaque progression, but also the development of atherothrombosis and the 
severity of the thrombotic response. This could potentially make the difference 
between complete artery occlusion and a fatal myocardial infarction and partial 
occlusion and survival.  
 
Despite numerous studies investigating the mechanism that underpin platelet 
reactivity, there is no clear consensus and the process remains unclear. Here we 
present data that challenges the current paradigm and demonstrates no role for 
hyperglycaemia in enhancing platelet reactivity in type 2 diabetes. It should be 
taken into consideration that less recent studies reporting an association between 
hyperglycaemia and platelet reactivity were using a diabetic cohort that were not 
taking lipid lowering medication, therefore any effects of hyperglycaemia may be 
dependent on higher LDL-C levels. 
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We identified platelets as proinflammatory mediators in type 2 diabetic patients, 
supporting other literature in this field of study (Frenette et al., 1995; Massberg et 
al., 2002). The positive correlations with inflammatory mediators and both sP-
selectin and P-selectin surface expression in resting platelets (section 5.2.3) 
indicated that type 2 diabetic patients with circulating platelets in a more active 
state have higher levels of inflammation. This would suggest that the combination 
of anti-platelet therapy with anti-inflammatory medication may improve anti-
thrombotic therapies in type 2 diabetic patients. Though it is not clear whether the 
inflammation causes the expression of activation markers on circulating platelets 
or whether activated platelets stimulate the inflammatory mediators. Enhanced 
adhesion receptor expression and inflammation may contribute to atherogenesis 
and plaque progression. The data however demonstrated that the level of 
inflammatory molecules in the plasma did not relate to the responsiveness of 
platelets to standard agonists.  
 
The most significant finding from this thesis is that LDL-C may be used as a 
potential biomarker for thrombotic risk in type 2 diabetic patients. LDL-C 
potentiates platelet aggregation in type 2 diabetic patients. Most importantly, 
patients with LDL-C above 2.0 mmol/L have significantly increased platelet 
aggregation. This potentiation is possibly caused by native LDL-C, not ox-LDL, 
and is independent of the diabetic condition. Cholesterol accumulation in the 
platelet membranes may disturb membrane structures, particularly lipid rafts, and 
enhance platelet receptor signalling, as shown in various hematopoietic cells 
(Zhu et al., 2010; Yvan-Charvet et al, 2010). Thus, plasma membrane cholesterol 
accumulation in platelets could potentially alter signalling via surface receptors, 
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such as P2Y12. This may lead to the increased receptor expression found in 
diabetic platelets (Hu et al., 2017). Moreover, we identified that LDL-C is 
associated with thrombopoiesis. Newly released platelets are more reactive, with 
greater prothrombotic potential (Mijovic et al., 2015), and younger platelets form 
the core of aggregates to recruit older platelets (Armstrong et al., 2017). 
Furthermore, diabetic patients do not respond well to antiplatelet therapy such as 
aspirin, and it is thought that this is due to the high levels of immature platelets 
because the newly released platelets have not been inhibited by the aspirin 
(Guthikonda et al., 2007).  
 
Together these findings indicate that high LDL-C levels in type 2 diabetic patients 
causes the accumulation of cholesterol in platelets. This elevates platelet 
production and increases reactivity which may contribute to atherothrombosis. 
The combination of antiplatelet therapy and lipid lowering treatment may reduce 
platelet production and hyperreactivity in type 2 diabetic patients with LDL-C 
above 2.0 mmol/L.  
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7.2 Summary of key findings from the whole study 
 
 
1. Hyperglycaemia enhances MPV in circulating platelets through osmosis. 
2. Hyperglycaemia does not increase platelet reactivity as previously 
reported. 
3. Enhanced activation of circulating platelets is accompanied by elevated 
inflammatory mediators. 
4. The most significant risk factor for platelet reactivity in type 2 diabetic 
patients is native LDL-C. 
5. LDL-C levels >2.0 mmol/L significantly increases platelet aggregation in 
type 2 diabetic patients. 
6. LDL-C is associated with elevated platelet production, independent of 
diabetes. 
7. LDL-C >3.0 mmol/L significantly increases platelet production compared 
to <2.0 mmol/L. 
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7.3 Clinical Significance 
 
 
This demonstrates that LDL-C may act as a biomarker to identify type 2 diabetes 
patients who would benefit from antiplatelet prophylaxis. Specifically, patients 
with LDL-C >2.0 mmol/L will benefit most from antiplatelet therapy as a primary 
prevention for cardiovascular disease. Additionally, lipid lowering medication 
indirectly provides antithrombotic benefit by reducing LDL-C levels. Moreover, 
enhanced thrombopoiesis mediated by elevated LDL-C may be responsible for 
reduced antiplatelet efficacy in type 2 diabetic patients. 
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7.4 Limitations 
 
1. A large number of patients were injecting insulin. This effected our ability 
to study the effect of insulin concentration on platelet reactivity, as patients 
would have elevated levels of insulin at certain times in the day due to the 
insulin treatment.  
2. While this study was designed to have a stringent exclusion criterion to 
eliminate patients on drug treatments that would affect platelet function 
(e.g. anticoagulants, antiplatelet therapy), patients were also taking other 
medications that could affect the results, (i.e. glucose-lowering treatments 
such as Metformin).  
3. The lack of standardisation associated with platelet function tests can 
affect the accuracy of the results. For example, preanalytical conditions 
(e.g. platelet count, lipid plasma, type of anticoagulant, haemolysis) and 
different procedural conditions (e.g. agonist concentration, PRP 
preparation) (Paniccia et al., 2015).  
4. Multiplex immunoassays allow the measurement of multiple analytes in a 
single 25–50 µl sample which is really useful for studying cytokine 
responses. However, such multiplex approaches may compromise the 
ability of these assays to accurately measure actual cytokine levels (Djoba  
5. Siawaya et al., 2008). Also, only one kit could be used in this study due to 
cost constraints, so sample replicates were unable to be used to improve 
accuracy of the results. 
6. Not all assays were performed on all blood samples due to the following 
reasons a) amount of plasma collected from the patient during 
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venepuncture b) equipment failures on the day of blood collection c) 
reagent shortages.  
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7.5 Further work 
 
 
To support the results from this study, it would be useful to focus on investigating 
the effects that LDL-C has on platelet activation and aggregation. For example, 
in vitro platelet function assays could be performed to determine whether platelet 
activity is increased in the presence of native-LDL and/or glycated-LDL. Also, 
further investigation into the mechanisms by which LDL promotes thrombopoiesis 
and enhances platelet reactivity. This could include using a megakaryocyte cell 
line (MEG-01 cells) to investigate whether LDL alters thrombopoietin signalling. 
It would also be useful to investigate platelets from patients with high and low 
LDL levels, and perform lipidomics and proteomics on the platelets to determine 
whether plasma LDL levels alter the membrane lipid constituents, and the lipid 
bases signalling molecules in platelets, or the levels of agonist receptors, 
particularly those which reside in lipid rafts e.g. P2Y12. Lastly, a clinical study to 
compare the platelet reactivity in statin- and non-statin-treated diabetic patients, 
to further investigate the efficacy of lipid lowering treatment in the diabetic sub-
population. 
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9.1 Dose responses 
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Figure 9.1: Dose response for the ADP in healthy PRP 
Maximal platelet aggregation (%) for PRP stimulated with increasing ADP concentrations (μmol/L) 
in healthy participants. Curves were fitted by non-linear regression. The EC50 was 2.445 μmol/L. 
Data presented as mean + SEM (n=8). 
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Figure 9.2: Dose response for ADP in healthy whole blood 
Maximal platelet aggregation (Ω) for whole blood stimulated with increasing ADP concentrations 
in healthy participants. The EC50 was 2.33 μmol/L. Data represented as mean + SEM (n=9). 
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Figure 9.3: Dose response for the collagen in healthy PRP 
Maximal platelet aggregation (%) for PRP stimulated with increasing collagen (undiluted) in 
healthy participants. Curves were fitted by non-linear regression. The EC50 was 0.50 μg/ml. Data 
presented as mean + SEM (n=4). 
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Figure 9.4: Dose response for collagen in healthy whole blood  
Maximal platelet aggregation (Ω) for whole blood stimulated with increasing collagen (undiluted) 
in healthy participants. The EC50 was 0.89 μg/ml. Data presented as mean + SEM (n=7). 
 
Note: The collagen reagent was difficult to dilute because it is an insoluble fibrous 
protein, therefore the agonist was added to the PRP and whole blood undiluted. 
For a 500μl PRP sample, an undiluted collagen concentration below 1.0 μg/ml 
cannot be added due to pipettes having a minimum volume of 0.5 μl. 
Consequently, it was decided that the minimum volume of 0.5 μl (1.0 μg/ml) would 
be used for all experiments, including those using PRP from diabetic patients.  
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Figure 9.5: Dose response for ADP in diabetic PRP 
Maximal platelet aggregation (%) for PRP stimulated with increasing ADP concentrations (μmol/L) 
in type 2 diabetic participants. Curves were fitted by non-linear regression. The EC50 was 3.77 
μmol/L. Data presented as mean + SEM (n=10). 
 
Note: the type 2 diabetic patients had a lower response to ADP than the healthy 
participants (possibly due to the statin medication) and 2.5 μmol/L did not induce 
secondary aggregation in the majority of patients, so 5.0 μmol/L ADP was used 
for all experiments using diabetic blood. 
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Figure 9.6: Dose response for SNP and PGE1 in ADP-activated platelets 
Figure A represents the dose response for SNP in ADP-activated platelets. The EC90 was 135.89 
μmol/L (n=4). Figure B represents the dose response for PGE1 in ADP-activated platelets. The 
IC90 was 0.35 μmol/L. Data presented as mean + SEM (n=3). 
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9.2 Standard Curve for ox-LDL ELISA 
 
 
Figure 9.7: Standard curve for ox-LDL ELISA 
Standard curve for the ox-LDL ELISA used to determine the ox-LDL concentration (pg/ml) 
for the EDTA plasma samples.  
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9.3 Ethical Documentation 
9.3.1 Participant consent form (MMU) 
All participants recruited for the data for chapter 3 were given a patient consent 
form before giving blood (see below):  
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9.3.2 Medical screening questionnaire (MMU) 
All participants were given a medical screening questionnaire to prevent risk of 
infection and to ensure that no medication will affect the platelet function assays 
(see below):  
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9.3.3 Cover letter: Hyperlipidaemic group 
Below is the cover letter that was posted to patients before their appointment at 
the Lipids Clinic in the MRI. It was posted together with the PIS > 24 hours prior 
to the patient having blood taken for the study. 
                                                                                         
 
Manchester Metropolitan University 
Faculty of Science and Engineering 
John Dalton East 
Chester Street 
Manchester 
M1 5GD 
sarah.daniels2@stu.mmu.ac.uk 
Tel: 07801574712 
Date XXXXXX 
Volunteers for a study to investigate cardiovascular disease in diabetes and 
hyperlipidaemia 
CMFT study number: R01789 
Study title: Changes in paraoxonase activity, HDL properties and inflammatory markers in 
post-bariatric surgery patients, type 1 diabetics with and without nephropathy, type 2 
diabetics, and during an oral glucose tolerance test 
Dear XXXX, 
Central Manchester University Hospitals NHS Foundation Trust (CMFT) and Manchester 
Metropolitan University are investigating factors that affect cardiovascular disease in 
Type 2 diabetic and hyperlipidaemic patients by analysing a small amount of blood 
collected from both groups of patients. 
In order to recruit participants for this ground-breaking study, we are writing to patients 
who will shortly be attending the Lipids Clinic. We have enclosed a Patient Information 
Sheet in order to give potential participants time to read the information and decide 
whether they would be happy to provide a small blood sample at the Lipids Clinic as part 
of their assessment.  
If you are interested in participating in the study, please email or phone/text Sarah 
Daniels (sarah.daniels2@stu.mmu.ac.uk or tel:07801574712) stating your name and date 
of visit. You will then sign a consent form on the day of your appointment. Please note 
that not all participants who consent to the study will be selected on any one visit to the 
centre.  
The study is part of a larger study at the hospital, consequently, the Patient Information 
Sheet contains details about other assessments that may, or may not, be undertaken 
while you are attending the Lipids Clinic. This letter however, specifically relates to the 
permission to obtain a blood sample for a specific aspect of the wider study. 
If you have any questions regarding this study, please do not hesitate to contact me. 
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Yours Sincerely, 
 
Sarah Daniels  
Cardio Vascular Trials Unit 
Central Manchester University Hospitals NHS Foundation Trust (CMFT) / Manchester 
Metropolitan University 
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9.3.4 Patient Information Sheet: Control group 
Below is the PIS used for healthy and hyperlipidaemic participants. PIS’s were 
posted or emailed to all patients/healthy subjects at least 24 hours prior to blood 
being taken for the study. 
 
                    
 
 
Study Title 
Changes in paraoxonase activity, HDL properties and inflammatory markers in 
post-bariatric surgery patients, type 1 diabetics with and without nephropathy, 
type 2 diabetics, and during an oral glucose tolerance test 
 
 You are being invited to take part in a research study to look at cholesterol (fat) 
metabolism and cardiovascular health.  
 This sheet provides you with the information about the study and how it 
involves you. 
 Before you decide it is important for you to understand why the research is 
being done and what it will involve.  
 Please take time to read the following information carefully before deciding on 
whether to take part or not.  
 
Introduction 
Changes to the levels of cholesterol (a type of fat) in the bloodstream have profound 
effects on the health of the heart and blood vessels. Some forms of cholesterol are 
beneficial to the body while others are harmful. The mechanisms by which these effects 
occur are not clear. One of the enzymes which can increase the effectiveness of the good 
cholesterol is called Paraoxonase 1 (or PON1).   
In this study, we try to determine which factors affect PON1 activity in patients with 
diabetes and patients undergoing tests for diabetes.  
What is the purpose of this study? 
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The purpose of this study is to relate changes of PON1 activity with function of blood 
vessels in subjects with diabetes and subjects undergoing tests for diabetes.  
Why have I been chosen? 
It is essential that we compare diabetic patients with healthy subjects to help us assess the 
results. You have been chosen because you are healthy and do not have heart disease and 
diabetes. 
What will I have to do if I take part? 
If you agree to take part, we will confirm that you have understood the study and that you 
meet with the study criteria. You will be asked to sign a consent form for the study and 
you will need to attend Central Manchester University Hospitals NHS Trust  for 1 visit.  
What will I have to do if I take part? 
During this visit, we will review your medical and medication history. You will be asked 
to attend for the visit having fasted overnight (for at least 10 hours) so that fasting blood 
samples can be taken from you. A total of 60ml (about 12 teaspoons) of blood will be 
taken from you. Most of the blood samples will be analysed in the Manchester laboratory. 
A small sample of serum or plasma will be retained for future research at the end of the 
study. In addition, a small frozen anonymised blood sample will be sent to laboratories in 
Switzerland or Australia for further tests. The tests to be carried out in these laboratories 
are for research and not for clinical / diagnostic purposes. The tests will provide more 
information on the relationship between fat metabolism and diabetes. When all the 
analyses are completed, the samples will be destroyed. You may be asked to give a urine 
or stool sample for analysis. 
What are the possible risks of taking part? 
The blood samples will be taken by an experienced doctor or nurse and the only risk 
involved may be some bruising at the puncture site. 
Are there any possible benefits? 
There are no immediate benefits to you. However, the knowledge gained from this study 
will improve our knowledge of factors leading to heart disease and develop new therapies 
to prevent it. 
Will I be paid for taking part in the study? 
No. But your travel expenses will be reimbursed. You have the option of receiving £30 
as a single payment for each visit, or you can be reimbursed at each visit on the production 
of taxi receipt for attending and we will arrange a taxi (paid for by the research team) for 
your return after your visit. 
Do I have to take part? 
No, taking part is entirely voluntary. If you do not wish to take part you do not have to 
give a reason. 
What will happen to my clinical and personal information? 
All the clinical information you provide will be encoded (so that your personal details 
such as name and address are secure) and stored securely. This information will not be 
revealed to anyone other than the researchers. We would ask for your permission to 
inform your GP of any clinically relevant abnormalities identified during the study.  
Complaints 
If you have any concerns about any aspect of this study, you should ask to speak with the 
researchers who will do their best to answer your questions (see below).  If you remain 
unhappy and wish to complain formally, you can do this through the NHS Complaints 
Procedure or the Patient Advisory Liaison Service (PALS).  Details can be obtained from 
the hospital. 
What do I do now? 
If you have any questions please contact: 
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 Dr Safwaan Adam, Cardiovascular Research Group, University of Manchester, 
Core Technology Facility (3rd floor), 46 Grafton Street, Manchester, M13 9NT). 
Tel: 07723526324.  
 
Thank you for taking the time to read this and considering taking part in our research. 
Please discuss this information with your family, friends or GP, if you wish. You will 
have at least 24 hours to read this information leaflet. After this time, we will contact you 
again to see if you are still interested in taking part.  
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9.3.5 Consent form: Control groups 
 
 
 
 
 
Changes in paraoxonase activity, HDL properties and inflammatory markers in 
post-bariatric surgery patients, type 1 diabetics with and without nephropathy, 
type 2 diabetics, and during an oral glucose tolerance test 
 
To be completed by the patient:       Please initial the boxes 
 
1. I confirm that I have read and understood the patient information 
sheet [version 4 03.05.2016] provided for the study and I have had 
opportunity to ask questions and have had these answered 
satisfactorily. 
 
2. I understand that my participation is voluntary and that I am free to 
withdraw at any time without my medical care or legal rights being 
affected. 
 
3. I understand that relevant sections of my medical notes and data 
collected during the study may be looked at by individuals from the 
NHS Trust or regulatory authorities, where it is relevant to my 
taking part in this research. I give my permission for these 
individuals to have access to my records.  
 
4. I agree to serum and plasma being retained and stored as a gift to 
the research team and used for future ethically approved research at 
the end of the study. 
 
5. I consent to my general practitioner being informed of my 
participation in the study and of any clinically relevant information.  
 
6. I agree for my anonymised blood samples to be transferred to 
Australia for research purposes. 
 
7. I give my consent to take part in the above study including: 
 
a. Blood tests 
 
b. Stool and urine samples 
 
 
 
 
 
Name………………………………………. Date of Birth…………………………. 
 
Signature…………………………………… Date………………………………….. 
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I confirm that I have fully explained and discussed with the patient the nature and 
purpose of the above study. 
 
Name……………………………….. Position………………… (e.g. Investigator) 
 
Signature…………………………… Date……………………. 
 
Signature of physician if consent was witnessed by a nurse…………………………… 
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9.3.6 Cover letter: diabetic patients 
Below is the cover letter posted with PIS to all type 2 diabetic patients >24 hours 
prior to blood being taken. 
 
                                                                                         
 
Manchester Metropolitan University 
Faculty of Science and Engineering 
John Dalton East 
Chester Street 
Manchester 
M1 5GD 
sarah.daniels2@stu.mmu.ac.uk 
date XXXXXX 
Volunteers for a study to investigate cardiovascular disease in Type 2 diabetes 
CMFT study number: R01789 
Study title: Changes in paraoxonase activity, HDL properties and inflammatory markers in 
post-bariatric surgery patients, type 1 diabetics with and without nephropathy, type 2 
diabetics, and during an oral glucose tolerance test 
Dear XXXX, 
Central Manchester University Hospitals NHS Foundation Trust (CMFT) and Manchester 
Metropolitan University are investigating factors that affect cardiovascular disease in 
Type 2 diabetic patients by analysing a small amount of blood collected from diabetic 
patients. 
In order to recruit participants for this ground breaking study, we are writing to patients 
who will shortly be attending the Diabetes Centre. We have enclosed a Patient 
Information Sheet in order to give potential participants time to read the information and 
decide whether they would be happy to provide a small blood sample at the Diabetes 
Centre as part of their assessment.  
If you are interested in participating in the study, please email Sarah Daniels 
(sarah.daniels2@mmu.ac.uk) stating your name and date of visit. You will then sign a 
consent form on the day of your appointment. Please note that not all participants who 
consent to the study will be selected on any one visit to the centre.  
The study is part of a larger study at the hospital, consequently, the Patient Information 
Sheet contains details about other assessments that may, or may not, be undertaken 
while you are attending the Diabetes Centre. This letter however, specifically relates to 
the permission to obtain a blood sample for a specific aspect of the wider study. 
If you have any questions regarding this study, please do not hesitate to contact me. 
Yours Sincerely, 
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Sarah Daniels  
Cardio Vascular Trials Unit 
Central Manchester University Hospitals NHS Foundation Trust (CMFT) / Manchester 
Metropolitan University 
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9.3.7 Patient Information sheet: Diabetic group 
Patient information sheet (PIS) used for diabetic participants. PIS’s were posted 
to all patients >24 hours prior to blood being taken. 
 
                    
 
Study Title 
Changes in paraoxonase activity, HDL properties and inflammatory markers in 
post-bariatric surgery patients, type 1 diabetics with and without nephropathy, 
type 2 diabetics, and during an oral glucose tolerance test 
 
 You are being invited to take part in a research study looking at cholesterol (fat) 
metabolism and cardiovascular health.  
 This sheet provides you with the information about the study and how it 
involves you. 
 Before you decide it is important for you to understand why the research is 
being done and what it will involve.  
 Please take time to read the following information carefully before deciding on 
whether to take part or not.  
 
Introduction 
Changes to the levels of cholesterol (a type of fat) in the bloodstream have profound 
effects on the health of the heart and blood vessels. Some forms of cholesterol are 
beneficial to the body while others are harmful. The mechanisms by which these effects 
occur are not clear. One of the enzymes which can increase the effectiveness of the good 
cholesterol is called Paraoxonase 1 (or PON1).   
In this study, we try to determine which factors affect PON1 activity in patients with 
diabetes and patients undergoing tests for diabetes.  
What is the purpose of this study? 
The purpose of this study is to relate changes of PON1 activity with function of blood 
vessels in subjects with diabetes and subjects undergoing tests for diabetes.  
Why have I been chosen? 
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You have been chosen because you have either Type 1 or Type 2 diabetes, or because 
you are undergoing tests to check for diabetes. 
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What will I have to do if I take part? 
If you agree to take part, we will confirm that you have understood the study and that you 
meet with the study criteria. You will be asked to sign a consent form for the study and 
you will need to attend Central Manchester University Hospitals NHS Trust for 1 visit 
only.  
You will be asked to attend the visit having fasted overnight (at least 10 hours). This is 
not essential if you are prone to hypoglycaemia. During the visit, we will review your 
medical and medication history. You will have a brief physical examination that includes 
measurements of height, weight, waist circumference and blood pressure. We will 
perform an ECG test to assess the health of your heart.  
A blood sample of 60ml (about 12 teaspoons) will be taken from you. Most of the blood 
samples will be analysed in the Manchester or Salford laboratory. A small sample of 
serum or plasma will be retained for future research at the end of the study. In addition, a 
small frozen anonymised blood sample may be sent to laboratories in Switzerland or 
Australia for further tests. The tests to be carried out in these laboratories are for research 
and not for clinical / diagnostic purposes. You will be asked to give a sample of urine for 
analysis. We may also ask you to provide a stool sample. 
The tests will provide more information on the relationship between fat metabolism and 
diabetes. When all the analyses are completed, the samples will be destroyed.  
If you have Type 1 diabetes you will also be invited to have an ultrasound scan looking 
at the main blood vessels in your neck.  
Subjects having an oral glucose tolerance test (OGTT) will be given a sugar drink, and 
further blood samples will be taken 30 minutes, 2 hours and 4 hours after the drink.  
Nerve Function Tests consist of: 
 Short questionnaire on pains (if any) in your legs 
 Nerve conduction study: Nerves in your legs are stimulated resulting in momentary 
muscle twitching. This may cause minor fleeting discomfort. Your ability to sense 
different temperatures and vibration in your lower legs will be measured. 
 Corneal sensitivity is assessed with an air puff stimulus to the front of your eyes 
with no direct contact. 
 A corneal confocal microscope will be used to examine the number of nerves in the 
front part of the eye. A drop of anaesthetic is applied to numb the front of the eye. 
This allows a gel on the lens of the camera to touch the front of the eye for 1-2 
minutes whilst we record images of the cornea. 
We will also ask your permission to obtain photographs of the blood vessels at the back 
of your eyes. The photographs of the back of your eye will be taken using a special 
camera that does not require the use of dilating drops. There will be no direct contact of 
the camera with your eyes when these photos are obtained. 
What are the possible risks of taking part? 
The blood samples will be taken by an experienced doctor or nurse and the only risk 
involved may be some bruising at the puncture site. 
Are there any possible benefits? 
There are no immediate benefits to you. However, the knowledge gained from this study 
will help us to understand the factors leading to heart disease in diabetes and develop new 
therapies for cardiovascular diseases. If the ultrasound scan shows reduced flow in the 
blood vessels in your neck this would be an important finding and we would arrange 
specialist follow-up.  
Will I be paid for taking part in the study? 
No. But your travel expenses will be reimbursed. You have the option of receiving £30 
as a single payment for each visit, or you can be reimbursed at each visit on the production 
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of taxi receipt for attending and we will arrange a taxi (paid for by the research team) for 
your return after your visit. 
Do I have to take part? 
No, taking part is entirely voluntary. If you do not wish to take part you do not have to 
give a reason and in no way will your future treatment be affected. 
What will happen to my clinical and personal information? 
All the clinical information you provide will be encoded (so that your personal details 
such as name and address are secure) and stored securely. This information will not be 
revealed to anyone other than the researchers.  We would ask for your permission to 
inform your GP of any clinically relevant abnormalities identified during the study.  
Complaints 
If you have any concerns about any aspect of this study, you should ask to speak with the researchers who will do their 
best to answer your questions (see below).  If you remain unhappy and wish to complain formally, you can do this 
through the NHS Complaints Procedure or the Patient Advisory Liaison Service (PALS).  Details can be obtained from 
the hospital. 
What do I do now? 
If you have any questions please contact the doctor whose clinics you are attending 
 Dr Handrean Soran, Consultant Physician, Manchester Royal Infirmary, Oxford 
road, Manchester, M13 9WL. Tel: 0161 276 4066 (secretary). 
 Dr Akheel Syed, Consultant Physician & Endocrinologist, Salford Royal NHS 
Foundation Trust, Hope Hospital, Stott Lane, Salford M6 8HD. Tel: 0161 789 
7373. 
 Dr Naveed Younis, Consultant Diabetologist, Wythenshawe Hospital, 
Southmoor Road. Manchester M23 9LT. Tel: 0161 291 2396. 
 Dr Deepak Bhatnagar, Consultant Chemical Pathologist, Royal Oldham 
Hospital, Rochdale Road, Oldham OL1 2JH. Tel: 01616 278388. 
 Prof Satyan Rajbhandari, Consultant Physician, Lancashire Teaching Hospitals, 
Preston Road, Chorley PR7 1PP. Tel 01257 245028 
 
Thank you for taking the time to read this and considering taking part in our research. 
Please discuss this information with your family, friends or GP, if you wish. You will 
have at least 24 hours to read this information leaflet. After this time, we will contact you 
again to see if you are still interested in taking part.  
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9.3.8 Consent form: Diabetic patients 
 
 
 
 
 
Changes in paraoxonase activity, HDL properties and inflammatory markers in 
post-bariatric surgery patients, type 1 diabetics with and without nephropathy, 
type 2 diabetics, and during an oral glucose tolerance test 
 
To be completed by the patient:       Please initial the boxes 
 
1. I confirm that I have read and understood the patient information 
sheet [version 6. 03.05.2016] provided for the study and I have had 
opportunity to ask questions and have had these answered 
satisfactorily. 
 
2. I understand that my participation is voluntary and that I am free to 
withdraw at any time without my medical care or legal rights being 
affected. 
 
3. I understand that relevant sections of my medical notes and data 
collected during the study may be looked at by individuals from the 
NHS Trust or regulatory authorities, where it is relevant to my 
taking part in this research. I give my permission for these 
individuals to have access to my records.  
 
4. I agree to serum and plasma being retained and stored as a gift to 
Manchester University and used for future ethically approved 
research at the end of the study. 
 
5. I consent to my general practitioner being informed of my 
participation in the study and of any clinically relevant information.  
 
6. I agree for my anonymised blood samples to be transferred to 
Australia for research purposes. 
 
7. I give my consent to take part in the above study including: 
 
a. Blood tests 
 
b. Stool and urine samples 
 
c. Oral glucose tolerance test                       (Not applicable if you already    
                                                                                                                   have diabetes) 
d. Carotid ultrasound 
 
e. Nerve function tests 
 
f. Eye blood vessel photographs   
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Name………………………………………. Date of Birth…………………………. 
 
Signature…………………………………… Date………………………………….. 
 
To be completed by the investigator or physician or nurse taking consent: 
 
I confirm that I have fully explained and discussed with the patient the nature and 
purpose of the above study. 
 
Name……………………………….. Position………………… (e.g. Investigator) 
 
Signature…………………………… Date……………………. 
 
Signature of physician if consent was witnessed by a nurse…………………………… 
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9.3.9 Questionnaire for control participants 
 
Baseline demographics (such as height, weight and medication) were available 
for diabetic and hyperlipidaemic patients on the hospital databases but 
unavailable for control participants (recruited for chapter 4) so a questionnaire 
was given to this cohort. 
 
Participant ID: ……………………………………….. 
QUESTIONNAIRE: 
 
D.O.B. ……………………………………. 
HEIGHT ……………………………………………. 
WEIGHT ……………………………………………. 
 
Do you take any medication?  Yes / No 
If yes, please give details:  
……………………………………………………………………………………………
……………………………………………………………………………………………
……………………………………………………………………………………………
……………………………………………………………………………………………
……………………………………………………………………………………………
……………………………………………………………………………………………
……………………………………………………………………………………………
……………………………………………………………………………………………
……………………………………... 
 
Do have any medical problems? Yes/No 
If yes, please give details: 
……………………………………………………………………………………………
……………………………………………………………………………………………
……………………………………………………………………………………………
……………………………………………………………………………………………
……………………………………………………………………………………………
……………………………………………………………………………………………
……………………………………………………………………………………………
……………………………………………………………………………………………
………………………………………. 
 
Have you taken any Aspirin, Ibuprofen or other non-steroidal anti-inflammatory 
drugs in the last 2 weeks? Yes / No 
 
Do you smoke? Yes / No 
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9.4 Flow Cytometry Optimisation 
 
 
 
Figure 9.8: Identification of platelets using CD42b 
Flow cytometric analysis of human platelets using a APC-conjugated CD42b antibody that 
recognises an epitope in the GPIb chain of platelets. Platelet population was gated from 10,000 
events positive for CD42b, from a sample of healthy whole blood. Platelets were incubated with 
CD42b antibody for 20 mins at room temperature before fixation.  
 
 
 
Figure 9.9: Inactivated platelets incubated with CD42b antibody 
A dot plot to represent a flow cytometric analysis of human platelets using a CD42b antibody. 
Platelet population was selected from 10,000 platelets from a sample of whole blood from a 
healthy participant. Platelets were incubated with CD42b antibody, without agonist, for 20 mins 
at room temperature before fixation.  
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Figure 9.10: Optimisation of the dual-fluorescent assay using CD62P and 
PAC-1 
Optimisation of the flow cytometry assay was performed to avoid bleed-through of PE and FITC 
fluorochromes in the dual-fluorescent assay. Figures A-D show dot plots to represent flow 
cytometric analysis of human platelets labelled with CD42b and either CD62P or PAC-1. The 
platelet population was selected from 10,000 platelets from a sample of whole blood from a 
healthy participant. Platelets were incubated with antibody for 20 mins at room temperature before 
fixation. Quadrant gates were set up to divide the populations into CD62P-/PAC-1-, CD62P+/PAC-
1-, CD62P-/PAC-1+ and CD62P+/PAC-1+. Figure A represents inactivated platelets incubated with 
CD42b and CD62P. Figure B represents inactivated platelets incubated with CD42b and PAC-1. 
Figure C represents ADP-activated platelets incubated with CD42b and CD62P. Figure D 
represents ADP-activated platelets incubated with CD42b and PAC-1. 
 
    
